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Abstract
Introduction
Cryotherapy is being used increasingly as a minimally invasive treatment 
option to treat salvage cases of prostate cancer after radiation therapy has 
failed. The technique of cryotherapy includes freezing the prostate by a 
number of iceballs created by cryoprobes. The process is monitored by 
thermosensors and transrectal ultrasound scan. There is a little agreement in 
the literature on the iceball characteristics; hence, variations of the technique 
of cryotherapy exist among clinicians particularly as to the positioning of the 
cryoprobes and thermosensors.
The current salvage therapies for prostate cancer have comparable early 
oncological outcome, and all have some adverse effects. Patients choosing 
treatment with different modalities tend to experience different morbidities, the 
significance of which may be subjective to each patient. Hence, the impact on 
quality of life is an important tool in assessing treatment outcome.
In this dissertation, the factors determining the characteristics of the iceballs 
formed during cryotherapy have been investigated in an in vitro model; aiming 
to help clinicians to increase the safety and efficacy of the procedure.
The impact of cryotherapy on quality of life has also been assessed using 
several validated instruments.
We assessed the correlation between the iceball temperature profile and the 
impact on quality of life of patients after salvage cryotherapy of the prostate in 
an aim to reduce the impact of salvage cryotherapy on the quality of life of 
patients.
Material and Methods
The thermal properties of three different probes (3.4mm and 2.4mm diameter 
cryoprobes produced by Endocare™ and the 1.47mm diameter cryoneedles 
produced by the Seednet™) were compared in vitro. The temperatures of 
several points within the iceball created within bovine muscle were measured 
using thermosensors. The effects of changing the freezing gas flow rate from 
100% to 20% on the properties of the resultant iceball were also investigated.
The impact of salvage cryotherapy on quality of life was investigated using a 
prospective study design and a number of validated questionnaires including: 
EROTC QLQ-C30, EROTC PR-25, IPSS and HEF.
The lowest temperatures at the apex of the prostate, at the external urethral 
sphincter area and at the Denonvillier’s fascia (between prostate and rectum) 
during salvage cryotherapy were obtained, and correlated to the changes in 
the global health, urinary problem domains, urinary incontinence question,
IPSS and quality of life question of the IPSS at 6 weeks post cryotherapy.
Results
1. There was a significant difference between the thermal properties of the 
iceballs (p <0.05). The 2.4 mm diameter probes produced an iceball with 
the highest ablative ratio (percentage of lethal iceball/ total iceball 
volume) and the least non-lethal ice thickness (the outer zone of the 
iceball where temperature ranges between 0° and 40°C). The 3.4mm 
diameter probes produced an iceball, which had larger dimensions than 
the 2.4mm probes, but had a statistically significant lower ablative ratio
(p<0.001).
The most important feature of the 1.47mm diameter cryoneedles was 
that they produced a small iceball with statistically significant short lethal 
ice (p<0.001) compared to both Endocare™ cryoprobes, and with 
smaller ablative ratio (P<0.001) compared to the 2.4mm diameter 
cryoprobes.
Reduction of the gas flow rate to 20% resulted in a decrease in the lethal 
iceball dimensions, cooling rates and the ablative ratios for all the 
iceballs which was more pronounced when using the 1.47 cryoneedles.
2. The quality of life study is ongoing and preliminary results are presented. 
The trend suggested worsening (of “a little” clinical significance) of the 
global health score temporarily for 3 months after cryotherapy. Urinary 
problems worsened until 9 months after cryosurgery at which time it 
became of no clinical significance. There were no clinically significant 
changes in sexual activity and function after salvage cryosurgery, as the 
majority (86%) were considered impotent before cryotherapy.
3. The study is ongoing and preliminary results showed no correlation 
exists between the lowest iceball temperature at the apex of the prostate, 
the external urethral sphincter or the Denonvillier’s fascia and the impact 
on the quality of life of patients after salvage cryotherapy.
Conclusions
There are differences between the iceball thermal properties of the different 
freezing probes, and the 2.4mm diameter probes appear to be superior to the 
other probes.
Conclusions cannot be drawn on the quality of life study, but the trends 
suggest that the changes in quality of life and symptoms, except for 
incontinence, are limited to 6-9 months post-operatively on average.
The lack of correlation between the lowest iceball temperatures and the 
quality of life should be interpreted with caution due to the small number of 
patients assessed in this study to date.
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Chapter
1
Introduction
1.1 Prostate Cancer Epidemiology
incidence
Prostate cancer is the most common cancer in men in western countries and 
is the second most common cause of cancer death (Moul et al, 2003).
In 2000, the number of new cases of prostate cancer was estimated at 
513,000 worldwide (Gronberg, 2003). This accounts for 9.7% of all cancers in 
men (15.3% in developed countries and 4.3% in developing countries).
The incidence of prostate cancer varies worldwide. United States, Canada, 
Australia and Scandinavia have the highest rates, with lower rates being 
found in China, India, Japan and Singapore (Gronberg, 2003; Quinn and 
Babb, 2002a). These differences may be caused by one or a combination of 
factors, including genetic vulnerability, unknown environmental factors or 
differences in healthcare and cancer registration (Gronberg, 2003).
In the United States, prostate cancer accounts for 33% of all newly diagnosed 
malignancies among men (reviewed by Crawford, 2003). According to the 
American Cancer Society, there were an estimated 220,900 men diagnosed 
with prostate cancer in 2003 and 28,900 men died from it, making it the 
second most common cause of cancer death in men.
2
In England and Wales, prostate cancer is the second most common cancer in 
men with 19,300 men diagnosed with prostate cancer in 1997(Quinn and 
Babb, 2002b)
The incidence of prostate cancer has changed over the last 30 years (figure 
1.1). The age-specific incidence rates increased gradually between the early 
1970s and the late 1980s in the USA. The apparent increase in the incidence 
of prostate cancer in the 1970s and 1980s have partly been attributed to the 
increased use of TURP for treating BPH, which resulted in the incidental 
detection of preclinical cases to approximately 10% of patients (reviewed by 
Quinn and Babb, 2002a). Between 1986 and 1992, the age-adjusted 
incidence increased from 91.4 to 190.4 per 100,000 men (Stephenson, 2002). 
The apparent rapid rise in the incidence may have occurred due to increased 
detection of prostate cancer by the use of PSA and improved ultrasound- 
guided biopsy techniques. The peak incidence in 1992 was followed by a 
sharp fall in 1994 and then stabilised at a new post-peak level through 1997, 
which is higher than the incidence before the PSA era. The decline in the 
incidence from 1992 to 1995 may be the result of a cull phenomenon whereby 
repeat screening in a relatively cancer-depleted population resulted in lower 
cancer case yields (Stephenson et al, 1996).
In addition to the changing incidence of prostate cancer, the advent of PSA 
testing brought several changes to the patterns of clinical presentation and 
treatment for prostate cancer. These include earlier disease stage at
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diagnosis and greater rates of treatment with curative intend by radical 
prostatectomy or radiation therapy (reviewed by Mettlin et al, 1998).
In England and Wales, the incidence rates were 2 to 3 times lower than in the 
USA (Quinn and Babb, 2002b); however, similar to USA, there was a steady 
increase in the incidence rates in all age groups during the 1970s and 1980s 
(figure 1.1). The sharp rise in the incidence rates due to the use of PSA began 
later in England and Wales than in USA (Quinn and Babb, 2002b). The all­
ages directly age-standardized incidence in England and Wales increased 
from 29 to 59 per 100 000 between 1971 and 1993 (Majeed et al, 2000).
Mortality
In contrast to the wide variation in the incidence of prostate cancer worldwide, 
there has been relatively little variation in mortality (Quinn and Babb, 2002a). 
The highest mortality rates are reported for the Caribbean and Scandinavia 
and the lowest in China and Japan, India and Singapore (reviewed by 
Crawford, 2003; Quinn and Babb, 2002a). Despite differences in prostate 
cancer mortality, there were large increases in mortality rates in virtually all 
the countries between the 1970’s and early 1990’s (reviewed by Quinn and 
Babb, 2002a). In USA, Canada, England, France and Austria, a decline in 
mortality was observed in the late 1990s.
In the USA, age-adjusted prostate cancer mortality rates rose gradually from
21.7 to 26.7 deaths per 100,000 men between 1973 and 1991 (figure 1.1). 
Mortality rates seemed to flatten in the early 1990s and then steadily declined
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through 1997 to equal the rate observed in the 1970s (Stephenson, 2002). 
The reasons for this decline is not clear but could have been contributed by a 
number of factors including better diagnostic methods with TRUS guided 
biopsy coupled with wide use of PSA leading to earlier detection, and 
improvement in curative treatments (reviewed by Roberts et al, 1999). Data 
suggest that most of the decline in mortality is explained by reductions in 
mortalities in men with distant-stage disease rather than from localised 
prostate cancer. However, the duration of follow-up in these studies is too 
short to detect changes in localised prostate cancer mortality since the use of 
PSA testing (Stephenson, 2002).
In England and Wales, the annual number of deaths from prostate cancer has 
increased by 113% between 1971 and 1998, from 4027 to 8570 (Majeed et al, 
2000). In 2000, 8300 men died from prostate cancer accounting for 12% of all 
cancer deaths and just over 3% of all deaths in men (Quinn and Babb, 
2002b).There was a little change in prostate cancer mortality in the 1970s 
(figure 1.1). Death rates began to increase from the 1980’s to peak in 1995 
(age-standardised death rate of 30 per 100,000). Death from prostate cancer 
declined in the subsequent 3 years to reach 27 per 100,000 in 1998 (an 
overall increase of 38% between 1971 and 1998) (Majeed et al, 2000).
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Figure 1.1.The age standardised incidence of (red) and mortality from (blue) prostate cancer 
in England and Wales (solid line) and USA (dashed line), 1971-1999 (Quinn and Babb, 
2002a).
Staging and Prognosis
Prostate cancer may either be confined to the prostate (so called localised or 
early prostate cancer), locally advanced (with local infiltration), or advanced 
where there has been metastasis to other sites including lymph node or 
bones. Early prostate cancer is the commonest comprising 65.5% of cancers 
detected in the UK, locally advanced disease making up 22.1% of cases and 
12.4% with advanced disease (baus.org.uk, 2005).
Prostate cancer progresses either through local infiltration resulting in 
invasion of adjacent structures including urethra, bladder, ureter or rectum, or 
by metastasis commonly to bone. Prognosis depends on the stage of the 
disease and the potential for the cancer to progress.
6
In the UK, prostate cancer is commonly staged according to the TNM 2002 
staging classification (Green, 2002) which uses clinical examination and 
imaging to determine the extent of the cancer (table 1.1).
Potential for cancer to progress has been shown to be associated with several 
microscopic features of the tumour. These features include: tumour grade 
(Gleason score); perineural invasion and the presence of high grade Prostatic 
Intraepithelial Neoplasm (DeMarzo A.M. et al, 2003; McNeal et al, 1986; 
Whitmore, 1984).
Gleason grade ranges from 1 to 5 depending on the degree of differentiation 
of the tumour (gradel for well differentiated and grade 5 for undifferentiated). 
Because prostate cancer is commonly heterogeneous and multifocal, it is 
more useful to consider more than one area of the prostate. Therefore, 
Gleason score or sum is widely used to determine the grade of the cancer 
where the two areas which make up most of the cancer are added together. 
The Gleason score is commonly expressed as the two Gleason grades added 
together. The first grade is the most commonly seen grade, while the second 
grade is the second most commonly seen grade (Pan et al. 2000). Therefore, 
although both 3+4 and 4+3 result in a Gleason score of 7, the latter is more 
aggressive.
Using a combination of PSA, Gleason score and clinical staging (T), three risk 
groups (low, intermediate and high) for prostate cancer have been established 
by a number of institutes to help predict outcome after treatment for early 
prostate cancer. Commonly used classifications include the Seattle risk score 
(Blasko et al, 2000), Mount Sinai risk score (Lee et al, 2002) and D’Amico risk 
score (D'Amico et al, 1998).
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1.2 Treatment Options for Early Prostate Cancer
There are several treatment options for early prostate cancer (table 1.2). 
However, there is a lack of prospective randomised trials (RCT) directly 
comparing outcomes following these treatments. Only one RCT has been 
published (Bill-Axelson et al, 2005) in which 695 patients were randomised to 
watchful waiting versus radical prostatectomy. After a median follow up of 8.2 
years, 177 patients in the watchful waiting arm received hormonal treatment 
compared to 110 in the radical prostatectomy arm. The results were in favour 
of radical prostatectomy with prostate cancer-specific mortality, overall 
mortality and the risk of metastasis and progression being reduced by 5.3%, 
5%, 10.2% and 25.1 % respectively compared to watchful waiting patients.
Comparison of the available retrospective data is difficult due to the 
differences in the definitions used for disease recurrence for various local 
treatment options. However, it is generally agreed that cohort and institutional 
series have suggested equivalent efficacy of radical prostatectomy, three- 
dimensional conformal EBRT and brachytherapy in the treatment of early 
prostate cancer (Kupelian et al, 2004; Potters et al, 2002).
Selection of treatment options depends on many factors including the 
patient’s age, race, cancer risk group, comorbidities, patients choice and his 
doctors’ advice (Kane et al, 2003). Urologists commonly prefer surgery whilst 
oncologists favour radiation therapy (Fowler, Jr. et al, 2000). It is possible that 
future decision making may depend on the degree of impact of treatment on
9
quality of life. Discussion of all treatment options is beyond the scope of this 
dissertation.
1 Active Surveillance
2 Radical Prostatectomy
i) Open (Retropubic/ Perineal)
ii) Laparoscopic
iii) Robotic
3 Radiation Therapy
i) External Beam Radiotherapy
ii) Brachytherapy
4 Cryosurgery
5 High Intensity Focused Ultrasound
6 Hormonal Therapy: usually in combination with other therapies, either:
i) Before (neoadjuvant)
ii) Immediately after (adjuvant).
7 Emerging / Rarely Used Treatments
i) Photodynamic Therapy
ii) Microwave
iii) Radiofrequency
iv) Particle Beam Radiation Therapy
Table 1.2 Treatment options for early prostate cancer.
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1.2.1 Radiation Therapy
Radiation can either be delivered with external beam (external beam radiation 
therapy or EBRT) or interstitially (also known as brachytherapy or seed 
implant therapy).
1.2.1.1 External Beam Radiation Therapy (EBRT)
This is widely accepted as a curative treatment choice for localised prostate 
cancer. The concept of this therapy is that the delivered radiation dose should 
be lethal to the tumour, whilst safe to the adjacent organs (e.g. bladder and 
rectum) to avoid toxicity.
Recent technological advances in radiation treatment planning and delivery 
has resulted in the development and implementation of sophisticated 
techniques including three-dimensional conformal radiotherapy (3D-CRT) 
and, more recently, intensity modulated radiotherapy (IMRT).
a. Conventional EBRT
The technique of conventional EBRT delivery involves patient immobilization, 
radiographic simulation (to define the anatomical landmarks) and treatment 
planning aiming to encompass the prostate with a 2-3cm margin.
Radiation is typically delivered as an out-patient procedure in 2 Gy fractions 
for 5 days a week over 5-7 weeks.
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Several retrospective long-term follow-up series of conventional EBRT are 
available. Most of these patients were non-surgical candidates, poorly 
selected, and referred for radiation therapy during the pre-PSA era.
Zietman et al (1995) reviewed 1044 men with T1-T4NxM0 prostate cancer 
treated with conventional ERBT between 1977 and 1991. After a median 
follow-up of 49 months, 40% and 18% of T1-2 and T3-4 patients were 
biochemically disease free respectively, where failure was defined as a serum 
PSA £ 1ng/ml 2 or more years after treatment.
In a shorter follow-up study, Preston et al (1999) reviewed 371 prostate 
cancer patients who had EBRT with a mean follow-up of 40.2 months. The 
overall 5-year disease-free survival was 55.3%.
Radiation induced rectal and genitourinary toxicities are frequently graded 
according to increasing severity from mild (grade 1) to severe (grade 4). The 
most frequently used grade scales are the Radiation Therapy Oncology 
Group (RTOG) scale for acute toxicity and the RTOG/ EORTC (the European 
organization for research and treatment of cancer) scale for late toxicity (Cox 
etal, 1995).
Zurlo et al (2002) reported the acute toxicity of 405 prostate cancer patients 
treated with conventional EBRT in the EORTC trial 22863. The incidence of > 
grade 2 acute genitourinary and lower gastrointestinal toxicities were 31.6% 
and 24.9% respectively. The late toxicity of the same trial was reported by
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Ataman et al (2004) which showed that 22.8% of the patients had £ grade 2 
urinary and intestinal complications.
b. Conformal Radiotherapy (3D-CRT)
During the past decade, the increased availability of CT scanners and the 
development of sophisticated three-dimensional (3D) planning and delivery 
systems have made the clinical use of 3D-CRT possible. This allows more 
precise delivery of higher doses of external beam radiation to the prostate 
with steep drop-off of the dose to the adjacent normal organs.
Long-term results are awaited; however, there is good evidence from 
intermediate follow-up studies to support the use of 3D-CRT.
Zelefsky et al (2001) reviewed 1100 patients who were treated with 3D-CRT. 
The 5-year actuarial recurrence-free survival for patients treated with <70.2 
Gy was 77%, 50% and 21% for favourable, intermediate and unfavourable 
prognostic features respectively. For those patients treated with 75.6-86.4 Gy, 
the corresponding 5-year actuarial PSA recurrence-free survival rates were 
90%, 70% and 47%.
The advantage of 3D-CRT is the ability to escalate the radiation dose 
delivered to the prostate without increasing complications. However, Pollack 
et al (2002) found that the benefit of dose escalation was only noted in 
patients with unfavourable prognostic features (PSA > 10 ng/ml). They 
randomised 301 men with T1-T3 prostate cancer to receive 70 Gy
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(conventional ERBT) or 78 Gy (3D-CRT). At 6-years, a significant difference 
in biochemical-free rates (43% vs 62%) was observed only in the 
unfavourable cancer patients in favour of the 3D-CRT arm.
Storey et al (2000) randomised 189 patients to receive either conventional 
ERBT (70 Gy) or 3D-CRT (78Gy). There were no statistical differences in 
early or late toxicities between the two groups.
Michalski et al (2005) analysed the toxicities of 218 patients treated with 3D- 
CRT (78 Gy) in a phase l-ll RTOG (Radiation Oncology Group) 9406 trial. 
They concluded that only 2% and 4% developed late bowel and bladder grade 
3 toxicities respectively and no patients had grade 4 toxicity.
c. Intensity Modulated Radiotherapy (IMRT)
A refinement of the 3D-CRT is the intensity modulated radiotherapy (IMRT) 
which involves the use of multiple small, non-uniform radiation beams of 
various intensities directed toward the target. One of the main advantages is 
the flexibility of devising a desired dose distribution of any 3D shape to match 
the clinical target. Thus, the desired dose to the tumour can be optimised, 
while the doses to various adjacent critical organs can be selectively 
minimised to reduce toxicity. However, long-term risks of larger volumes of 
normal tissue receiving low doses of radiation are unknown.
Another potential of IMRT is the ability to escalate radiation dose to other 
targets including pelvic lymph nodes.
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Short-term data suggest that IMRT is comparable to 3D-CRT in terms of PSA 
outcome without increasing toxicity. Zelefsky et al (2002) followed a series of 
772 patients for a median of 24 months. The 3-year actuarial PSA recurrence- 
free rates were 93%, 84% and 81 % in patients with low, medium and high-risk 
features. The incidences of acute grade 2 rectal and genitourinary toxicities 
were 4% and 28% respectively. The corresponding figures of late toxicities 
were 1.5% and 9.5% respectively.
De Meerleer et al (2004) reported 114 patients treated with a IMRT (mean 
does of 77 Gy). Grade 2 acute gastrointestinal and genitourinary toxicity was 
observed in 29% and 36% of patients respectively. The corresponding figures 
for grade 3 complications were 0% and 7% respectively.
1.2.1.2 Brachytherapy
‘Brachy’ comes from the Greek meaning ‘close’ and as such the name is apt 
in describing targeted radiation therapy using radioactive seeds where high 
dose of radiation is delivered to a focused area of the prostate. Modern 
brachytherapy was born in the 1980’s following the development of the 
transrectal ultrasound scan (TRUS).
The technique involves TRUS imaging of the prostate, seed configuration 
measurement, loading needles with the seeds and finally insertion of the 
needles into pre-determined positions under TRUS guidance where the seeds 
are implanted. Postoperative CT scan are performed at either day 1 or 1
15
month from the implant to assess the quality of implant, allowing correction of 
poor positioning.
The choice of the radioactive isotope for the implant is controversial. Iodine- 
125 (I125) has a half-life of 60 days compared to 17 days for Palladium-103 
(Pd103). Urologists have commonly used I125 for slower growing tumours and 
Pd103for faster growing tumours (reviewed by Mangar et al, 2005). However, 
clinical data has shown no differences between the two isotopes in terms of 
cancer control (Cha et al, 1999).
The minimum prescribed dose to the prostate gland is 145Gy using Iodine- 
125 implants with approximately 50% of the gland receiving 150% of the dose 
(i.e. 217Gy). The implants are arranged to allow relative sparing of the 
prostatic urethra to minimize urinary toxicity.
Results of brachytherapy suggest that it is a feasible treatment option for 
localised prostate cancer particularly in patients with low and intermediate -  
risk disease.
Potters et al (2005) reviewed 1449 patients with 12-years biochemical 
disease-free rates for low, medium and high-risk prostate cancer patients 
were 91%, 80% and 66% respectively using the American Society for 
Therapeutic Radiology and Oncology (ASTRO) definition of biochemical 
failure (3 successive PSA rises).
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In the UK, Joseph et al (2004) presented their series of 667 patients treated 
with I125 which were comparable with most USA series. After a mean follow-up 
of 8.2 years, the biochemical recurrence-free rates were 84.3%, 73.9% and 
52.6% for low, Intermediate and high-risk prostate cancer patients.
Side effects of brachytherapy are predominantly urinary, though rectal toxicity 
and erectile dysfunction are also known risks. Most patients experience a 
temporary worsening of urinary function with increased irritative and 
obstructive symptoms which tend to improve after 2-3 months (Henderson et 
al, 2004). Toxicities include: acute urinary retention (2-22%), Incontinence 
<1% and proctitis 4-11% (Blasko et al, 2000; Henderson et al, 2004; Merrick 
et al, 2003; Terk et al, 1998).
A wide range of erectile dysfunction rate has been reported after 
brachytherapy (6% to 90%). This is likely due to differences in follow-up, 
mode of data collection, patient selection and use of neoadjuvant androgen 
deprivation and EBRT(reviewed by Langley and Laing, 2004; Merrick et al, 
2003).
17
1.2.2 Cryosurgery
The word “cryo” comes from the Greek word “Kruos” for cold. Cryosurgery, 
also known as cryotherapy or cryoablation is a technique in which freezing is 
used to destroy undesirable tissues.
1.2.2.1 History and Development of Cryosurgery
The first physician to use cold or congelation to treat cancers was Dr James 
Arnott (figure 1.2) from Brighton (1797-1883), UK (Arnott J., 1850). He used a 
mixture of saline and ice applied to advanced breast and cervical cancer to 
reduce pain, discharge and haemorrhage.
Fig. 1.2. Dr James Arnott
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In 1877 Cailletet of France and Pictet of Switzerland began developing 
adiabatic expansion systems for cooling gases. This led to liquefaction of 
oxygen, air and nitrogen. In 1895, Linde of Germany and Hampson of UK 
began using throttle expansion or the so called the Joule-Thompson effect 
which will be explained later (1.2.2.3) that enabled the production of 
continuous operating air liquefiers.
Liquid nitrogen became commercially available in 1940’s, and was used 
clinically in 1950’s by Allington of Oakland, California (Allington, 1950) but 
only to treat superficial skin conditions as delivery systems for deeper tissues 
were not available.
One of the most important steps in the history of cryosurgery was the 
development of the closed liquid nitrogen system in 1961 by a neurosurgeon, 
Irving Cooper and an engineer, Arnold Lee (Cooper I.S. and Lee A.St.J., 
1961).They designed a cannula capable of delivering liquid nitrogen to deep 
tissue, which was essentially the model from which future liquid nitrogen 
probes were manufactured.
In 1964, Maurice J Gonder from New York and colleagues began 
experimenting on canine prostate (Gonder et al, 1964) using liquid nitrogen. 
Two years later, the same group published the first report of prostate 
cryosurgery in 50 patients with BPH and prostate cancer (Gonder et al, 1966; 
Soanes and Gonder, 1969). The prostate was frozen using a single 26 Fr 
diameter liquid nitrogen probe, only the tip of which was cooled (-160°C). The
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probe was placed urethrally and the freezing process was continuously 
monitored by a single thermocouple positioned between the rectal wall and 
the prostate and by regular digital examination. Freezing was stopped when 
the thermocouple temperature reached 0°C or if any fixation of the rectal 
mucosa was felt. Although they achieved sufficient outcome in terms of BPH 
symptoms and cancer control, complications were significant. These included 
urethral sloughing of necrotic tissue which required removal, frequent 
infections such as epididymitis, prolonged catheterization and incontinence. 
Despite technical modifications of cryosurgery including open perineal (Flocks 
et al, 1972) and percutaneous transperineal (Megalli et al, 1974) approaches, 
complications remained a problem as surgeons were still unable to precisely 
place the cryoprobes or monitor the freezing process. Therefore, urologists 
lost interest in cryosurgery in the 1980’s.
Another significant landmark in the development of modern cryosurgery which 
led to the revival of interest was the development of real-time trans-rectal 
ultrasound scan monitoring by Onik et al (1993). This enabled surgeons to 
accurately place the cryoprobes and continuously visualise iceball 
progression. At the same time, a multi-probe liquid nitrogen system 
(Accuprobe™) was introduced (figure 1.3a). This allowed a synergistically 
uniform and effective distribution of lethal low temperature throughout the 
iceball. In addition, it permitted some flexibility to the surgeon.
In the 1990’s, cryosurgery developed rapidly. Lee et al (1994) described the 
use of transperineal thermocouple probes placed at specific points providing 
real-time temperature information of the iceball, sphincter and rectal wall.
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A year later, a double-lumen urethral warming catheter was developed 
(Cohen et al, 1995) in order to preserve the urethral mucosa. These 
developments facilitated more effective tumour destruction and significantly 
reduced complications including incontinence, urethral sloughing and recto- 
urethral fistula.
In 1996, Endocare, Inc., Irvine, CA. introduced the multiple-port high-pressure 
gas system (Cryocare™) which later became more known as the second 
generation system (figure 1.3b). The system utilizes the Joule-Thompson 
effect, which will be discussed later in the chapter (1.2.2.3), using pressurised 
argon gas for freezing and helium for active thawing. The system is compact, 
responds rapidly to user input and able to create an iceball faster with steeper 
internal temperature gradients than the liquid nitrogen systems (Rewcastle et 
al, 1999a).
In the late 1990’s, Galil Medical, Inc., Plymouth Meeting, PA introduced the 
third generation (SeedNet™) system (figure 1.3c) using ultra-thin 17-gauge 
needle probes aiming to produce higher resolution freezing and more uniform 
coverage of the prostate; however more needles are required to freeze the 
entire prostate (Han et al, 2003).
In 2003, Endocare introduced the fourth generation (Cryocare™ CS) system 
with (figure 1.3d) integrated biplaner ultrasound which allows intra-operative 
real-time planning. This new system is designed to simplify the procedure and 
allow more flexibility.
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(a) (b)
(c) (d)
Figure 1.3. Cryosurgery systems. The Accuprobe™ system (a), the Cryocare™ (b), the 
Seednet™ (c) and the Cryocare CS™ (d).
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I1.2.2.2 Equipment for Cryosurgery
a. Transrectal Ultrasound Systems
Biplanar TRUS allows for viewing the prostate and monitoring the progression 
of the iceball both in transverse and longitudinal views. The leading edge of 
the iceball appears as a bright line as the sound waves reflect off the 
frozen/unfrozen interface (figure 1.4). The tissue behind the iceball edge is 
concealed in the acoustic shadow; therefore, TRUS cannot monitor beyond 
the anterior boundary of the iceball.
Figure 1.4. TRUS view of the iceball during prostate cryosurgery. The tissue behind the 
iceball edge is concealed (appears dark).
Rectal wall
The leading edge of 
the iceball
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b. Freezing Probes
Double-lumen cryoprobes are used, where high-pressure gas is delivered via 
a thin central tube to the tip of the probe. The gas is then released to the 
expansion chamber where it expands rapidly as its pressure decreases to 
room temperature (15 pounds per square inch or psi). The expanded gas is 
then circulated back to the cryogenic unit through the outer lumen of the 
cryoprobe and the supply hose where it is vented into the room (figure 1.5). 
This sudden change of gas pressure results in temperature change via the 
Joule-Thompson (J-T) effect. High-pressure argon gas (300 bar) is used for 
freezing as its temperature decreases to -186°C while helium is used for 
thawing (+67°C) according to the J-T effect. The shaft and base of the probe 
is insulated with an air chamber to protect perineal tissue from freezing. The 
Cryocare™ system uses 3.4mm or 2.4mm diameter probes, while the 
Seednet™ system utilizes smaller diameter (1.47mm) cryoneedles.
Gas returnHigh-pressure gas
}  —
Expansion chamber
Air chamber
Figure 1.5. Diagram of the tip of a Joule-Thompson type freezing probe
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c. Urethral Warming Device
This consists of a closed double-lumen catheter made of polyethylene 
membrane, through which heated saline (38-40°C) is continuously circulated 
by a special pump.
d. Thermosensors
To monitor the iceball temperature, 1.5mm diameter probes with T-type 
0.07mm diameter copper/constantan alloy thermocouple wire are used.
e. Cryogenic Systems
Two cryosurgical systems are available for prostate cancer treatment. The 
Cryocare™ system (Endocare Inc, Irvine, CA) allows the use of up to 8 
freezing probes and 8 thermosensors. The system enables the user to control 
the rate of cooling by changing the rate of freezing gas flow rate between 5 to 
100% in 5% increments. Endocare produced a newer generation (Cryocare™ 
CS) system which has a biplaner ultrasound built in.
The Seednet™ system (Galil Medical, Plymouth, Meeting, PA) allows the use 
of up to 30 cryoneedles and 5 thermosensors. The users can change the gas 
flow rate between 20 to 100% in 20% increments.
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1.2.2.3 The Joule-Thompson Effect
The Joule-Thompson effect is a process in which high-pressure gas changes 
temperature when expands adiabatically; argon cools to -186°C while helium 
warms to +67°C.
For a fixed pressure, a gas has a Joule-Thompson inversion temperature 
which determines if the gas cools down or warms up upon expansion. The 
value of this temperature is -233°C for helium and +450°C for argon. 
Therefore, at room temperature helium results in warming while argon causes 
cooling on expansion.
The reason of this difference is explained by the difference in the 
intermolecular forces of each gas. In any gas, there are attractive and 
repulsive forces present between the molecules or atoms. When a system 
goes to a more stable state, it gives off energy; the process is exothermic, 
whereas if a system goes to a less stable state, energy must come from 
somewhere for the process to occur. In the process of gas expansion, this 
energy is in the form of heat.
In the case of argon gas, the attractive forces predominate, upon expansion, a 
larger average separation of molecules leads to a less stable state, and 
energy in the form of heat must be taken from the surroundings, hence 
cooling is observed upon expansion. When helium is used, heating is 
observed upon expansion as the repulsive forces predominate, and a greater 
separation of molecules results in a more stable state, releasing energy in the 
form of heat.
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1.2.2.4 Cryobiology
The destructive effect of freezing on tissues can be due to many mechanisms: 
direct cellular injury, vascular injury, increased apoptosis and a possible 
immunogenic effect.
a. Direct Cellular Injury
There are 2 biophysical changes in water that occur in cells during freezing 
that have been linked to direct cell injury. As the temperature falls to less than 
0°C, water crystallizes and ice starts to form. This first occurs in the 
extracellular spaces creating an extracellular hyperosmotic environment. This 
in turn withdraws water from the cells causing cellular dehydration. The 
resulting high concentration of intracellular solute has been hypothesised to 
cause cellular injury by damaging vital enzymes and destabilization of the cell 
membrane through increased protease activity and lipid peroxidation 
respectively (reviewed by Hoffmann and Bischof, 2002). Effective cellular 
dehydration occurs predominantly between 0°C and -20°C and with relatively 
low cooling rates when the cells have sufficient time to dehydrate completely.
The second biophysical response is intracellular ice formation (IIF), which 
occurs when the temperature drops below -40°C (Theodorescu, 2004). I IF is 
more efficient when the cooling rate is rapid, not allowing sufficient time for 
water to leave cells which keeps their solute freezing point higher. The ice 
crystals are purported to cause injury to the organelles and membranes and 
regarded more lethal than extracellular ice, although the precise mechanism
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whereby I IF destroys cells is still debated (reviewed by Hoffmann and Bischof, 
2002).
During thawing, ice crystals fuse to form larger crystals (a process called 
recrystallization) which can disrupt the cell membrane and causes additional 
cell damage. As the ice melts, the extracellular environment becomes 
hypotonic, and water enters the damaged cells which subsequently increases 
cell volume leading to cell membrane rupture (Theodorescu, 2004).
b. Vascular Injury
The initial response to the cooling of tissue is vasoconstriction, a decrease in 
the flow of blood and eventually the circulation ceases with freezing. During 
thawing, the circulation returns with vasodilatation. This hyperaemic response 
is brief and associated with increased vascular permeability leading to tissue 
oedema.
Cryotherapy has also shown to cause endothelial damage which results in a 
further increase in capillary wall permeability and oedema, platelet 
aggregation, and microthrombus formation resulting in stagnation of the 
circulation (Han et al. 2004). The loss of blood supply deprives all cells of any 
possibility of survival and results in tissue necrosis.
c. Apoptosis
Apoptosis is a form of cell death designed to eliminate unwanted cells through 
activation of a coordinated, internally programmed series of events. 
Biochemical features of apoptotic cells include protein cleavage, protein 
cross-linking and DNA breakdown. Apoptosis may happen in normal tissues
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such as endometrial cell breakdown during the menstrual cycle, and also 
occurs in pathological conditions including cancers, cytotoxic chemotherapy, 
heat injury and irradiation. Apoptosis is also seen after tissue freezing 
predominantly in the peripheral zone of the cryogenic lesion where the 
temperature was not sufficiently cold to kill all the cells (Hollister et al, 1998). 
Studies have shown apoptosis occurs at temperatures between 6°C and 
-10°C (reviewed by Hoffmann and Bischof, 2002), and that cells were 
susceptible to entering the apoptotic state up to eight hours after re-warming 
(reviewed by Baust and Gage, 2005).
Most of the studies examining the role of apoptosis in cold and freezing injury 
have been in vitro, and the effect of apoptosis in vivo is still unclear.
d. Immunogenic Effect
Soanes et al (1970) have suggested a possibility of an “immuno-cryothermic 
response” following a spontaneous regression of metastatic lesions in two 
men after cryotherapy for primary prostate cancer. According to this 
hypothesis, after cryosurgery, the immune system of the host is sensitized to 
the tissue destroyed by the cryosurgery. Any tissue remaining undamaged by 
the freezing insult is destroyed by the immune system during the time after 
cryosurgery.
Since then many investigators have examined the role of cryo-immunological 
response in animals, however, their results were inconsistent. While several 
studies showed immunogenic response, many showed little or no response 
and others have shown that cryosurgery increases tumour growth and 
metastasis (reviewed by Hoffmann et al, 2001).
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The role and mechanism of cryo-immunological stimulation in still unclear, 
and is currently under investigation.
1.2.2.5 Parameters of Cryosurgical Injury
Studies have shown that the degree of cryosurgical injury is a function of five 
different parameters: end tissue temperature, cooling rate, duration of 
freezing, thawing rate and number of freeze-thaw cycles.
a. End Tissue Temperature
The temperature range over which cells die is -5° to -50°C (reviewed by Gage 
and Baust, 1998). Extensive tissue damage occurs at -20°C to -30°C, but cell 
destruction is uncertain or incomplete. As explained before, I IF, which is more 
effective, occurs commonly in temperatures below -40°C. Therefore, 
temperatures between -40°C and -50°C are essential to ensure complete 
damage of all cancer cells.
b. Cooling Rate
The cooling rate should be as fast as possible to increase the potential to 
produce the more effective I IF. Studies have shown that IIF occurs over a 
wide range of temperatures, i.e. at cooling rates from 20-50 C/min, and in 
tightly packed cells even a slower cooling rate may produce intracellular ice 
(reviewed by Gage and Baust, 1998). From these variances, the cooling rate 
appears to be less critical to cell injury than other factors.
In cryosurgery, rapid freezing of the order of 50°C per minute or more occurs 
only close to a cryosurgical probe. The further away from the probe, the lower
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is the cooling rate. At about 1 cm from the probe, the cooling rate may only be 
10-20°C/min, where there is no IIF. However, experimental work in this area 
supports the view that cooling rate is not the primary factor in determining cell 
survival.
c. Duration of Freezing
Increasing the duration of freezing can allow the intracellular space to 
equilibrate with the extracellular space, thereby increasing cellular 
dehydration. Holding longer at subzero temperatures can also increase the 
amount of IIF. Increasing hold time may also allow recrystallization, whereby 
smaller ice crystals fuse to form larger ice crystals, (reviewed by Hoffmann 
and Bischof, 2002). It has been recommended that the prostate should be 
held in the frozen state for 5 minutes, although the optimum duration of 
freezing is not well defined (Baust and Gage, 2005).
d. Thawing Rate
The rate of thawing should be as slow as practical, and is best done by 
allowing the tissues to thaw passively with no assistance by heating. The 
longer the duration of the thaw, the greater the damage to the cells because 
of solute effects, ice-crystal restructuring (recrystallization), prolonged 
oxidative stress and growth of ice crystals (Schmidt et al., 1998). The large ice 
crystals that form during ‘warming’ recrystallization create shearing forces 
which disrupt the tissues.
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e. Number of Freeze-Thaw Cycles
Repeating the freeze cycle produces faster cooling and more extensive tissue 
destruction. It has been shown that repetition of freeze cycle increases tissue 
necrosis to include about 80% of the previously frozen volume (Dilley at el., 
1993). This means, in the prostate, the border of tissue destruction moves 
closer to the outer limit of the frozen volume, permitting a closer approach to 
the margins of the gland without endangering the rectum. Therefore, repetition 
of the freeze-thaw cycle is thought to be critical in the treatment of prostate 
cancer.
1.2.2.6 The Cryogenic Lesion
This is characterized by a central uniform coagulation necrosis surrounded by 
a peripheral zone in which only partial cell death has occurred. This tissue 
change develops several days after freezing. Soon after thawing, the tissue 
appears congested and hyperaemic, and becomes oedematous.
The extent of necrosis becomes evident in about 2 days. In the central zone, 
near the cryoprobe/cryoneedle, cell death is uniform, but in the border zone at 
the periphery of the previously frozen tissue, where the tissue temperature 
was 0°C to -20° C, some cells survive, other cells are dead, and others are in 
the balance between life and death. Apoptotic cells are seen in this peripheral 
zone. The process of wound repair begins in the peripheral zone in the areas 
in contact with viable tissue. Inflammatory cells infiltrate and new blood 
vessels may grow into the injured tissue. Over the following weeks or even 
months, the dead tissue is slowly replaced by fibroblasts and new collagen 
formation. The end result is a contracted healed area.
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1.2.2.7 Technique of Modem Cryosurgery
Patients undergo bowel preparation the night before the operation with a 
phosphate enema. Under general or spinal anaesthesia, the patient is placed 
in extended lithotomy position. A brachytherapy-type template, stabilised with 
a stepper, is placed in front of the perineum. A biplaner TRUS probe is used 
to image the prostate and measure its dimensions. Guided by the TRUS, the 
freezing probes are then placed (figure 1.6), the number of which depends on 
the volume of the prostate and the type of the probe used. Typically 6 freezing 
probes are used (2 anterior and 4 posterior) for the Cryocare™ system probes 
(2.4mm or 3.4mm diameter) (figure 1.7a). The recommended maximum 
distance between 2 adjacent probes ranges between 18 to <30mm, and 
probes should not be placed more than 10mm from the prostatic capsule. 
(Donnelly and Saliken, 2002; Lee et al, 1999). However, if the Seednet™ 
system is used, then more cryoneedles are required. Commonly 12-15 
cryoneedles are used divided into 3 to 4 rows with needles placed not more 
than 10mm apart and within 5-7mm of the capsule (Zisman et al, 2001) (figure 
1.7b).
Depending on the surgeon’s preference, up to 5 thermosensors are then 
placed at the level of external urethral sphincter, right and left neurovascular 
bundles, Denonvillier’s fascia and either at the apex or the middle of the 
prostate.
Once the probes are all in place, a flexible cystoscopy is performed to ensure 
that none of the probes has been placed accidently through the urethra. A 
guidewire is then placed through the cystoscope and into the bladder, 
followed by insertion of a urethral warming catheter over the guidewire.
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Freezing is then commenced by running argon gas starting in the anterior 
probes followed by the posterior group to maintain TRUS visibility throughout 
the procedure. Freezing is stopped when the temperature of the 
neurovascular bundles and the apical thermosensors reach -40°C or when the 
temperatures of the Denonvillier’s fascia or the external sphincter is 
approaching 0°C or when the edge of the iceball becomes close to the rectal 
wall indicated by TRUS picture. Both cryosurgical systems have incorporated 
treatment software which enables surgeons to pre-set endpoint temperatures 
of thermosensors and freezing stops automatically when the temperatures are 
reached. Commonly, the iceball is allowed to thaw passively; however, helium 
has also been used to facilitate thawing.
Double freeze-thaw cycles are used for effective freezing. The urethral 
warming catheter is then left for 5-20 minutes after completion to minimize the 
risk of urethral sloughing (Fahmy and Bissada, 2003; Han and Belldegrun, 
2004).
A urethral catheter is left for between 3 days to 3 weeks postoperatively.
In a long prostate, a “pull back” technique is performed where the freezing 
probes are pulled back by few millimetres and then freezing is repeated to 
cover the apex of the prostate. When the Cryocare™ probe is used, “pull 
back” is rarely performed due to longer iceball; however for the Seednet™ 
cryoneedles, the recommended prostate length at which “pull back” is 
performed varies between different surgeons ranging from 26 to 35mm 
(Witzsch et al, 2005; Zisman et al, 2001).
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Figure 1.6. View of the perineum showing both the template and TRUS probe on the stepper 
and the first cryoneedle is already placed in the prostate.
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Figure 1.7. configuration of the cryoprobes in Cryocare™ system (a) and the Seednet™ 
system (b).
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1.2.2.8 Anatomical Considerations of the Prostate During Cryosurgery
The prostate is often described as an ovoid or chestnut-shaped gland with an 
approximate length of 3cm and width of 4cm in a normal man. However, it is 
commonly larger in older men due to benign prostatic enlargement. The 
prostate has an anterior, posterior and lateral surfaces, with a narrow apex 
inferiorly and a wide base superiorly (figure 1.8).
The base of the prostate is adjacent to the base of the bladder, while the apex 
is closely related to the external urethral sphincter. During cryosurgery if the 
iceball extends below the apex, it could damage the sphincter resulting in 
incontinence. Therefore, during the procedure, a thermosensor is placed at 
the external urethral sphincter region as explained before (1.2.2.7); when the 
temperature reaches 0°C, freezing is terminated to avoid damage.
Anteriorly the dorsal vein complex separates the anterior wall of the prostate 
from the symphysis pubis. This vein complex may act as a heat source during 
freezing which may prolong the freezing process anteriorly. Osteitis pubis has 
been reported from iceball extension to the pubic bone (Seigne et al, 1996).
The prostate is closely related to the rectum posteriorly, only separated by the 
Denonvillier’s fascia which is a strong collagenous fascia enriched with elastic 
fibres and smooth muscles. During the procedure, the iceball must not be 
allowed to reach to and damage the rectum, hence, resulting in recto-urethral 
fistula formation. The surgeon monitors the iceball progression with TRUS 
and a thermosensor at the Denonvillier’s fascia (as described in 1.2.2.7).
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Laterally, the prostate is embraced by the levator ani muscle, and on the 
posterior-lateral surface of the prostate, the neurovascular bundle run on each 
side. This contains the cavemosal nerves which are responsible for achieving 
erection. During cryosurgery, the iceball is allowed to extend to and freeze 
the neurovascular bundles (-40°C) as described before (1.2.2.7) as it is a 
common site for micro-metastasis to occur. Hence, erectile dysfunction is a 
common complication after cryosurgery.
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Figure 1.8. Sagittal (a) and cross (b) sections of the male pelvis through the middle of the 
prostate demonstrating the anatomical relationships of the prostate.
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1.2.2.9 Technical Considerations of Prostate Cryosurgery
Prostates larger than 50cc are difficult to freeze effectively due to pubic arch 
interference and such patients may benefit from 3 month neoadjuvant 
androgen deprivation to reduce the target volume (Connolly et al, 1997).
Patients with a prior history of TURP are at higher risk of sloughing and 
urinary retention; hence, cryotherapy is best avoided in this group of patients 
especially when the TURP defect is large on the TRUS picture (Lam and 
Belldegrun, 2004).
There is a relative contraindication for cryotherapy in patients with significant 
symptoms of obstruction prior to treatment due to high risk of developing 
urinary retention after cryotherapy. (Lam and Belldegrun, 2004)
Patients with a history of abdominoperineal resection for rectal cancer, rectal 
stenosis or other major rectal pathology that preclude the use of TRUS are 
also not eligible for cryosurgery (Lam and Belldegrun, 2004).
1.2.2.10 Results of Prostate Cryosurgery
Short to medium-term results of recent studies of prostate cryosurgery are 
available. Derrick et al (2005) reviewed 230 patients (low-risk 34.7%, 
intermediate-risk 38% and high-risk 21.1%). After a mean follow-up of 62 
months, 64% of the patients were biochemically disease-free (PSA <0.5 
ng/ml).
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Bahn et al (2002) published their series of 590 patients, of which, 53.7% had 
high-risk disease, 30.3% had intermediate-risk and 15.9% were with low-risk 
disease. Using the American Society for Therapeutic Radiology and Oncology 
(ASTRO) definition for biochemical failure (3 consecutive PSA rises), the 7- 
years actuarial biochemical disease-free rate were 92%, 89% and 89% for the 
low, intermediate and high-risk groups respectively.
Jones el al. (2008) published the largest series of 1198 patients from the 
COLD (Cryo On-Line Data) registry which is the largest multi-centre database 
for cryotherapy patients. The overall 5-year biochemical-free survival rate 
(ASTRO) was 77.1%.
Short-term results of the Seednet™ system were published from more than 
one centre. In a multi-institutional study, Han et al (2003) presented a total of 
106 patients treated with cryotherapy, 89 of which were for primary disease. 
At 12 months, 66/89 (74%) were biochemically disease-free using PSA value 
of >0.4 ng/ml for failure.
Gowardhan et al. (2007) followed up 49 patients for a mean of 19.16 months 
after primary cryotherapy using the Seednet™ system. At 1 year, they 
achieved 59% biochemical disease-free rate using a PSA cut-off of 0.5 ng/ml 
to define biochemical failure.
Complications following cryosurgery have declined significantly with 
advancement of technology and modification of technique (Beerlage et al,
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2000). Impotence is the commonest complication of cryosurgery with the 
majority of the studies reporting a greater than 70% impotence rate, although, 
late recovery has been reported (Rees et al, 2004; Robinson et al, 2002). 
Recent series have reported rates of incontinence and recto-urethral fistula as 
between 1.3 -7.5% and 0 - 0.5% respectively (reviewed by Han and 
Belldegrun, 2004).
Urethral sloughing which may present with irritative or obstructive lower 
urinary tract symptoms, pyuria and possibly urinary retention has commonly 
been reported as occurring between 9-10% (reviewed by Rees et al, 2004). 
The incidence of prolonged perineal pain ranges from 0.4% to 12% (reviewed 
by Rees et al, 2004). The origin of the pain is not clear and may be multi­
factorial including ischaemia of the rectal wall, extravasation of urine into the 
periprostatic tissue and freezing of the local tissue (Ahmed and Davies, 2005).
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1.3 Prostate Cancer Recurrence after Radiation Therapy
As discussed earlier in the chapter (1.2.1), and despite advancements in the 
delivery of radiation therapy, a number of interventions still fail.
The aetiology of prostate cancer cell resistance to ionising radiation remains 
unclear. Theories of tumour resistance to radiotherapy include ineffective cell 
kill, pre-existing radio-resistant clones, inadequate tumour localization and de 
novo tumour development (Schellhammer et al, 1991).
For patients who have not received neoadjuvant androgen suppression 
therapy, serum PSA declines slowly after completion of RT. The time to nadir 
has been shown to be inversely proportional to disease-free survival. The 
median time to nadir in patients who remain free from failure is 22 to 33 
months.
Several different definitions of biochemical failure have been used previously, 
which has led to difficulties in deciding if or when a biochemical failure has 
occurred in an individual patient, and has also made it difficult for physicians 
and increasingly well-informed patients to interpret reported experiences.
At the American Society for Therapeutic Radiology and Oncology (ASTRO) 
Consensus Conference (ASTRO, 1997), a standardized definition of 
biochemical failure after Radiotherapy has been developed. The new 
definition defined biochemical failure as three consecutive increases in PSA
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after achieving a nadir, recommending that the PSA determinations be 3 to 4 
months apart in the first 2 years after radiation and every 6 months thereafter. 
The requirement for three readings and the temporal spacing between the 
readings are necessary to avoid overcalling failure due to “PSA bounce”, 
which is a transient PSA rise (usually < 3 ng/ml) during follow-up and occurs 
typically between 12-30 months in up to one third of the patients (ASTRO, 
1997; Merrick etal, 2002).
Recurrent disease after radiotherapy is typically a higher grade than the 
primary cancer in the majority of cases (Wheeler et al, 1993). This is thought 
to be due to time-dependent tumour progression, new tumour development or 
radiation-induced transformation (Wheeler et al, 1993).
Untreated local recurrence will usually result in the development of distant 
metastasis and ultimately death with a median survival of only 30 months 
(Hanks et al, 1989).
Treatment Options for Locally Recurrent Prostate Cancer after Radiation 
Failure
Historically, hormonal therapy was the main treatment option to control the 
disease in these men; however, early detection of recurrence, using PSA 
measurement, will render some of the patients suitable candidates for salvage 
treatment with curative intent. Selection criteria for salvage treatment include 
positive histological finding of localised disease recurrence with no evidence 
of metastasis on staging imaging (Bone and MRI scans). Salvage treatment 
options include: radical prostatectomy, cryotherapy, brachytherapy and HIFU.
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a. Salvage Radical Prostatectomy
Operating in a previously irradiated field is challenging due the associated 
vasculitis, fibrosis and loss of tissue plane, resulting in significant 
complications (see below).
Several groups reported the outcome of salvage radical prostatectomy in 
terms of oncological outcome and complications (reviewed by Ahmed et al, 
2005; Sokoloff, M. H. et al 2008). The rates of biochemical disease-free rate 
ranged between 23-55%. They showed that men with positive surgical 
margins (15.3% - 70%) and seminal vesicles involvement (40 - 50%) had 
higher biochemical failure rates.
A number of prognostic factors have been found to predict improved outcome 
after salvage radical prostatectomy including pre-radiation and pre-operative 
localised clinical stage (Gheiler et al, 1998), pre-operative PSA < 10ng/ml 
(Rogers et al, 1995), Gleason score < 7 and aneuploid tumour cells (Cheng et 
al, 1998). Bladder neck invasion has been found to correlate with poor 
biochemical outcome (Rogers et al, 1995).
Complications after salvage radical prostatectomy were common including 
incontinence 10-58%, impotence 100%, rectal injury 0-10% and bladder neck 
contracture in 11-29 % (reviewed by Ahmed et al 2005; Sokoloff, M. H. et al 
2008).
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The mean blood loss following salvage prostatectomy ranges from 1000 to 
1650ml per patient. Amling et al (1999) reported that 43% of their patients 
required transfusion post-operatively.
b. Salvage Cryotherapy
In addition to the technical aspects described for primary cryotherapy which 
was discussed earlier in the chapter (1.2.2.9), there are a few technical 
aspects that need to be addressed in relation to salvage cryotherapy. 
Complications associated with salvage cryotherapy are higher than for 
primary intervention (Bales et al, 1995; Pisters et al, 1997). This is thought to 
be due to poor vascular circulation in the surrounding tissues limiting healing 
abilities post radiotherapy (Shinohara and Carroll, 2002). Therefore, freezing 
must be stopped once the leading edge of the iceball has reached the capsule 
of the prostate (Katz and Ghafar, 2002). If the target temperature of -40 °C is 
not achieved then an additional freeze/thaw cycle can be performed (Wong et 
al, 1997). Some surgeons inject 30-50 ml of sterile saline into the 
Denonvillier’s fascia in order to separate the rectum and prostate and hence 
facilitate more adequate freezing posteriorly (Donnelly and Saliken, 2002). 
Other surgeons have found that 3 months androgen deprivation pre- 
operatively can increase the distance between the anterior rectal wall and the 
posterior prostatic capsule by few millimetres (Shinohara and Carroll, 2002) in 
addition to the overall reduction in prostate size.
In patients who had undergone brachytherapy, the seeds can mimic the 
cryoprobe ultrasonically. Therefore in this group of patients probe placing is
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more challenging. Using TRUS in the longitudinal view could help to 
differentiate between the seeds and the probes (Katz and Ghafar, 2002).
In our experience, patients with histological recurrence grade of Gleason 
score 8-10 are at high risk of pelvic lymph node involvement; therefore, pelvic 
lymph node biopsy is performed (via mini laparotomy or laparoscopy) before 
the cryotherapy in those group of patients. Patients with lymph node 
involvement are not suitable for salvage cryotherapy.
Lastly during insertion of the cryoprobe (particularly the 17 gauge needle) 
resistance might be encountered due to fibrosis (Ahmed et al, 2005).
Recent studies reported comparable cancer survival rates to salvage radical 
prostatectomy with intermediate-term biochemical disease -free rates ranging 
between 34-77% (reviewed by Ahmed et al, 2005; Ismail et al. 2007; Pister et 
al. 2008). However, they reported significantly lower complication rates than 
salvage radical prostatectomy (excluding potency) with incontinence rates
6.3-13.8% and recto-urethral fistula 0-3.4%. Erectile dysfunction is common 
after salvage cryotherapy, ranging between 62.2% and 100% (reviewed by 
Ahmed et al, 2005; Ismail et al. 2007; Pister et al. 2008). However, it is difficult 
to assess the true incidence of impotence due to salvage cryosurgery as 
several patients already have sexual impairment prior to the operation 
particularly in men on hormonal therapy.
46
Positive predictors of biochemical control include pre-operative PSA< 
10ng/ml, Gleason score of ^ 8 and postoperative PSA nadir of £ 0.5 ng/ml 
(Chin et al, 2003; Greene et al, 1998; Pisters et al, 1999).
c. Salvage Brachytherapy
Additional radiotherapy is unlikely to be effective in tumours that have already 
demonstrated radiation resistance, and it has been associated with 
substantial additional risks (Cumes et al, 1981; Wallner et al, 1990). However, 
two small series reported five-year biochemical disease- free rates of 34% 
and 53% (Beyer, 1999; Grado et al, 1999). Complications included 
incontinence 24%; lower urinary tract symptoms requiring TURP in 14%; 
rectal ulcer 4%, and 2% of patients had colostomy due to rectal bleeding. 
Larger and longer follow-up studies are required to draw conclusions on the 
efficacy and safety of salvage brachytherapy.
d. Salvage High-lntensity Focused Ultrasound (HIFU) Therapy
The principle of HIFU involves focusing high-energy ultrasonic waves emitted 
from a transducer into a small region of the prostate, which results in a sharp 
focal temperature rise to 70° -100°C within a few seconds leading to protein 
denaturation and eventually coagulative necrosis (Colombel et al, 2004). The 
procedure is performed under general or spinal anaesthetic. The ultrasound 
probe is placed transrectally inside a balloon-shape latex cooling device 
containing degassed coupling liquid to keep the temperature of the rectal wall 
below 37°C throughout the procedure.
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Using the imaging mode, the boundaries of the treatment area and the 
position of the rectum are first defined. The distance between the rectal 
mucosa and the posterior prostatic capsule is also measured. Once the data 
have been entered, the computer places the firing head in the target region 
and treatment proceeds automatically. A beam of focused ultrasound waves 
is emitted from the transducer intermittently for 3-5 seconds followed by 5 -6 
seconds gap, during which the transducer changes position. The shot creates 
an elliptical-shape elementary lesion which measures approximately 2mm in 
thickness and 10-18mm in length. The treatment continues layer by layer until 
the whole area is covered.
The role of HIFU as salvage therapy for localised recurrence of prostate 
cancer after radiotherapy has been studied in two short-term reports.
Mai lick et al (2006) reported on 50 patients treated with salvage HIFU with a 
median follow-up of 16 months. At 12 months, 54% of the patients remained 
biochemically disease-free. Complications included: incontinence 10%, 
impotence 47% and none had recto-urethral fistula.
Murat et al (2006) treated 118 patients with HIFU after failing radiotherapy 
with mean follow-up of 16.4 months. After HIFU, 84% had negative prostate 
biopsy and 62% had PSA nadir <0.5 ng/ml within 4 months. Survival free 
rates were 58%, 44% and 14% for patients with pre-operative Gleason scores 
of ^6, 7 and £8 respectively. Adverse events included recto-urethral fistula in 
3%, incontinence in 28% and bladder neck stricture in 10%.
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In a recently published study, Zacharakis et al. (2008) followed up 31 patients 
for a mean of 7.4 months after salvage HIFU. Overall, 22 of the patients 
(71%) had no evidence of disease at the last follow-up. Complication rates 
included urethral stricture (36%), incontinence (7%) and recto-urethra fistula 
(7%).
These results suggest that HIFU provided a high local control rate, but longer 
follow-up is required to determine efficacy. Complications rates were not 
insignificant.
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1.4 Thermal Properties of the Freezing Probes and their 
Iceballs
Although the development of Trans Rectal Ultrasound Scan (TRUS) 
monitoring has resulted in the rejuvenation of prostate cryosurgery, it does 
have its own limitations. As previously described in this chapter (1.2.2.5), not 
all the cells frozen by the cryoprobes subsequently die. Experiments have 
shown that to kill prostate cancer cells effectively, it is necessary to freeze the 
prostate twice to a temperature of -40°C or below (Larson et al, 2000; 
Tatsutani et al, 1996). Therefore, the inner zone of the iceball, where the 
temperature is £ -40°C is considered the lethal zone of the iceball (also called 
zone of complete necrosis). Clinically, it is important to ensure that the entire 
prostate is within the lethal zone (Ellis, 2002). This necessarily means that the 
outer non lethal zone will extend beyond the prostate. Although this zone is 
not entirely lethal to cancer cells, it has been shown that damage of normal 
tissue can still occur (Larson et al, 2000; Tatsutani et al, 1996). Damage to 
the external urethral sphincter and the rectum may be caused during prostate 
freezing, hence, it has been recommended that, in these regions, 
temperatures should not drop below 0°C (Ellis, 2002). We can conclude from 
this, that the thinner the outer zone is, the less risk of complications. In 
experimental studies, the ablative ratio (the volume of the lethal zone ice 
divided by the total iceball volume) was introduced to objectively quantify and 
compare the killing efficiency of iceballs (Rewcastle et al, 1999b). Hence, a 
higher value of the ablative ratio implies more effective killing with less 
collateral tissue damage.
50
For the reasons mentioned above, information about temperature distribution 
within the iceball is important. One limitation of ultrasound is that it does not 
provide information on the temperature within the iceball. Another problem is 
that almost all the ultrasound waves reflect off the interface between the 
frozen and unfrozen tissue (Onik et al, 1988), therefore, the surgeon becomes 
blind to any structure behind the iceball (see page 23). In addition, as the 
ultrasound signals strike the curved edge of the iceball obliquely on the lateral 
surfaces, the sound wave not only reflects but also refracts away from the 
edge of the iceball (a phenomenon called “critical angle shadowing”). This 
results in the iceball appearing to be significantly larger on the ultrasound 
image than its true size (Wong et al, 1997). Therefore, TRUS alone is not 
sufficient to monitor the progression of the iceball. This was verified in clinical 
studies by Grampsas et al (1995), who performed radical prostatectomy after 
cryosurgery. They showed that the zone of necrosis of the excised prostate is 
much smaller than predicted by per-operative TRUS. In another study, Steed 
and colleagues (1997) were able to demonstrate that operators made 
significant mistakes in predicting the subzero temperatures at the 
neurovascular bundle region by TRUS alone.
Thermocouple probes were introduced (Lee et al, 1994) to measure the real 
time temperatures of the Denonvillier’s fascia, external sphincter and both 
neurovascular bundles. This ensured adequate freezing of the prostate and at 
the same time a significant reduction in complication rates (Wong et al, 1997). 
Despite these advantages, thermocouples have not yet been unanimously 
accepted as part of the standard procedure (Rewcastle et al, 1999a). This 
may be explained by the fact that temperature mapping using thermocouples
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is prone to considerable error (Rewcastle et al, 2001). The operator must 
guess the location of the lethal temperature isotherm given knowledge of the 
iceball boundary provided by TRUS image, the cryoprobe location and 
temperature reading of the thermocouple. In addition, thermocouples only 
assess temperatures where the sensing tips are placed; therefore, inaccurate 
readings can occur with misplacement, displacement or migration of the 
thermocouple. Furthermore, the current systems allow using up to 5 or 6 
thermocouples at a time, limiting temperature monitoring to a few individual 
locations within the iceball. Lee et al (1999) performed cryosurgery on 81 men 
using 6-8 cryoprobes and double freeze-thaw cycle. Despite using 5 
thermosensors, sextant biopsy at 6 months showed that 47% of the patients 
had residual epithelial acini.
There are two available prostate cryosurgery systems available. The 
Cryocare™ system (Endocare Inc., Irvine, CA), which has two types of 
probes: the Cryo-40 (3.4mm diameter) and the thinner less invasive Cryo-44 
(2.4mm diameter). Surgeons can adjust the speed of the freezing by changing 
the rate of argon gas flow from a maximum of 100% flow to a minimum of 5% 
flow. The second system (Seednet™) produced by (Galil Medical Inc, 
Plymouth Meeting, PA) uses smaller cryo-needles (1.47mm diameter), with 
the gas flow ranging between 100% and 20%.
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In-vitro Models to Predict and Optimise Temperature Distribution around 
Cryoprobes
Several in-vitro models for thermal prediction around a single and multiple 
probes have been developed based on a finite difference formulation of bio­
heat transfer equation (reviewed by Rewcastle et al, 2001). The type of the 
probe assessed was either the outdated liquid nitrogen probe or the 3.4mm 
diameter probe. The majority of these models have not been validated 
(reviewed by Rewcastle et al, 2001). Rewcastle et al (1998) developed a 
computer model to provide a time-dependant simulation of the three- 
dimensional thermal distribution within a homogenous tissue iceball 
surrounding a single 3.4mm diameter probe. They used the thermal properties 
of water assuming their close proximity with those of soft tissue. They also 
assumed that the thermal properties remain constant and only changes below 
freezing point. They compared the temperature predictions with experimental 
data using seven thermosensors. These experiments were carried out in 1.4% 
gelatine solution at a temperature of 1.5°C. This model predicted 
temperatures with ± 4.3°C accuracy. The same group developed a second 
model to predict thermal distribution around 1, 3 and 5 cryoprobes 
configurations (Rewcastle et al, 2001). They validated the model by 
comparing temperature predictions with a limited number of thermosensors 
readings within iceballs in experimental studies carried out in similar 
conditions to the first model. All the predictions were accurate; however, one 
of the drawbacks of these experiments was that the room-temperature 
gelatine media has different thermal properties to the prostate as will be 
explained later in the chapter.
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The model of Budman and colleagues (1986) has not made accurate 
predictions at a distance more than 2mm from the probe surface. Hong et al 
(1994) calculated temperatures within an iceball given the probe temperature 
and the location of the iceball interface as determined with MRI. When they 
validated their results using experiments measuring a single point 
temperature close to the shaft of the probe, they predicted temperatures 
within 5°C accuracy. Gilbert et al (1997) determined the temperature 
distribution around a single liquid nitrogen probe placed in live rabbit liver 
using MRI. They compared the estimated temperatures with measured 
temperatures in only two regions of the iceball using thermocouples. The 
differences were within ± 1 °C. Mala et al (2001) estimated the temperature 
distribution around a single 3.2mm in diameter probe placed in a live pig liver 
using MRI. They validated their work by measuring the temperature of a 
single point within the iceball. They concluded that the median distance 
between the estimated and the measured temperature location was ±0.7mm.
Several groups have created multiple cryoprobe heat transfer models for use 
with optimization algorithm for cryosurgery planning. Jankun et al (1999) 
developed three-dimensional multiple probe algorithm called CryoSim which 
accurately predicted the location of a single probe iceball edge as verified by 
ultrasound. No comparisons for the temperature distribution within the iceball 
were made. In 2003, a newer, faster and more accurate version of the 
software CryoSim was developed by the same group (Wojtowicz et al, 2003), 
however, it was not validated.
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Baissalov et al (2000) presented a three-dimensional model for optimizing 
multiprobe prostate cryosurgery. A comparison of the predicted 0° C isotherm 
with the actual iceball boundary imaged by CT demonstrated a difference of 
±2 mm. No validation of the predicted temperature within the iceball was 
made.
In-vitro Assessment of the Temperature Distribution around Cryoprobes
A number of in vitro experiments were carried out to assess the thermal 
profile and size of the iceball of the liquid nitrogen probe (Chang et al, 1994; 
Lam et al, 1998; Popken et al, 2000; Saliken et al, 1995). The freezing media 
used were gelatine and ex vivo pig liver. Although there were discrepancies in 
the results between authors, perhaps due to different experimental conditions 
or the inconsistency in the freezing capacity of the liquid nitrogen probe which 
was observed by many urologists (Saliken et al, 2002), there was a common 
observation of differences in the characteristics of the iceball produced in gel 
and the liver tissue. The iceball in gel was larger and with a lower core 
temperature.
To date, there has been only one published study assessing the Cryocare™ 
machine probe. Hewitt et al (1997) compared the iceball of the 3.4mm 
cryoprobe (Cryo-40) with the liquid nitrogen probe using both fresh sheep liver 
at room temperature and warm water. Their conclusions were that the 
Cryocare™ system was faster than the liquid nitrogen system, but produced a 
smaller iceball in the water bath.
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Discrepancies exist between the iceball and lethal zone (temperature < -40°C) 
dimensions of the currently used cryoprobes. Table 1.4 illustrate the 
dimensions as quoted by the manufacturers (Endocare, 2005; oncura.com, 
2005). This is based on experiments carried out in gelatine medium; using a 
single probe.
Theodorescu (2004) suggested that the maximum diameter of the iceball and 
lethal zone of a single 3.4mm cryoprobes was 40 and 20mm respectively. 
Zisman et al (2001) explained the technique of prostate cryosurgery using the
1.47mm cryoneedles based on iceball radius of 13mm at 10 minutes of 
freezing. All these different measurement were based on single probe 
iceballs. However, as described previously (1.2.2.7), the technique of modern 
prostate cryosurgery involves freezing the prostate with a minimum of 6 
cryoprobes with a maximum distance between two adjacent probes of no 
more than 18mm for the Cryocare™ probes and 10 mm for the Seednet™ 
needles. Experiments have shown that the temperature distribution and 
cooling rate are different between single and multiple probe configurations. 
Saliken et al (1995) demonstrated that the iceball temperature is much colder 
and with faster cooling rate at a point between two cryoprobes than at any 
point on the same radius around a single probe. Therefore, all the studies that 
examine the dimensions of the iceball formed by a single cryoprobe are not 
applicable to clinical situation.
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Manufacturer
Cryoneedle 
(1.47mm diameter) 
Seednet™ system
Cryo-44 
(2.4mm diameter) 
Cryocare™ system
Cryo-40 
(3.4mm diameter) 
Cryocare™ system
Galil Medical*® 18x27 (8X17) 42 x 61 (20 X 35) 43 x 67 (20 X 48)
Endocare*® n/a 40 X 59 (19 X 38) 40 X 64 (19 X 43)
n/a: not available
Table 1.4 Diameter x length in mm of the iceballs and (lethal zones) according to 
manufacturers. Galil Medical® is the producer of the Seednet™ system and Endocare® 
produces the Cryocare ™ system (Endocare, 2005; oncura.com, 2005). Oncura used to have 
the ownership rights of the Seednet™ system before Galil Medical®.
In-vivo assessment of the probes is not possible since it requires a large 
number of tests, each involves accurate placement of a number of cryoprobes 
and thermosensors. In our study, we investigated iceballs of multiple probes 
in a medium that is closer to the clinically relevant tissue than gelatine. The 
choice and condition of the medium used will be discussed later in chapter 2 
(2.1.3).
Hypothesis
The properties of the iceballs formed using different cryoprobes and 
conditions of cooling may have a clinically significant impact on the efficacy of 
cryosurgery.
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1.5 Quality of Life in Early Prostate Cancer
Contemporary interpretations of health-related quality of life (HQoL) are based 
on the 1948’s World Health Organisation’s definition of health as not merely 
the absence of disease, but a state of physical, emotional and social well­
being. It includes the burden associated with specific complications, any 
impact on normal function or social roles, and a composite of other 
psychosocial domains.
Men with early prostate cancer are generally asymptomatic at the time of 
diagnosis, and treatment-related complications, such as changes in sexual, 
bowel, and urinary functions, are especially troublesome for this group (Litwin 
et al, 1999; Lubeck et al, 1997). Crawford et al (1997) reported in a survey 
the treatment goals of 1000 prostate cancer patients. Approximately 45% of 
the patients’ goal was to preserve quality of life; 29% of the men’s aim was to 
extend life and only 13% to delay progression.
HQoL is measured by self-administered instruments or questionnaires. 
Interviewer assistance may be required in answering the questions; however, 
it must be from a neutral third party. It has been shown that physicians 
typically underestimate the impact of treatment on quality of life impairment, 
perhaps because their queries are not sensitive enough or because patients 
tend to understate their quality of life impairment when speaking directly with 
physicians (da Silva et al, 1996; Litwin et al, 1998). Therefore, questionnaire 
studies of morbidities are more valuable in measuring patient’s treatment 
experience.
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In clinical practice, questionnaires are unlikely to be used routinely due to time 
restrictions. However, in a research setting they are useful tools to improve 
medical care through several ways including: improving patient’s education 
and information feedback; facilitating medical decision-making; assessing the 
overall treatment efficacy and safety; and determining whether the goals of 
treatment have been met.
The selection of a questionnaire has a significant impact on the ability of a 
study to answer a research question. HQoL instruments must be shown to 
have the following properties (Higginson and Carr, 2003):
1. Reliability: is the measure reproducible?
2. Validity: does the instrument measure the attribute it is intended to 
measure?
3. Responsiveness: is the measure sensitive to changes over time?
4. Appropriateness: are the measure’s length, format and language 
appropriate?
5. Interpretability: do the results from using the measure have clinical 
relevance?
Researcher must be pragmatic in the selection of HQoL instruments. While 
longer instrument may provide a richer database, fatigue may limit the ability 
of patients to provide useful information, a phenomenon called “response 
burden”.
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It is also preferable to collect HQoL data prospectively including baseline 
information to avoid recall bias and the disadvantages of retrospective 
symptomatic recall (Chouinard and Walter, 1995; Emberton et al, 1995).
Repeated administration of questionnaires in a longitudinal study design is 
necessary to reveal any time-dependant evolution of symptoms (Talcott et al, 
1997). Cross-sectional studies, where instruments are administered once at 
variable time after treatment, rely on direct comparisons between appropriate 
groups. It is less accurate as late toxicity following prostate cancer treatment 
may occur, which can be overlooked.
1.5.1 Early Prostate Cancer Assessment Instruments
A number of validated questionnaires are used in research to assess HQoL in 
early prostate cancer. They can be general HQoL, cancer specific or prostate 
cancer specific quality of life.
General HQoL instruments address the component of overall well-being 
including physical, emotional and social functioning. Example of a commonly 
used instrument is the RAND Short Form 36 (SF36), which is regarded as the 
“gold standard”. It has 36 items and takes less than 10 minute to complete.
Cancer specific quality of life instruments assess the impact of cancer on 
patients’ routine activities. The European Organisation for Research and
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Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ -C30) is a 
widely used instrument in oncological trials, and well-validated in most 
European languages. Another example is Functional Assessment of Cancer 
Therapies- General (FACT-G) which has 28 items and usually coupled with 
FACT- Prostate (FACT-P).
Commonly used prostate cancer specific questionnaires include FACT-P 
which is used in combination with FACT-G. EORTC-PR-25 is a more 
comprehensive questionnaire (25 items) which assesses erectile dysfunction 
(ED), bowel, urinary and toxicity from androgen deprivation. It is a new 
questionnaire, often paired with EORTC QLQ -C30, but still awaiting the 
publication of validation studies. The University of California Los Angeles- 
Prostate Cancer Index (UCLA-PCI), commonly used with SF36, is a well 
validated and comprehensive instrument which measures urinary, sexual and 
bowel function and bother. However, it does not assess irritative lower urinary 
tract symptoms (LUTS).
Two further well-validated instruments are commonly used to assess 
symptom index. The International Prostate Symptom Score (IPSS) which is a 
familiar index of LUTS, but it does not assess incontinence, haematuria or 
dysuria. The International Index of Erectile Function (IIEF) is a comprehensive 
fifteen items questionnaire measuring ED; however, it does not assess the 
effect of ED on HQoL.
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1.5.2 HQoL following Salvage Treatments for Recurrent 
Prostate Cancer after Radiation Failure
The current salvage therapies have comparable early oncological outcome 
and all have some adverse effects on either urinary, sexual and bowel 
function. Patients choosing treatment with different modalities tend to 
experience different morbidities, the significance of which may be subjective 
to each patient. The currently published studies of HQoL after salvage 
treatments are limited to one longitudinal study assessing quality of life 
following salvage cryotherapy and two cross-sectional studies comparing 
salvage treatment with other therapies.
Robinson et al. (2006) assessed quality of life in 46 men treated with salvage 
cryotherapy of the prostate following EBRT failure. Patients were invited to 
complete the EORTC QLQ-C30 and UCLA-PCI questionnaires pre- 
operatively and at 6 weeks, 3, 6, 12, 18 and 24 months follow-up. There was 
a temporary worsening of all the domain and subscale scores, which returned 
to baseline levels at 24 month, with the exception of urinary and sexual 
function scores. At 24 months, 29% of the patients reported urinary bother as 
a “moderate to big” problem, and 56% reported sexual bother as a “moderate 
to big” problem.
Tefilli et al (1998) compared HQoL of 44 men after salvage radical 
prostatectomy with 24 men who had salvage EBRT after radical 
prostatectomy. Questionnaires FACT-G and FACT-P were mailed to patients 
at variable follow-up length (mean 36.1 - 37.2 months). In addition, they used
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the Functional Assessment of Incontinence Therapy-Urinary (FAIT-U) 
instrument to assess incontinence. The only statistical differences between 
the two groups, in favour of salvage ERBT, were the physical well- being and 
urinary continence.
Anastasiadis et al (2003) compared HQoL of 89 men with primary prostate 
cryosurgery with 42 men after salvage cryosurgery for radiation failure 
recurrence. The study design was cross-sectional, patients were asked to 
complete, at least 6 months post-operatively, the EORTC QLQ-C30 and a 
prostate-specific supplementary instrument, which has been validated in a 
single institution. The time interval between surgery and completion of 
questionnaire was significantly different between the two groups (25.6 vs.
11.4 months for primary and salvage groups respectively). The overall HQoL 
scores were high in both groups, with the primary group faring significantly 
better in the physical and social functioning domains compared to the salvage 
patients. The most prominent and significance prostate- specific symptom 
was sexual dysfunction, which was equal between the two groups. Urinary 
symptoms domain was significantly worse in the salvage group.
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1.6 The Impact of Iceball Temperature on HQoL during 
Salvage Cryotherapy
Temperature of ^ -40°C is required to ensure effective ablation of the prostate, 
whereas incomplete tissue damage occurs at temperatures between 0 and 
-406C (Tatsutani et al. 1996). During prostate cryosurgery, the lethal zone of 
the iceball (£ -40°C) is allowed to cover the entire prostate. Hence, the outer 
non-lethal ice zone (0 to -40°C) extends beyond the prostate which may 
potentially damage the external urethral sphincter, cavernosal nerves 
(neurovascular bindles) and Denonvillier’s fascia resulting in urinary, sexual 
and bowel problems respectively. The severity of tissue damage is related to 
the iceball temperature; the lower the temperature, the more extensive is the 
tissue damage (Larson et al, 2000), and hence, a higher risk of co-morbidities 
and perhaps greater impact on HQoL.
The impact of the iceball temperature at the external urethral sphincter, 
neurovascular bundles or Denonvillier’s fascia during cryosurgery on the 
quality of life of the patients has not been studied before.
In our study we will assess the impact of the temperature the external urethral 
sphincter, the apex of the prostate which is closely related to the external 
urethral sphincter and Denonvillier’s fascia on HQoL of patients.
The majority of the patients have erectile dysfunction prior to the procedure, 
which will be demonstrated later, hence it will difficult to assess the effect of 
iceball temperature at the neurovascular bundles on sexual function.
If we could demonstrate that the temperature of the iceball has an impact on 
HQoL, and if we could also demonstrate, in the in-vitro iceball study, that 
different cryoprobes and conditions of cooling have an impact on the iceball
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thermal properties then we may be able to reduce the impact on HQoL of 
patients by using different freezing probes or by modifying the technique of 
procedure.
Hypothesis
Treatment variables during salvage cryotherapy can affect quality of life.
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1.7 The Specific Objectives of the Research
1 To assess the thermal distribution, and compare the dimensions of the 
total iceball and kill zone using 1.47mm cryoneedles, with 2.4 and 
3.4mm cryoprobes in vitro.
2 To measure and compare the thicknesses of the non-lethal ice zone 
from the side and the top of the iceball.
3 To measure and compare the distance between cryoprobe and the 
- 40°C isotherm (lethal ice thickness from the side of the freezing probe) 
which indicates the distance at which the cryoprobe should be placed 
away form the prostatic capsule.
4 To calculate and compare the thickness of lethal ice below the tips of 
the cryoprobes. This would indicate how far to place the cryoprobes 
from the base of the prostate.
5 To analyse and compare the cooling rate in the centre of the iceballs of 
the three different cryoprobes.
6 To estimate and compare the “kill” efficiency of the iceballs by 
measuring the ablative ratio.
7 To study the effect of slowing the argon gas flow from100% to 20% on 
the above mentioned parameters
8 To assess the HQoL changes after salvage cryotherapy for radiation 
failure prostate cancer recurrence.
9 To assess the correlation between HQoL of the patients and the iceball 
temperature at the external urethral sphincter and Denonvillier’s fascia 
during salvage cryosurgery.
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Chapter
2
Material and 
Methods
2.1 In-vitro Assessment of Three Different Cryoprobes used 
for Prostate Cryosurgery
2.1.1 Instruments
1. Cryosurgery machines:
I. Cryocare™ (Endocare Inc., 201 Technology Drive, Irvine, 
CA 92618, USA)
II. Seednet™ (Galil Medical Inc, 401 Plymouth Road, Suite 130 
Plymouth Meeting, PA 19462-1645, USA)
2. Probes (figure 2.1) (all probes are marked at 5mm interval from the tip):
a. Cryo -  44 (2.4mm diameter)
b. Cryo -  40 (3.4mm diameter)
c. Cryoneedles (1.47mm diameter)
3. Thermosensor probes, each contains:
T-type 0.07mm diameter copper/constantan alloy thermocouple 
wire (OMEGA Engineering Inc., One Omega Drive, Stamford, 
Conn 06907-0047, USA) with the following features:
•  Operating temperature range: -200°C to + 250°C
• Time response: 0.22 seconds.
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•  All thermosensors were calibrated with Fluke® 714 
thermocouple calibrator (Fluke Corp., 6920 Seaway Blvd., 
Everett, WA 98203, USA) at +50, 0 and -50°C achieving 
accuracy of ± 1 °C.
•  Thermocouple probe diameter: 1.5mm.
4. Travel Logger Thermacq data acquisition box (Dianachart Inc., 
Rockaway, NJ) connected to Compaq laptop (dv5000z). Insta-Trend 
(Dianachart Inc., Rockaway, NJ) software was used to digitally display 
the temperatures.
5. Sony digital camera (Cybershot DSC-V1) mounted on a tripod.
6. Four polyvinyl chlorine templates measuring110mm X 70mm with a 
thickness of 20mm. Further details will be discussed later (2.1.6)
7. Plastic container with internal dimensions of 150mm (W) X 90mm (D) x 
100mm (H) for the water bath used to place freezing medium.
8. Argon and helium gas cylinders (Messer Group GmbH, Otto-Volger- 
StraBe 3c, Sulzbach, D-65843, Germany) with connecting tubes and 
pressure gauges:
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I. Argon 5.0 F50 300 bar (used for freezing) with the following
specifications:
Ar > 99.999 vol %
02 < 2 vol ppm (parts per million)
N2 < 5 vol ppm
H20 < 3 vol ppm
THC < 0.1 vol ppm
C02 < 0.1 vol ppm
Cylinder size 
Valve connection 
Filling pressure 
Content
F50
NEVOC CEN 30 
300 bar 
15.3 m3
II. Helium 5.0 F50 300 bar (for thawing with the Cryocare™
machine) with the following specifications:
He > 99.999 vol %
02  < 1  vol ppm
N2 < 4  vol ppm
H20 < 3 vol ppm
THC < 0.5 vol ppm
Ne < 1  vol ppm
Cylinder size F50
Valve connection NEVOC CEN 30
Filling pressure 300 bar
Content 13.2 m3
III. Helium 5.0 L50 200 bar (for thawing with the Seednet™ 
machine) with the following specifications:
He > 99.999 vol %
02  < 1 vol ppm
N2 < 4 vol ppm
H20 < 3 vol ppm
THC < 0.5 vol ppm
Ne < 1 vol ppm
Cylinder size L50
Valve connection BS 341 no.3
Filling pressure 200 bar
Content 9.1 m3
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10. Ex vivo bovine (cow) skeletal thigh muscle as the freezing medium.
11. Special jig to hold the probes, thermosensors and the water bath 
(figure 2.2).
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Figure 2.2. Special jig holding the probes and thermosensors
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2.1.2 Setup of the Experiments
The argon and helium gas cylinders were connected to the cryomachine. The 
probes, held by the special jig, were placed into the freezing media in the 
water bath using special templates. The templates were used to place the 
cryoprobes and thermosensors in specific locations; this will be discussed 
later in this chapter (2.1.6). The cryoprobes were connected to the 
cryomachine. The thermosensors were connected to the cryomachine and to 
the Travel Logger Thermacq data acquisition box which was subsequently 
connected to the Compaq laptop. The Sony digital camera, mounted on the 
tripod, was placed in front of the laptop and cryomachine screens (figure 2.3).
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2.1.3 The Freezing Medium
Initially we intended to use animal prostate as the freezing medium. However, 
the bovine prostate does not have a solid-structure prostate and porcine 
prostate consist of two narrow cylindrical structures. Therefore, they were not 
suitable for our experiments. We reviewed the thermal properties (thermal 
conductivity and specific heat capacity) of various materials (Duck, 1990; 
Jankun et al, 1999). From table 2.1, it is obvious that cow skeletal muscle has 
thermal properties most similar to human prostate. Therefore, beef was used 
as the freezing media in all our experiments.
Material Thermal conductivity (k) 
(W m'1 K'1)
Specific heat capacity (c) 
( Jg- ’ KT1 )
Human Prostate 0.45 3.52
Cow skeletal muscle 0 .434 -0 .467 3 .4 3 -3 .81
Pig skeletal muscle 0.43 -  0.51 3.72, 3.87
Cow liver 0.488 3.37
Pig liver 0.52 3.51
Water (20°C) 0.600 4.18
Water (40°C) 0.628 4.17
2% Gelatine (20°C) 0.619 n/a
Table 2.1. Thermal properties of various medium
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2.1.4 Freezing Probes Configurations
In the operative setting, the anterior (anterior to the urethra) group of 
cryoprobes is important as it sets the pace of formation and dimensions of the 
entire iceball and is responsible for freezing the entire width of the prostate 
(Zippe, 1996). Therefore, we have designed our experiments to simulate the 
arrangements of the anterior probes. As discussed in chapter 1 (1.2.2.7), for 
the Cryocare™ system, 2 probes are regularly used to freeze the anterior 
prostate (figure 2.4 a). The recommended distance between the two probes 
has varied between surgeons, although, the commonly used distance is a 
maximum of 18mm. Therefore, we assessed each of the Cryocare™ probes 
(Cryo -40 and Cryo- 44) in a two probe configuration, using 18mm as the 
distance between the probes. For the more widely used Cryo-44 probe, we 
have carried out an additional experiment by reducing the distance between 
the two probes to 15mm, and assess the effect on all the parameters. We 
also explained in chapter 1 (1.2.2.7) that in the Seednet™ system, the 
recommended distance between two adjacent cryoneedles (probes) should 
be 10mm. The number of the probes used in the anterior group varies 
according to the size of the prostate, but commonly 8 probes are used (2 
rows X4 probes) to freeze the anterior prostate as shown in figure 2.4 b. 
Therefore, we used this configuration in assessing the Seednet™ 
cryoneedles.
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base
anterioranterior
posterior 
(cross-sectional view)
anterior
base
posterior 
(side view)
posterior 
(cross-sectional view)
anterior
posterior 
(side view)
(a) (b)
| | p  urethra
O  cryoprobe
Figure 2.4. Diagram of the prostate showing the arrangement of the cryoprobes of the 
Cryocare™ system (a) and the Seednet™ system (b).
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2.1.5 Experiments
We performed 4 experiments. In each experiment, several tests were carried 
out to measure the temperature of the iceball using a number of 
thermosensors:
1. Two cryo-44 (2.4mm diameter) probes, 18mm apart.
2. Two cryo-44 (2.4mm diameter) probes, 15mm apart.
3. Two cryo-40 (3.4mm diameter) probes, 18mm apart.
4. Eight Cryoneedles (1.47mm diameter) in a two rows X four probes
Before carrying out the experiments, we performed three freezing tests in 
water for 10 minutes, evaluating the shape and size of the iceballs to assist in 
determining the configuration of the thermosensors later on during the 
experiments. The first test was carried out on single probes using the 2.4mm 
and the 3.4mm probes with 100% gas flow rate (figure 2.5) in 20°C water. 
This showed that the 3-dimension shape of the 2.4mm probe was more or 
less a lemon-shape, while the 3.4mm is more like tear-drop. The iceball of the 
2.4mm probe was smaller than the 3.4mm probe with maximum dimensions 
(diameter X length) of 26.5 X 48.2mm and 27 X 53.1mm respectively. The 
second test was carried out on two 3.4mm probes (18mm apart) with100% 
gas flow rate in 20°C water (figure 2.6). The two iceball fused in the middle 
after 6 minutes. The maximum width and length was 45 X 55.1mm 
respectively. The last test was performed on eight 1.47mm probes (2 rows X  
4 probes) with 20% gas flow rate in 20°C water (figure 2.7). The iceball
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started fusing after 5 minutes, and at 10 minutes the maximum length and 
width measured 17.5 and 42.1mm respectively.
reiuiQG!
Figure 2.5. Iceballs of the 2.4mm (a) and the 3.4mm (b) probes with 100% gas flow rate 
in water at 20°C.
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Figure 2.6. Iceball of two 3.4mm probes (18mm apart) with 100% gas flow rate in 20°C water.
/ I
Figure 2.7. Iceball of eight 1.47mm cryoneedles with 20% gas flow rate in 20°C water.
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2.1.6 Templates
The templates were designed to allow the placement of the thermosensors in 
parallel to the freezing probes measuring the temperature between and 
around the probes. Each thermosensor has a unique identifying number. In 
experiments 1-3 (figure 2.8 to 2.10), sixteen thermosensors were used, 
divided into two groups: the first group (thermosensor 1-9) which were placed 
between the cryoprobes, were used to estimated the depth of the iceball. 
Group two (thermosensor 10-16) were placed on the outside of cryoprobe 
number 1 and they were used to assessed the width of the iceball. The 
method for calculating the width and depth of the iceball will be explained 
later in this chapter (2.1.12). In experiment 4 (figure 2.11), because of the 
larger number of cryoprobes, twenty six thermosensors were used.
The thickness of the template is 20mm; probe channels diameters were made 
only 0.1mm larger than the corresponding probes to prevent unnecessary 
shakes and probe misplacement.
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1. Template 1 (for experiment 1): Two 2.4mm probes, 18mm apart 
(Figure 2.8). The distances between each thermosensor and the 
cryoprobes are displayed in table 2.2
0  Cryoprobe 
O Thermosensor 
O Unused
Figure 2.8. Diagram of template 1
Thermosensor Cryoprobe 1 Cryoprobe 2
1 9 9
2 10.2 10.2
3 16 9.7
4 16.8 16.8
5 22.5 18.5
6 14 6
7 13 13
8 19 14
9 20.9 20.9
10 5.6 -
11 8.6 -
12 11.6 -
13 14.6 -
14 17.6 -
15 20.6 -
Table 2.2. The distances (mm) between each thermosensor and the cryoprobes of
template 1
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2. Template 2 (for experiment 2): Two 2.4mm probes, 15mm apart (figure
2.9). Table 2.3 demonstrates the distances between each 
thermosensor and the cryoprobes.
0  Cryoprobe 
O Thermosensor 
O Unused
Figure 2.9. Diagram of template 2
Thermosensor Cryoprobe 1 Cryoprobe 2
1 7.5 7.5
2 8.8 8.8
3 14 9.5
4 16 16
5 21 18.4
6 11.8 5.5
7 12 12
8 17.3 13.8
9 20 20
10 5.6 -
11 8.6 -
12 11.6 -
13 14.6 -
14 17.6 -
15 20.6 -
Table 2.3. The distances (mm) between each thermosensor and the cryoprobes of template
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3. Template 3 (for experiment 3): Two 3.4mm probes, 18mm apart (figure
2.10). The distances between each thermosensor and the cryoprobes 
are shown in table 2.4.
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Cryoprobe 
O Thermosensor 
O Unused
Fig 2.10. Diagram of template 3
Thermosensor Cryoprobe 1 Cryoprobe 2
1 9 9
2 10.2 10.2
3 16 9.7
4 16.8 16.8
5 22.5 18.5
6 14 6
7 13 13
8 19 14
9 20.9 20.9
10 5.6 -
11 8.6 -
12 11.6 -
13 14.6 -
14 17.6 -
15 20.6 -
Table 2.4. The distances (mm) between each thermosensor and the cryoprobes of template
3.
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4. Template 4 (for experiment 4): Eight 1.47mm probe in a two row X four 
probes (figure 2.11).
o o o m • • ©
o o o o m • © © ©
o o o o • <D © ©
o o o © o © • © © © © © ©
o o o o o o m • © © © © ©
o o o © o © o o o © o o o
o o o o o o o o o
o o o o o o o o o
o o o o o o o
• Cryoprobe
o Thermosensor
o Unused
Fig 2.11. Diagram of template 4. The distances between two adjacent thermosensors or 
a thermosensor and cryoprobe is 5mm horizontally or vertically and 7.1mm diagonally.
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2.1.7 Temperature Measurement
The thermosensors were connected to:
•  The cryomachine using the standard thermocouple ports and the 
cryoprobe thermocouple ports of the cryoprobe™ system (maximum 
13 thermocouples)
•  The Thermacq data acquisition box connected to the laptop 
(maximum 4 thermocouples).
The thermal distribution of the iceball was assessed by measuring the 
temperatures of several horizontal slices (5mm apart). The thermal mapping 
of each slice was assessed using a number of thermosensors as follows:
• Experiments 1 - 3:15 thermosensors were required.
•  Experiment 4: 26 and 17 thermosensors were required during the 
100% and 20% gas flow tests respectively.
Since the setup only allowed measuring the temperature of up to 17 
thermosensors at a time, each run of experiment four had to be carried out 
twice to cover the 26 points.
The temperature sensitive region of the thermosensor is located in the distal 
5mm of the probe. We decided to consider the middle point of this region (i.e. 
2.5mm from the tip) as the reference point for temperature measurement. The 
thermosensor probes were marked at 5mm intervals form this reference point.
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2.1.8 The Experiment
The following steps were followed in each experiment:
1. The beef was cut into cubes with dimensions of approximately 80mm X  
80mm X100mm. The cube was placed in water at a temperature of 50°C 
for 20 minutes to increase the temperature, and once the temperature of 
the muscle reached between 30-38°C, it was placed in the plastic 
container on its square surface. To help maintain the temperature, the 
container was filled with water at 40°C up to the upper level of the cube. 
Then, the appropriate template was placed on the container (above the 
cube) and secured in place using 2 strips of adhesive tape. Since the 
height of the cube equals the internal height of the container (100mm), 
there was no gap between the template and the cube of muscle.
2. Through the template, the freezing probes were placed 70mm deep into 
the muscle. This was to ensure that the entire iceball was contained with 
a minimum of 10-15mm margin of the cube of muscle throughout the 
experiments, as the initial experiments in water (2.1.5) suggested that 
the maximum height of the iceball is not more than 55mm.
3. For the first test, all the thermosensors were inserted into the muscle at 
the same level as the level of the cryoprobes tips (figure 2.12).
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4. The temperatures of thermosensors (digitally displayed on the screens 
of the cryomachine and the Compaq laptop) were record by taking a 
digital picture of the screens (figure 2.13). They represent pre-freeze or 0 
time temperatures. An 8X5cm white card displaying the details of the 
test was also included in each picture through out the tests. The 
temperatures displayed on the captured pictures were manually entered 
and stored into Microsoft excel database. To minimize errors in this 
process, random figures were double checked personally and by one of 
my colleagues
5. Freezing commenced by running the argon gas on full flow (100%) 
through the cryoprobes and pictures of the screens were taken at 2, 5, 7 
and 10 minutes of freezing as determined by the timer displayed on the 
cryomachines screens.
6. Once the last picture was taken, freezing was stopped and the iceball 
was thawed by running helium gas. Then all the probes were removed, 
the muscle cube was discarded.
7. Using a new muscle cube, steps 1-6 were repeated for the second test 
except step 3. On this occasion the thermosensors were placed 5mm 
above the cryoprobes tips. In test 3, the thermosensors were placed at 
10mm above the tip levels and we continued to measure the 
temperatures of all the levels above the tips of the cryoprobes until ice 
disappears (when all the thermosensors readings remain above 0°C at
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ten minutes of freezing). Using the same principle, temperature 
measurement of the levels below the cryoprobes tips was carried out. 
This completes the thermal mapping of the entire iceball.
8. All the tests were repeated but using a lower gas flow (step 5) of 20%.
After completing all four experiments, they were repeated twice more for 
verification. The gas cylinders were replaced each time the pressure dropped 
to the lowest acceptable level (220 bar) according to the manufacturer 
guidelines.
In summary (figure 2.14), each of the four experiment tests repeated three 
times. In each experiment, the temperature distribution of the iceball was 
assessed in two situations: using 100% and 20% gas flows.
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Figure 2.12. Freezing and thermosensor probes are placed inside the beef cube in the 
water bath using a special template. Two strips of adhesive tape were then used to 
secure a template in place.
[I B P R  ST A T E !
' I p r o j e o J
DENOHUimER'S T ftS lin
OENCV* l ^ N  VB
Figure 2.13. Photograph of the temperature monitoring screens of the cryomachine and the 
Compaq laptop taken before freezing. The white card displays the details of the experiment 
(2.4mm probe, 18mm apart, 100% gas flow, level 7 and first freeze)
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2.1.9 Thermal Mapping
In each test, the probe type and freezing condition is the same. Therefore, if 
we divide each template into two equal virtual halves horizontally or vertically, 
as seen in figure 2.15, we assumed that the temperature distribution of each 
half mirrors the opposite one.
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Figure 2.15. Diagram of one of the templates divided in half horizontally (a) and vertically (b) 
by imaginary lines.
92
Based on this, we mapped the thermal distribution of each level of the iceball 
using the mean temperatures at 10 minutes of freezing as follows:
1. Using Microsoft PowerPoint, the diagram of the template was placed on 
a 1 X 1 mm grid.
2. The ice-water interface temperature was considered to be 0°C.
3. When the mean temperature of a thermosensor is 0°C at 10 minutes, 
then the edge of the iceball passes through the centre of that 
thermosensor at that point.
4. More commonly, the 0°C lies between 2 adjacent thermosensors and the 
position of the iceball edge was estimated as follow:
a. We divided the two probe temperature gradient by the distance 
between the two probes in millimetres. This yields the
temperature gradient per 1 millimetre at this point.
b. The lower temperature of the two thermosensors (closer to the 
centre of the iceball) is then divided by the 1mm temperature
gradient (ignoring the negative sign). This represents the
distance (mm) at which the 0°C lies outside the centre of the 
cooler thermosensor (the most peripheral thermosensor of the 
iceball). An example is shown (figure 2.16):
As we assumed, the temperature of the thermosensor marked 
with yellow equals thermosensor number 9, and will be called 9 
in this example.
The temperature gradient between thermosensor 4 & 9 equals
11.3 -  (-7.3) =18.6. The distance between 4 &9 is:
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5mm.Therefore, the 1mm temperature gradient between 4 & 9 
is: 18.6-5 = 3.72
The lower temperature thermosensor is number 4, hence the 
distance between the iceball edge and thermosensor 4 is: 7.3 -  
3.72 = 1.96mm. Knowing that each square on the grid 
represents 1mm, the position of the iceball edge was marked.
Probe
No.
Mean 
temp, at 
10min (°C)
1 -48.4
2 -43.3
3 -32.7
4 -7.3
5 9.4
6 -51.0
7 -25.0
8 -7.9
9 11.3
10 -44.3
11 -28.2
12 -10.0
13 -0.4
14 18.0
15 23.2
Figure 2.16. Mean temperatures and thermal mapping of a single level of an iceball at 10 
minutes of freezing
I | 0 to -1 9 .9 °C  zone 
| | -20  to -39.9 °C zone 
] < -40°C  zone
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5. All the 0°C points were placed on the grid. By joining all the points 
together, we drew the iceball border at one specific level.
6. The same principle was used to graph the £ -20°C and the ^ -40°C 
isotherm within the iceball. The only modification was in step 4b, where 
-20 and -40 were subtracted from the lower temperature respectively 
before dividing it by the 1 mm gradient.
7. The 1mm temperature gradient could not be accurately measured 
beyond the most peripheral thermosensor using our method. In very few 
occasions when the iceball extended beyond thermosensor 9, we 
estimated the temperature gradient using the gradient between 4 & 9.
8. The method, described above, measuring the distance between the 0°C 
and the -40°C isotherms and the adjacent thermosensor has become the 
basis for iceball and lethal zone dimensions measurement (as will be 
described later in this chapter).
The thermal distribution of the entire iceball was obtained by combining the
entire cross-sectional levels together as illustrated in figure 2.17.
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Figure 2.17. Illustration of a 3 -  dimensional reconstruction of the thermal distribution of 
all the horizontal levels providing a model of the thermal mapping of the entire iceball.
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2.1.10 Longitudinal Views
1. Experiments 1 - 3 : two views were created for each experiment:
a. View 1: created by a plane through the cryoprobes, dividing the 
iceball into two equal halves, showing the width (W) and the length 
(L) of the iceball (figure 2.18).
(b)
Figure.2.18. Illustration of the longitudinal view 1 of experiments 1-3 iceballs showing the 
iceball plane (a) and dimensions [Width (W) and Length (L)] (b)
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b. View 2: created by a plane halfway between the cryoprobes, 
dividing the iceball into two equal halves, showing the length (L) 
and depth (D) of the iceball (figure 2.19).
Figure.2.19. Illustration of the longitudinal view 2 of experiments 1-3 iceballs showing the 
iceball plane (a) and dimensions [Depth (D) and Length (L)] (b)
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2. Experiment 4: two views were created.
a. View 1: created by a plane between the two rows, dividing the 
iceball into two equal halves, showing the width (W) and the length 
(L) (figure 2.20).
(b)
Figure 2.20. Illustration of the longitudinal view 1 of experiment 4 iceball showing 
the iceball plane (a) and dimensions [Width (W) and Length (L)] (b)
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b. View 2: created by a plane passes through the middle of both rows, 
dividing the iceball into two equal halves, revealing the depth (D) of 
the iceball (figure 2.21).
Figure 2.21. Illustration of the longitudinal view 2 of experiment 4 iceball showing 
the iceball plane (a) and dimensions [Depth (D) and Length (L)] (b)
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2.1.11 Determination of the Level of Maximum Iceball width 
and Depth
The temperatures of all the horizontal levels of the four experiments were 
recorded and a thermal map of each level was created from the 10 minutes 
mean temperatures as described before (2.1.9). From these thermal maps, 
the horizontal levels at which the maximum dimensions (widths and depths) of 
the iceballs occurred were determined. From the horizontal thermal map, 
longitudinal views were created for ail the iceballs as explained before in the 
chapter (2.1.10). The maximum dimensions levels could also be concluded 
from these views.
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2.1.12 Measuring the Maximum Dimensions of the Iceball
a. Width
The maximum width of the iceball at this level was measured at the maximum 
dimension level as follows:
1. Experiments 1 -  3 (figure 2.22):
o °  ® o
o
Figure 2.22. An example of the thermal distribution of a single iceball level of experiments 
1-3. The width (W) = a+b+c
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•  Width (W)= a + b + c
•  (a) equals the distance between thermosensor (12) (in this
example) and cryoprobe (1) (this distance is known as discussed 
before in 2.1.6) + the distance between the edge of the iceball 
and thermosensor (12) (can be calculated as described before in 
(2.1.9) point 4.
•  (b) is the distance between the cryoprobes which is known.
•  (a) was assumed to equal (c) (as explained before in 2.1.9).
Therefore, Width (W) = (2 X a) + b
•  Using the same rules, the width of the lethal zone (^ -40°C or the 
purple colour) was measured.
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2. Experiment 4 (figure 2.23):
Figure 2.23. An example of the thermal distribution of a single iceball level of experiment 4. 
The width (W)= a+b+c
The same principle of previous experiments was used to measure (W), 
knowing the distance between 2 adjacent thermosensors is 5mm.
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b. Depth
Depths of the lethal and total ice (figure 2.24) were measured across the 
centre of the iceball, at the maximum dimension level in similar way to the 
width. However, the distance between 2 adjacent thermosensors was 5 mm in 
all experiments.
In experiments 1 and 3 at 100% gas flow and experiment 2, the edge of the 
iceball (0°C isotherm) extended just beyond thermosensor 9. Hence, the 1 mm 
temperature gradient and subsequently the distance between iceball edge 
and thermosensor 9 could not be precisely calculated. In these situations, we 
estimated the distance between the edge of the iceball and thermosensor 9 
using the 1 mm temperature gradient between thermosensor 4 and 9. All the 
lethal zones remained within the thermosensor coverage area.
0 0 0 (9 ) 0  0
Figure 2.24. An example of the thermal distribution of a single iceball level of experiments 
1-3. The depth (D) = a+b+c
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c. Length
The length (L) demonstrated in the longitudinal views, was calculated by 
measuring the length of the longitudinal axis passing through the centre of the 
iceball:
1. Experiments 1-3 (figure 2.25)
The centre of the iceball is located at thermosensor number 1.
Figure 2.25. An example of the longitudinal view thermal distribution of experiments 1-3 
iceball. Length (L) = a + b + c
•  Iceball length equals a + b + c.
• b equals to the number of levels X 5mm. a & c are the distances 
between the upper and lower edges of the iceball and the first and the 
last horizontal levels within the iceball respectively at thermosensor 1. 
These distances are located in a similar way as described in thermal 
mapping point 4.
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2. Experiment 4
Similar principle was used in this as for the other experiments, 
however, the centre of the iceball passed through thermosensor 
number (4) instead.
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2.1.13 Anterior Prostate Dimensions
As explained previously in the chapter (2.1.4), we have assessed and 
compared the iceballs and the lethal zones of the anterior group of probes. In 
order to assess the adequacy of these dimensions, we have compared the 
iceball dimensions with dimensions of the anterior part of 40 patients’ prostate 
that underwent cryosurgery of the prostate following radiotherapy failure. 
These dimensions, which will be presented in the next chapter (3.1.4), were 
measured as illustrated in figure 2.26 using TRUS. The measurements were 
then compared with corresponding iceball and lethal zone dimensions.
anterior
posterior
anterior
posterior
(a) (b)
Figure 2.26. Diagram (top) and ultrasound (bottom) pictures of the prostate demonstrating the 
dimensions of the anterior part of the prostate. In the cross-sectional view (a), the depth (D) 
represented the distance between the anterior prostatic capsule and the urethra. The width 
(W) was the distance between the sides of the prostate at the mid point of the depth. In the 
side view (b), the length (L) measured from the distance between the base and apex of the 
prostate.
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2.1.14 The Distance between the Cryoprobe and the Edge of 
the Lethal Zone
The length between the centre of the cryoprobe and the edge of the lethal 
zone (figure 2.27) determines the maximum distance at which cryoprobes can 
be placed away from the edge of the capsule. This distance was assessed at 
the maximum iceball dimensions level using the principles of measurement 
method described before in this chapter (2.1.12).
Figure 2.27. Illustration of the longitudinal view of the iceball. The red arrow represents 
the distance between the cryoprobe and the edge of the lethal zone.
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2.1.15 The Thickness of the Non-Lethal Ice Zone
The outer zone of the iceball, where the temperature ranges between 0 and 
-39.9°C, is considered the non-lethal zone. We have measured the thickness 
of this zone using the same principles as described before (2.1.12) in three 
places (Fig. 2.28)
Figure 2.28. Illustration of the longitudinal views of the iceball. Arrow number 1 stands for 
the thickness of the non-lethal zone on the side of the iceball across the width. Arrow 2 
represents the non-lethal zone thickness across the depth of the iceball. Both 1 and 2 
were measured at the maximum dimensions level. Arrow 3 represents the non-lethal 
zone thickness at the top of the iceball, midway between the cryoprobes.
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2.1.16 The Length of the Lethal Iceball below the Tip of the 
Cryoprobes
This length was measured through the central longitudinal axis of the iceball 
using the same principle described before in the chapter (figure 2.29).
The level of 
cryoprobes tips
Figure 2.29. Illustration of the longitudinal view of the iceball. The arrow represents the length 
of the lethal ice below the level of cryoprobes tips.
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2.1.17 Cooling Rate
Although the cooling rate does not appear to be a critical factor for cell injury, 
as explained in chapter 1 (1.2.2.5), it is still a valuable tool to compare the 
efficiency of iceball formation. The cooling rate of each iceball was measured 
in the centre of the iceball (corresponding to thermosensors 1 for experiments 
1-3 and 4 for experiment 4 at the maximum dimensions (width and depth) 
horizontal level. We have compared the cooling rates (degree/minute) of the 
first 5 minutes of freezing by using the 0 -5 minutes temperatures gradients.
2.1.18 Ablative Ratio
This is a tool used to quantify the efficiency of iceball and is estimated by 
dividing the lethal zone volume by the total iceball volume (Rewcastle et al, 
1999b). The higher the value of the ablative ratio, the more effective the killing 
and the less collateral damage is likely to occur.
There is no validated formula which can used to measure the volume of the 
iceball or the lethal zones since they both have irregular shapes. In our 
experiments, the iceballs were intended to cover half of the prostate in the 
majority of the cases and from examining longitudinal views of the iceballs 
and the shape of the iceball in water, there were similarities between the 
shape of the iceball and the prostate. Based on these factors, we have used 
the same prostate volume measurement formula to assess the volume of the 
total iceball and lethal zones. In clinical practice, several methods have been 
described to measure the prostate volume using TRUS. The step-section
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planimetry method is regarded the most accurate (Terris and Stamey, 1991). 
In this method, the prostate is divided into several sections; the volume is 
measured by taking the sum of the prostate sections surface areas multiplied 
by the inter-section interval. This method is time consuming, and requires 
operator experience and cumbersome equipment; therefore, it is not 
commonly used in clinical practice (Littrup et al, 1991). We did not consider 
using this method in our study because it relies on outlining the boundary of 
the iceball to measure the surface area at each section, which we were 
unable to achieve accurately using our methodology. TRUS could have been 
used to assess the boundaries of the total iceball but not the lethal zone. 
Several formulas have been examined to measure prostate volume using 
TRUS (Aarnink et al, 1996; Eri et al, 2002; Littrup et al, 1991; Terris and 
Stamey, 1991) including:
1. Prolate ellipsoid: volume= (width X depth X length) X Jl/6 (most 
commonly used in clinical practice).
2. Spherical: volume= (diameters)3 X Jl/6
3. Prolate spheroid: volume= (major axis)2 X (minor axis) X Jl/6
4. Spheroid: volume= [(length + width + length)/3]3 X Jl/6
5. Quick spheroid: Volume= [(length + width)/2]3 X Jl/6
Although the prolate ellipsoid formula is probably the most commonly used in 
practice, it has been challenged and shown to be less accurate than the 
prolate spheroid and the spheroid formulas (Aarnink et al, 1996; Terris and 
Stamey, 1991). However, it was believed that the inaccuracies are caused by 
errors in the measurement of primarily the length and then transverse
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diameter (Terris and Stamey, 1991; Yip et al, 1991). Nathan et al (1996) 
concluded that these errors resulted from operators’ failure to locate the 
maximum diameters image for each dimension on the TRUS. When the 
measurements are accurately taken, then prostate volumes calculated from 
prolate ellipsoid formula correlate better with the step planimetry technique 
than other methods (Dahnert, 1992; Nathan et al, 1996). Therefore, we have 
used the prolate ellipsoid formula to estimate the volumes of the iceball and 
lethal zone for each experiment.
2.1.19 Statistical Analysis
Data are expressed as means (standard deviation). For each parameter at 
100% gas flow, comparisons were made between the means of the four 
experiments using the one way analysis of variance (ANOVA) with 95% 
confidence intervals to determine if there was a significant difference between 
the means. If differences were present, then we used the Least Significant 
Difference (LSD) (as the pos hoc test) to compare the means against each 
other. Comparisons were also made between the means of the 100% and 
20% gas flow parameters using independent samples t-test. We considered a 
P value of ^ 0.05 to be significant for all the statistical tests.
We also measured the coefficient of variation (CV) within each experiment 
and between the experiments for all the data. It was measured by dividing the 
standard deviation to the mean, and was presented as percentage. The CV 
provides a relative measure of data dispersion compared to the mean, with 
the smaller the CV value, the less scattered the data is around the mean.
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2.2 Treatment Protocol for Salvage Cryotherapy
The technique of and technical considerations during primary and salvage 
cryotherapy have been described before (1.2.2.7, 1.2.2.9 and 1.3.). The 
protocol for salvage cryotherapy is summarised in figure 2.30.
All patients were thoroughly assessed with history, clinical examination and 
transrectal ultrasound scan. Prostate biopsy was performed on all patients; 
patients with positive histology were investigated with pelvic MRI and bone 
scan. Pelvic lymph nodes biopsy was performed if the lymph nodes were 
enlarged on MRI scan and/or when the prostate biopsy Gleason was =>8. 
Patients were suitable if the prostate biopsy was positive for recurrence, MRI 
indicated disease stage <T3b (no seminal vesicles involvement), negative 
bone scan and no pelvic lymph nodes involvement. Previous history of TURP 
was considered a contraindication for cryotherapy if they had a large residual 
TURP defect on TRUS. Cytoreductive androgen deprivation was given to 
patients with prostate volume larger than 40cc. Following cryotherapy, 
ciprofloxacin was prescribed for 1 week, an indwelling urethral catheter was 
used for 2 weeks and patients were prescribed alpha-blockers for 4 week. 
Patients with rising PSA after salvage cryotherapy underwent a repeat 
prostate biopsy which if positive underwent repeat cryotherapy. If the biopsy 
showed no evidence of residual malignant tissue, patients were treated with 
androgen deprivation.
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No
Yes
Positive
egative,
Cryotherapy
Androgen
deprivation
Androgen
deprivation
Repeat Cryotherapy
Suitable
Androgen deprivation 
(Selected cases)
Repeat prostate biopsy 
(Patients with rising PSA)
Pelvic lymph nodes biopsy (selected cases)
Three consecutive PSA rises after radiation
therapy
Bone scan 
Prostate volume (TRUS)
Assessment: 
Prostate biopsy 
Pelvic MRI
Figure 2.30. Summary of treatment protocol of salvage cryotherapy
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2.3 HQoL Study Design and Questionnaires Selection
The study was intended to assess HQoL changes after salvage cryotherapy 
for recurrent prostate cancer post-radiation therapy using a number of 
questionnaires in a longitudinal study design.
2.3.1 Study Design
A prospective longitudinal study collecting data to measure various outcomes 
to assess the impact of salvage cryotherapy on men with locally recurrent 
prostate cancer and their partners. Figure 2.31 summarises the study design
Consent and Collection of Clinical Data
Baseline (Pre -Cryotherapy) Questionnaires
Patients Eligible for Salvage Cryotherapy
Study completed at 24 months
Follow-up Questionnaires at 6 wk,3,6,9,12,18 & 24 months 
PSA progression and recurrence recorded prospectively
Figure 2.31. Summary of HQoL Study Design
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2.3.2 Study Population
Men who were suitable for and choose salvage cryotherapy (1.2.2.9 and 1.3), 
with or without partners, were invited to take part in the study. Patients were 
excluded from the study if: they received androgen deprivation therapy before 
cryotherapy only, received androgen deprivation after cryotherapy only, and 
patients who had repeat cryotherapy. All patients were recruited from 2 
centres in Guildford, Surrey (one surgeon): The Royal Surrey County 
Hospital, Egerton Road, GU2 7XX (NHS) and The Mount Alvernia Hospital,
46 Harvey Road, GU1 3LX. (private).
Patients were excluded from the study if they failed to complete their baseline 
questionnaire after a reminder.
2.3.3 Questionnaires
A series of questionnaires (summarised in table 2.5) were used to assess 
various aspects of HQoL and symptoms following salvage cryotherapy. These 
were combined with a further questionnaire collecting data on concurrent 
treatment for erectile dysfunction, urinary retention and health services usage. 
The questionnaire booklet is reproduced in appendices B and C.
118
Name Type Items Assesses Notes
EORTC QLQ C30
(Aaronson et al, 
1993)
Cancer 
specific QoL
30
Cancer 
specific QoL
Well validated and widely 
used in oncological trials
EORTC PR-25
(Aaronson and Van 
Andel, 2001)
Prostate 
cancer 
specific QoL
25
ED, bowel, 
urinary and 
toxicity form 
androgen 
deprivation
Comprehensive, suitable for 
localised and metastatic 
prostate cancer. Awaiting 
full validation.
IIEF
(Cappelleri et al, 
1999)
Symptom
index
15 ED Well validated
IPSS
(Barry and O'Leary, 
1995)
Symptom
index
8 LUTS Well validated and familiar
TPSM
(Cliff and
MacDonagh, 2000a)
Paired 
patient and 
partner
10
Cancer 
distress and 
social impact
Validated and previously 
used in UK prostate cancer 
trials
ED-EQoL
(Meyer et al, 2003)
Symptom 
specific QoL
15
Impact of ED 
on QoL
Validated specific measure
Table 2.5. Questionnaires used in the health related quality of life study.
European Organization for research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ-C30), Quality of Life (QoL), EORTC Prostate-25 (EORTC PR-25), Erectile 
Dysfunction (ED), International Index of Erectile Function (IIEF), International Prostate 
Symptom Score (IPSS), Lower Urinary Tract Symptoms (LUTS), Taunton Psychosocial 
Morbidity questionnaire (TPSM), Erectile Dysfunction Effect on Quality of Life questionnaire 
(ED-EQoL).
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2.3.4 Questionnaires Administration
All questionnaires, except the IIEF and ED-EQoL, were administered prior to 
operation (baseline) and at 6 weeks, 3, 6, 9, 12, 18, and 24 months post- 
operatively. The IIEF and ED-EQoL questionnaires (assessing sexuality) were 
administered less frequently at baseline and at 6 ,12 ,18  and 24 months post- 
operatively to reduce “burden response” where fatigue from completing 
lengthy questionnaires may limit the ability of patients to provide useful 
information. The arrangement of administering sexuality questionnaires 6 
monthly was based on observations from the ongoing trial of quality of life 
assessment following early prostate cancer treatment where no significant 
changes in sexuality were observed in 3 months period (personal 
communication Prof. S. E. Langley). The baseline questionnaires (before 
cryotherapy) were handed to patients after obtaining consent. The post­
operative questionnaires were mailed to the patients, with a stamped 
addressed return envelope, 1 week prior to the due date. The TPSM partners’ 
questionnaires were sent in a separate envelope.
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2.3.5 Scoring of Questionnaires
EORTC QLQ C30 version 3.0
The QLQ-C30 is composed of both multi-item scales and single-item 
measures. These include five functional scales, three symptom scales, a 
global health status /  QoL scale, and six single items. Each of the multi-item 
scales includes a different set of items (table 2.6).
Scale Number 
of items
Item
range*
Version 3.0
Item numbers
Function
scales
Global health status / QoL
Global health status/QoL QL2 2 6 29,30
Functional scales
Physical functioning PF2 5 3 1 to 5 F
Role functioning RF2 2 3 6 ,7 F
Emotional functioning EF 4 3 21 to 24 F
Cognitive functioning CF 2 3 20, 25 F
Social functioning SF 2 3 26,27 F
Symptoms scales /items
Fatigue FA 3 3 10,12,18
Nausea and vomiting NV 2 3 14,15
Pain PA 2 3 9,19
Dyspnoea DY 1 3 8
Insomnia SL 1 3 11
Appetite loss AP 1 3 13
Constipation CO 1 3 16
Diarrhoea Dl 1 3 17
Financial difficulties FI 1 3 28
Table 2.6. Scoring the EORTC QLQ-C30 version 3.0
* Hem range is the difference between the possible maximum and the minimum response to 
individual items; most items take values from 1 to 4, giving range = 3.
All of the scales and single-item measures range in score from 0 to 100. A 
high scale score represents a higher response level.
Thus a high score for a functional scale represents a high / healthy level of 
functioning; a high score for the global health status / QoL represents a high
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QoL, but a high score for a symptom scale /  item represents a high level of 
symptoms / problems.
The principle for scoring these scales which is described in the EORTC QLQ 
C-30 manual is the same in all cases (Fayers et al, 2001):
1. Estimate the average of the items that contribute to the scale; this is the 
raw score.
2. Use a linear transformation to standardise the raw score, so that scores 
range from 0 to 100; a higher score represents a higher ("better") level of 
functioning, or a higher ("worse") level of symptoms.
In practical terms, if items /*, h , ... In are included in a scale, the procedure is 
as follows:
1. Raw Score = RS= (h + h + In )n
2. Linear transformation: apply the linear transformation to 0-100 to obtain 
the score S,
For the Functional scales:
(RS — 1) >
S= 1 -----------------
range
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For the Symptom scales I items and Global health status I QoL:
S = {(RS -1 ) range} *100
Examples:
Emotional ftmctioning RmvScore = (Q21 +Qyy+Q21+  Q24 )/4
EF Score -  {l -  {RmvScore — l)/3}x 100
Fatigue RmvScore = (Ql0 + On + Q1S )/3
¥ A  Score = ^RmvScore -  l)/3}x 100
These algorithms have been included in a program produced by Fayers et al 
(2001) to process the EORTC QLQ C-30 raw data into symptom scales using 
the SPSS statistical package.
The clinical significance of QLQ-C30 score changes was assessed by Osoba 
et al (1998) using the Subjective Significance Questionnaire (SSQ). The SSQ 
asks patients about perceived changes in physical, emotional, and social 
functioning and in global QoL, using a 7-point scale ranging from ‘much 
worse’ over ‘no change’ to ‘much better1. Patients who reported ‘a little’ 
change for better or worse on a particular scale (function or symptom) had 
QLQ-C30 changes about 5 to 10 %.Those reporting ‘moderate’ change had 
changed about 10 to 20%, and ‘very much’ change corresponded to a change 
> 20%.
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EORTC PR-25
Full validation of the PR-25 is still ongoing. Factor analysis, discriminant 
validity and test-retest reliability have been assessed and published in a 
summary form indicating all were satisfactory (Aaronson and Van Andel, 
2001). The PR25 has been used in HQoL studies published in international 
journals (Davison and Goldenberg, 2003; Lintz et al, 2003). The EORTC has 
provided a tentative scoring system for the questionnaire, unlike the QLQ C- 
30. Formal scoring manual may become available in the near future. The 
current available scoring system divides the questionnaire into 5 separate 
multi-items scale as shown in table 2.7.
Scale Number 
of items
Item
range
PR25
Item numbers
Symptoms scales /  items
Urinary Problems UR 8 3 1 to 7 and 9
Urinary Incontinence Ul 1 3 8
Bowel Symptoms BS 4 3 10 to 13
T reatment Symptoms TS 6 3 14 to 19
Sexual Activity SA 2 3 20, 21
Sexual Functioning SF 4 3 22 to 25
Table 2.7. Scoring the EORTC PR-25
It is assumed that items 1 to 9, excluding 8, forms a multi-item scale 
assessing urinary function. Item 8 is for patients using an incontinence device, 
hence not relevant to all patients.
Items 10 to 13 and 14 to 19 are assumed to represent multi-item scales 
addressing bowel function and treatment-related symptoms respectively.
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The scoring of the multi-scale and individual items (1 to 19) is such that the 
higher scores represent the more problems/symptoms.
It is hypothesised that two scales assess sexual function: the first scale 
comprises of items 20 and 21 is for all patients and the second scale 
comprises items 22 to 25 which is conditional for sexually active patients only. 
The scoring of the sexual function scales is such that the higher the score 
represent the higher (better) sexual functioning.
International Prostate Symptom Score (IPSS)
The IPSS is a well-validated 7-item instrument to assess LUTS, excluding 
incontinence (Barry et al, 1992). Each of the 7 items has six possible 
answers; items 1 to 6 answers range from “not at all” scoring 0 to “almost 
always” scoring 5. While the seventh item, which addresses nocturia, score 
ranges from 0 for “none” to 5 for “5 times or more”. The total IPSS score 
ranges between 0 and 35; patients scoring 0 to 7 are mildly symptomatic, 
those who scores 8 to 19 have moderate symptoms and a score of => 20 
indicates severe LUTS. IPSS scores will be expressed as a continuous 
variable and changes of more than 3 points considered clinically significant 
(Barry and O'Leary, 1995).
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International Index of Erectile Function (IIEF)
The IIEF is self-administered tool to assess ED in both clinical and research 
setting (Rosen et al, 1997). It has 5 multi-item domains with a total of 15 
items; each item has either 5 or 6 possible answers (table 2.8).
Domain Items Score Minimum 
range score
Maximum
score
Erectile Function (EF) 1,2,3,4,5,15 0 (or 1) -5 1 30
Orgasmic Function (OF) 9,10 0-5 0 10
Sexual Desire (SD) 11,12 1-5 2 10
Intercourse Satisfaction (IS) 6,7,8 0-5 0 15
Overall Satisfaction (OS) 13,14 1-5 2 10
Table 2.8. The IIEF questionnaire domain scoring
An abridged five-item version (IIEF-5) was developed to identify the presence 
and severity of ED. This comprises of items 2, 4, 5, 7 and 15 of the original 
IIEF. Both versions have been extensively validated in heterosexual patients 
(Rosen et al, 1997; Rosen et al, 1999). The scoring of IIEF-5 ranges between 
1 and 25 (the lower the score the more significant ED), based on which, five 
severity classes of ED has been developed as demonstrated in table 2.9 
(Rosen et al, 1999). The table suggests that a change in the score of 4 points 
would be clinically significant, and men are considered potent if they score £ 
12. The scores of IIEF were expressed either as mean scores or percentage 
of each severity class of ED.
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ED severity IIIEF-5 score
Normal 22-25
Mild ED 17-21
Mild-Moderate ED 12-16
Moderate ED 8-11
Severe ED 1-7
Table 2.9. Severity classes of ED according to IIEF-5 score.
Taunton Psychosocial Morbidity Questionnaire (TPSM)
This questionnaire assesses psychological morbidity in patients with prostate 
cancer and in their partners. It comprises of 2 multi-item scales and five single 
items (Cliff and MacDonagh, 2000a). The scoring of each subscale or item, 
which is demonstrated in table 2.10, will be expressed as a continuous 
variable. The higher the score the more is the distress or worry. The primary 
end point of interest is the general cancer distress subscale for both patients 
and partners. Cliff and MacDonagh (2000b) defined the mean differences of 
the items and scales scores between morbid and non morbid patients (shown 
in table 2.10) after comparing the scores with the Hospital Anxiety and 
Depression Scale. They also concluded that people with scores of £ 4 on the 
general cancer distress subscale can be classified as morbid.
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Scales/Items Score
range
Mean score 
difference 
between morbid 
and not morbid
General cancer distress 0 -1 2 3.7
Fear of diagnosis 0 - 4
Future worries 0 - 4
Emotional distress 0 - 4
Social Subscales 0 - 8 2.3
Social functioning 0 - 4
Role functioning 0 - 4
Items
Worry from pain 0 - 4 0.7
Worry from urinary symptoms 0 - 4 0.9
Worry from physical limitation 0 - 4 0.6
Worry from treatment 0 - 4 0.9
Worry from sex 0 - 4 0.8
Table 2.10. Score range and the mean scoring difference between morbid and non morbid 
patients of the Taunton Psychosocial Morbidity questionnaire domains
Erectile Dysfunction Effect on Quality of Life (ED-EQoL)
This is a validated questionnaire which comprises 15 questions (items), each 
scoring between 0 and 4. The scoring of the ED-EQoL, which represents the 
total of the 15 items scores, is such that the higher the score the more effect 
on QoL. Based on this, three groups of patients have been identified: men 
with ED-EQoL total score <15  have mild impact of ED on QoL; score 15-29 
represents a moderate effect on QoL and scores >30 represent severe effect 
on QoL (MacDonagh et al, 2002; MacDonagh et al, 2004).
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2.3.6 Statistical Analysis
A power calculation (table 2.11) was determined by comparing baseline and 
follow-up data from the first 10 patients using paired t-test with p-value of 
<0.05 to determine significance and allowing 80% power. The comparison 
was based on the most important and sensitive domains of well validated 
questionnaires which are the global health status domain of the EORTC QLQ- 
C30 and the IPSS. Although the IIEF-5 is well validated, it was not used in 
power calculations as the number of patients who are expected to be potent 
at baseline was small. From the first 10 patients’ data, only one patient had 
IIEF-5 score of >12 (potent), therefore in order to assess the impact of 
salvage cryotherapy on the potent men, significant number of men is required 
to achieve the required 18 potent men (table 2.11). This will significantly over­
power and delay the study with a huge increase in the workload of data 
collection and cost.
We aimed to assess the outcome by comparing follow-up with baseline data 
using paired t-test using p-value of 0.05 to determine significance. The study 
is currently ongoing; therefore, we present preliminary results without 
statistical analysis as recruitment is incomplete.
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Name Key
endpoint
Minimum clinically 
significant change in 
score
Estimated
mean
difference
Estimated 
SD of 
difference
Number of 
patients 
required to 
achieve 80% 
power
EORTC
QLQ-C30
Global 
. HQoL
5-10%  = little 5 17 91
10 - 20%= moderate 10 17 23
>20% =very much 20 17 6
EORTC
PR-25
Urinary
problem
Unknown but likely to be 
similar to QLQ-C30
As above As above As above
IIEF Change in 
IIEF-5
4 points 4 6 18
IPSS Change in 
symptoms 
scale
4 points 4 7.7 29
TPSM General
cancer
distress
Unknown. Mean score 
difference between 
morbid and non morbid 
ranges between 0.6 to 3.7
1 2.0 32
ED-EQoL ED QoL Unknown - - -
Table 2.11. Quality of life instruments, key endpoints and power calculations measured based 
on the first 10 patients data.
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2.4 The Impact of Iceball Temperature on HQoL during 
Salvage Cryotherapy
Operative data were collected from patients taking part in the HQoL study. 
The lowest temperature measured by the thermosensors at the external 
urethral sphincter, the apex of the prostate and the Denonvillier’s fascia were 
recorded.
The following HQoL domains/items were assessed: global health status 
domain of the EORTC QLQ C30 questionnaire; urinary problem scale and 
urinary incontinence question of the EORTC PR25; IPSS and the quality of 
life question of the IPSS questionnaire. The differences between the 6 week 
and the baseline scores of these domains/items were calculated to measure 
the impact on HQoL.
2.4.1 Statistical Analysis
Two-tailed bivariate correlation test with Spearman correlation coefficient was 
used to compare the lowest temperature at each point with the baseline - 
6weeks differences in the HQoL domains/items scores. P-value of <0.05 was 
used to consider significance.
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Chapter
3
Results
3.1 In-vitro Assessment of Three Different Cryoprobes 
Used for Prostate Cryosurgery
Temperatures of all the horizontal slices of the four experiments were 
recorded and thermal mapping of each level was created from the 10 minutes 
mean temperatures (appendix A). Maximum dimension (widths and depths) 
levels of the iceballs (Table 3.1) were determined as discussed in chapter 2 
(2.1.11). This showed that for the 2.4mm and 3.4mm diameter probes, the 
maximum iceball dimensions level was 10-15 mm above the tip of the probes 
(level 8 &9); however it was only 5mm above the tip of the 1.47mm diameter 
probe.
From the horizontal levels thermal mapping, longitudinal views were created 
(figures 3.1 to 3.8) for all the iceballs as described before in the chapter 2 
(2.1.10). None of the thermosensor temperatures in experiment 4 iceball 
reached -40 C° or below at 20% gas flow rate, hence, the iceball was 
considered to be devoid of a lethal zone. Therefore, we considered the 
measurements to equal zero in calculating the maximum iceball dimensions. 
However, when measuring the non-lethal ice thicknesses and the lethal ice 
thickness below the tips of the probes, we regarded the measurements “Not 
Applicable” (n/a) rather than zero to avoid the wrong impression that lethal ice 
is present, and in this situation, statistical tests were not carried out.
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Experiments 100% gas flow
20% gas 
flow
1
(2.4mm, 18mm apart) 8 9
2
(2.4mm, 15mm apart) 8 8
3
(3.4mm, 18mm apart) 9 8
4
(1.47mm, 10mm apart) 10 10
Table 3.1. The corresponding levels at which maximum dimensions (width and depth) of 
the iceballs of each experiment took place.
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2.4m m /18m m
L e v e l
(view 1)
2.4m m /18m m
L e v e l  4
(view 2)
Figure 3.1. Reai-size longitudinal thermal mapping views of experiment 1 iceball at 100% gas 
flow.
: i 0 to -1 9 .9 °C  zone 
1 -20  to -3 9 .9  °C  zone 
1 < -40°C zone
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2.4m m /18m m
L e v e l  5
(view 1)
20%2.4m m /18m m
' e l  2
L e v e l  4
L e v e l  11
Level 1
(view 2)
Figure 3.2. Real-size longitudinal thermal mapping views of experiment 1 iceball using 20% 
gas flow.
-20 to -39.9 °C zone
< -40°C zone
0 to -19.9:’C zone
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2.4m m/15mm
L e v e l  1
L e v e l  2
L e v e l  3
L e v e l  4
Levels
L e v e l  6
L e v e l  7
L e v e l  8
L e v e l  1 0
L e v e l  1 1
I e v e l  1 2
L e v e l  1 4
(view 1)
100%
L e v e l  4
L e v e l  6
I e v e l 7
L e v e i 8
L e v e l s
L e v e l  11
L e v e l  1 2
L e v e l  1 3
L e v e l  1 4
100%2.4m m /15m m
L e v e l  3
-j L e v e l  5
(view 2)
Figure 3 .3 . R e a l-s ize  longitudinal therm al m apping view s o f experim ent 2  iceball using 10 0%  
gas flow.
0 to -1 9 .9 °C  zone
-20  to -39 .9  °C  zone
< -4 0 °C  zone
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2.4m m /15m m
(view 1)
20%2.4m m/15mm
L e v e l  3
L e v e l  4
L e v e l  5
L e v e l  7
L e v e l  1 0
L e v e l  1 1
L e v e l  1 2
L e v e l  1 3
L e v e l  1 4
(view 2)
Figure 3 .4 . R e a l-s ize  iongitudinai therm al m apping view s of experim ent 2  iceball using 2 0 %  
gas flow.
i I 0 to -1 9 .9 C'C zone  
|  -20  to -3 9 .9  °C  zone  
j < -4 0 °C  zone
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L e v e l  1
L e v e l  2
L e v e l  3
L e v e l  4
L e v e l  6
L e v e l  7
L e v e l  8
L e v e l  9
L e v e l  1 0
L e v e l  1
L e v e l  1 2
L e v e l  1 3
L e v e l  1 4
(view 1)
100%
L e v e l  1
l e v e l  2
L e v e l  4
Level 5
L e v e l  6
L e v e l  7
L e v e l  8
L e v e l  9
L e v e l  1 0
L e v e l  1 1
L e v e l  1 3
L e v e l  1 4
100%
(view 2)
Figure 3 .5 . R e a i-s ize  longitudinal therm al m apping view s o f experim ent 3 iceball using 
gas flow.
3.4m m/18mm 100%
-20  t o -3 9 .9  °C  zone
< -4 0 °C  zone
0 to -1 9 .9 °C  zone
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3.4mm/18mm
L e v e l 3
L e v e l  1 3
(view 1)
3.4mm/18mm
L e v e l 8
(view 2)
Figure 3.6 . R e a l-s ize  longitudinal therm al m apping view s o f experim ent 3 iceball using 2 0 %  
gas flow.
□  0to-19.9°C zone 
|  -20 to -39.9 °C zone 
1 < -4Q°G zone
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1.47mm/10mm
L e v e l  5
L e v e l  6
(view 1)
L e v e l  5
1.47mm/10mm 100%
(view 2)
Figure 3.7 . R e a i-s ize  longitudinal therm al m apping view s o f experim ent 4  iceball using 100%  
gas flow.
< -4Q °C zone
-20 to -39.9 yC zone
0 to -19.9-C zone
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20%1.47mm/10mm
L e v e l  3
L e v e l  4
L e v e l  6
L e v e l  7
L e v e l
- [ L e v e l  1 0
Level 12
L e v e l  1 3
L e v e i  1 4
(view 1)
20%1.47mm/10mm
.e v e l  2
L e v e l 3
L e v e l  6
L e v e l
L e v e l  9
L e v e l  1 0
L e v e l
L e v e i  1 3
L e v e l  1 4
(view 2)
Figure 3.8 . R e a l-s ize  longitudinal therm al m apping  view s of experim ent 4 iceball using 2 0 %  
gas fiow.
0 to -1 9 .9 ‘JC zone  
-20  to -3 9 .9  °C  zone
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3.1.1 Maximum Width of the Icebalis and Lethal Zones
The means and standard deviations of the maximum iceball and lethal zone 
widths were measured (table 3.2). Comparing the 100% and the 20% icebalis, 
in experiment 1, reducing the freezing rate to 20% resulted in a significant 
decrease in the width of the kill zone. This reduction was not observed in the 
total iceball width. No significant width reductions were found in experiment 2 
for both the total and kill zone. However, in experiment 3, the reduction in the 
freezing rate resulted in icebalis and kill zones that had significantly less 
width. A more pronounced width reduction was noted in experiment 4.
Experiment
iotai icebaii width 
(mm) Sig.100% 
gas flow
20%
gas flow
1 50.04(0.71)
50.49
(1.43)
2 49.59(1.95)
48.16
(0.66)
3 52.93(0.23)
48.19
(0.9) II
4 57.96(2.07)
38.44
(1.52) §
If Significant at p value of 0.01 
§ Significant at p value of 0.001
Kiii zone width
(mm)
Sig.100% 20%
gas flow gas flow
37.23 33.95
II(0.62) (1.12)
34.33 33.28
(0.52) (0.72)
38.01 34.38
§(1.28) (0.56)
39.38 0
§(2.36) (0)
Table 3.2. Means (standard deviation) of the maximum width of the total iceball and the kill 
zone at 100% and 20% gas flow rates. Each experiment was performed three times. 
Comparisons were made between the means of the 100% and the 20% widths for each 
experiment for both the total ice and kill zone widths using independent samples t- test.
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Using one way analysis of variance (ANOVA) to compare the kill zone widths 
between the experiments icebalis at 100% gas flow rate, there was a 
significant difference (p = 0.013). Post hoc analysis between the four groups 
(LSD) (Table 3.3) showed that experiment 2 produced significantly smaller kill 
zone width than all the other experiments. The width of kill zone 4 was larger 
than the other icebalis; however, the difference was only significant with 
iceball 2. There were no significant differences between iceball 1 and 3.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 +2.9 *
Experiment 1 vs, 3 -0.77
Experiment 1 vs. 4 -2.15
Experiment 2 vs. 3 -3.67 *
Experiment 2 vs. 4 -5.05 11
Experiment 3 vs. 4 -1.37
* Significant at p value of 0.05 
Significant at p value of 0.01
Table 3.3. The mean difference in mm of the kill zone width between each experiment at 
100% gas flow rate using the Least Significant Difference (LSD) test. The negative sign (-) 
indicates smaller while the positive sign (+) indicates larger.
The differences were also significant comparing the total ice widths at 100% 
gas flow using one way ANOVA (p <0.001). Post hoc analysis (LSD) (Table 
3.4) confirmed that iceball 4 was significantly wider than the other icebalis.
The difference between icebalis 1 and 2 was not significant; however, both 
had significantly smaller total widths than iceball 3.
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Comparison Difference(mm) Sig.
Experiment 1 vs. 2 +0.45
Experiment 1 vs. 3 -2.88 *
Experiment 1 vs. 4 -7.91 §
Experiment 2 vs. 3 -3.33 *
Experiment 2 vs. 4 -8.36 §
Experiment 3 vs. 4 -5.03 IF
* Significant at p value of 0.05 
Significant at p value of 0.01 
§ Significant at p value of 0.001
Table 3.4. The mean difference in mm of the total iceball width between each experiment at 
100% gas flow rate using the Least Significant Difference (LSD) test. The negative sign (-) 
indicates smaller while the positive sign (+) indicates larger.
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3.1.2 Maximum Depth of the Icebalis and Lethal Zones
The means and standard deviations of the maximum total iceball and lethal 
zone depths were measured (table 3.5). By reducing the freezing rate to 
20%, the depths have reduced significantly for all the icebalis except the total 
iceball depth in experiment 2, where the depth reduction was not significant. 
The total iceball depth reduction in experiment 4 was the most significant.
Kill zone depth 
(mm) Sig.100% 
gas flow
20%
gas flow
23.54
(0.75)
18.62
(0.52) §
24.09
(1.13)
21.71
(1.48) If
23.53
(0.9)
16.61
(0.19) §
24.26
(0.86)
0
(0) §
Experiment
Total iceball depth 
(mm) Sig.100% 
gas flow
20%
gas flow
1 43.69(2.14)
37.61
(1.04) §
2 44.65(2.94)
41.89
(0.62)
3 45.02(1.14)
37.33
(0.56) §
4 38.29(0.37)
23.57
(2.05) §
11 Significant at p value of 0.01 
§ Significant at p value of 0.001
Table 3.5. Means (standard deviation) of the maximum depth of the total iceball and the kill 
zone at 100% and 20% gas flow rates. Each experiment was performed three times. 
Comparisons were made between the means of the 100% and the 20% depths for each 
experiment for both the total ice and kill zone widths using independent samples t- test.
There were no significant differences (p = 0.699) between the kill zone depths 
of the icebalis at 100% gas flow rate using one way ANOVA. However, the 
differences were significant for the total ice depth (p= 0.009). Post hoc 
analysis between the four groups using the LSD (Table 3.6) showed that only 
experiment 4 was significantly different (smaller total iceball depth) from the 
other icebalis.
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Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -0.96
Experiment 1 vs. 3 -1.33
Experiment 1 vs. 4 +5.4 11
Experiment 2 vs. 3 -0.37
Experiment 2 vs. 4 +6.36 ir
Experiment 3 vs. 4 +6.73 IF
Significant at p value of 0.01
Table 3.6. The mean difference in mm of the total iceball depth between each experiment at 
100% gas flow rate using the Least Significant Difference (LSD) test. The negative sign (-) 
indicates smaller while the positive sign (+) indicates larger.
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3.1.3 Maximum Length of the Icebalis and Lethal Zones
The means and standard deviations of the maximum total iceball and lethal 
zone lengths were measured (table 3.7). When reducing the gas flow, the 
length of all the icebalis and the lethal zones has decreased, although the 
reduction was not statistically significant for the total iceball in experiment 1. 
The largest length reduction was noted in the total length of iceball 4.
Experiment
Total iceball length 
(mm) Sig.100% 
gas flow
20%
gas flow
1 50.33
(0.38)
49.07
(0.35)
2 52.56
(0.49)
50.57
(1.59)
*
3 59.39
(1.41)
52.88
(1.96)
§
4 42.66
(0.31)
23.27
(0.37)
§
Kill zone length 
(mm) Sig.100% 
gas flow
20%
gas flow
35.71 33.53 *
(0.62) (2.41)
39.3 34.13 §
(0-7) (1.26)
37.58 31.96 §
(0.63) (1.46)
22.62 0 §
(0.48) (0)
* Significant at p value of 0.05 
§ Significant at p value of 0.001
Table 3.7. Means (standard deviation) of the maximum length of the total iceball and the kill 
zone at 100% and 20% gas flow rates. Each experiment was performed three times. 
Comparisons were made between the means of the 100% and the 20% lengths for each 
experiment for both the total ice and kill zone widths using independent samples t- test.
One way ANOVA showed significant differences in both the kill zones 
(p=<0.001) and the total icebalis length (p=<0.001) between the experiments 
icebalis at 100% gas flow rate. LSD (Tables 3.8 and 3.9) showed that the 
differences were significant for all the experiment. The tables showed that 
iceball 4 had the lowest lethal zone and total iceball lengths by big margins.
On the other hand, iceball 2 had the largest kill zone length, but not the total
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length as we would have expected. Instead, iceball 3 had the highest total 
iceball length.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -3.59 §
Experiment 1 vs. 3 -1.87 H
Experiment 1 vs. 4 +13.09 §
Experiment 2 vs. 3 +1.72 %
Experiment 2 vs. 4 +16.68 §
Experiment 3 vs. 4 +14.96 §
Significant at p vaiue of 0.01 
§ Significant at p value of 0.001
Table 3.8. The mean difference in mm of the lethal zone length between each experiment at 
100% gas flow rate using the Least Significant Difference (LSD). The negative sign (-) 
indicates smaller while the positive sign (+) indicates larger.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -2.23 If
Experiment 1 vs. 3 -9.06 §
Experiment 1 vs. 4 +7.67 §
Experiment 2 vs. 3 -6.83 §
Experiment s vs. 4 +9.9 §
Experiment 3 vs. 4 +16.73 §
[ Significant at p value of 0.01
§ Significant at p value of 0.001
Table 3.9. The mean difference in mm of the total iceball length between each experiment at 
100% gas flow rate using the Least Significant Difference (LSD). The negative sign (-) 
indicates smaller while the positive sign (+) indicates larger.
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3.1.4 Anterior Prostate Dimensions
The mean (SD) dimensions of the anterior part of the 40 prostates, which 
were measured using TRUS as described in chapter 2 (2.1.13) were as 
follows:
1. Width (W): 31.23 (4.43) mm
2. Depth (D): 17.18 (2.62) mm
3. Length (L): 35.21 (5.8) mm
3.1.5 The Distance between the Cryoprobe and the Edge of
the Lethal Zone
The distance between the centre of the cryoprobe and the lethal zone edge 
for each iceball was measured (table 3.10). Reducing the freezing rate to 
20% resulted in a significant reduction in the distance in experiment 1 and 3. 
Comparisons were not made between experiment 4 icebalis due to the lack of 
lethal ice when freezing at 20% gas flow.
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Experiments 100% gas flow
20% gas 
flow Sig.
1 10.81 9.17 C
(0.31) (0.56) s
2 10.84
(0.25)
10.28
(0.32)
3 11.74 9.79
§(0.16) (0.12)
4 3.28(0.96) n/a
§ Significant at p value of 0.001 
n/a: not applicable
Table 3.10. Means (standard deviation) of the distance in mm between the cryoprobe and 
the edge of the lethal zone at the maximum dimension level of the iceball. Each experiment 
was performed three times. Comparisons were made between the means of the 100% and 
the 20% distances for each experiment using independent samples t- test. Iceball 4 at 20% 
freeze rate did not have lethal ice.
There was a significant difference (p = <0.001) using the one way ANOVA to 
compare the means of the distances between the icebalis at 100% gas flow 
rate. LSD (Table 3.11) test showed that the differences between experiment 
1,2 and 3 icebalis were not statistically significant, all of which had 
significantly longer distance than iceball 4.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -0.33
Experiment 1 vs. 3 -0.93
Experiment 1 vs. 4 +7.53 §
Experiment 2 vs. 3 -0.9
Experiment 2 vs. 4 +7.56 §
Experiment 3 vs. 4 +8.46 §
§ Significant at p value of 0.001
Table 3.11. The mean difference in mm of the cryoprobe-lethal ice distance between each 
experiment at 100% gas flow rate using the Least Significant Difference (LSD). The negative 
sign (-) indicates smaller while the positive sign (+) indicates larger.
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3.1.6 The Thickness of the Non-Lethal Ice Zone
The thickness of this zone was measured in three places:
1. The side of the iceball across the width
The means and standard deviations of the non-lethal zone thickness 
across the width were measured (table 3.12). The thickness has 
significantly increased only in iceball 1 when the freezing rate was 
reduced to 20%. Comparison was not made in experiment 4 due to the 
lack of lethal ice when freezing at 20% gas flow.
Experiments 100% gas flow
20% gas 
flow Sig.
1 6.4 8.27 11(0.24) (0.44)
2 7.63
(0.81)
7.47
(0-67)
3 7.46
(0-6)
6.9
(0.38)
4 9.28
(0.5) n/a
If Significant at p value of 0.01 
n/a: not applicable
Table 3.12. Means in mm (standard deviation) of the thickness of the non-lethal ice zone on 
the side of the iceball across the width at 100% and 20% gas flow rates. Each experiment 
was performed three times. Comparisons were made between the means of the 100% and 
the 20% thicknesses for each experiment using independent samples t- test. Iceball 4 at 20% 
freeze rate did not have lethal ice.
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Comparing the means at 100% gas flow, there was a significant difference 
[one way ANOVA (p=0.002)]. Iceball 4 had, statistically, the largest thickness 
compared to the other icebalis (table 3.13) and iceball 1 had the shortest 
distance, however, the difference was not statistically significant compared to 
experiment 3.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -1.22 *
Experiment 1 vs. 3 -1.05
Experiment 1 vs. 4 -2.88 §
Experiment 2 vs. 3 +0.17
Experiment 2 vs. 4 -1.65 11
Experiment 3 vs. 4 -1.82 *
* Significant at p value of 0.05 
If Significant at p value of 0.01 
§ Significant at p value of 0.001
Table 3.13. The mean difference in mm of the non-lethal ice distance across the width 
between each experiment at 100% gas flow rate using the Least Significant Difference (LSD). 
The negative sign (-) indicates smaller while the positive sign (+) indicates larger.
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2. The side of the iceball across the depth.
The means and standard deviations of the non-lethal zone thickness 
across the depth were measured (table 3.14). There were no significant 
differences between the thicknesses of the non-lethal ice across the 
depth in experiment 1-3 when reducing the freezing rate. Comparison 
was not made between the 100% and 20% experiment 4 icebalis, as the 
iceball at 20% gas flow did not have lethal zone.
Experiments 100% gas flow
20% gas 
flow Sig.
1 10.07 9.49
(0-87) (0.71)
2 10.28 10.08
(1.28) (0.42)
3 10.74 10.35
(0-43) (0.21)
4 7.01
(0.44) n/a
n/a: not applicable
Table 3.14. Means in mm (standard deviation) of the thickness of the non-lethal ice zone on 
the side of the iceball across the depth at 100% and 20% gas flow rates. Each experiment 
was performed three times. Comparisons were made between the means of the 100% and 
the 20% thicknesses for each experiment using independent samples t- test. The differences 
were not significant. Iceball 4 at 20% freeze rate did not have lethal ice.
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Comparisons between the 100% gas flow icebalis suggested significant 
differences [one way ANOVA (p=0.002)] which, according to table 3.15, was 
due to shorter thickness of iceball 4 only.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -0.2
Experiment 1 vs. 3 -0.67
Experiment 1 vs. 4 +3.06 IF
Experiment 2 vs. 3 -0.46
Experiment 2 vs. 4 +3.27 §
Experiment 3 vs. 4 +3.73 §
U Significant at p value of 0.01 
§ Significant at p value of 0.001
Table 3.15. The mean difference in mm of the non-lethal ice distance across the depth 
between each experiment at 100% gas flow rate using the Least Significant Difference (LSD). 
The negative sign (-) indicates smaller while the positive sign (+) indicates larger.
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3. The top of the iceball
The means and standard deviations of the non-lethal zone thickness 
from the top of the iceball were measured (table 3.16). Changing the 
freezing rate has not shown to cause significant differences between 
the icebalis in experiment 1-3. Experiment 4 iceball did not have lethal 
zones when frozen at 20% gas flow rate; hence, comparison was not 
made with 100% iceball.
Experiments 100% gas flow
20% gas 
flow Sig.
1 6.83 7.41
(0.96) (1.75)
2 7.26 9.76
(1.2) (1.41)
3 13.34 12.06
(1.83) (0.88)
4 11.34
(0.65) n/a
n/a: not applicable
Table 3.16. Means in mm (standard deviation) of the thickness of the non-lethal ice zone from 
the top of the iceball at 100% and 20% gas flow rates. Each experiment was performed three 
times. Comparisons were made between the means of the 100% and the 20% thicknesses for 
each experiment using independent samples t- test. The differences were not significant. 
Iceball 4 at 20% freeze rate did not have lethal ice.
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The one way ANOVA comparing the means at 100% gas flow showed that 
there was a significant difference between the icebalis (p=<0.001). The post 
hoc test (table 3.17) concluded that the difference was not significant between 
iceball 1 and 2, both of which had significantly shorter non-lethal ice than 
iceball 3 and 4. Although Iceball 4 had longer non-lethal than iceball 3, it was 
not statistically significant.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -0.42
Experiment 1 vs. 3 -6.5 §
Experiment 1 vs. 4 -4.5 IF
Experiment 2 vs. 3 -6.08 §
Experiment 2 vs. 4 -4.08 11
Experiment 3 vs. 4 +2
f Significant at p value of 0.01
§ Significant at p value of 0.001
Table 3.17. The mean difference in mm of the non-lethal ice distance from the top of the 
iceball between each experiment at 100% gas flow rate using the Least Significant Difference 
(LSD). The negative sign (-) indicates smaller while the positive sign (+) indicates larger.
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3.1.7 The Length of the Lethal Iceball below the Tips of the 
Cryoprobes
The means and standard deviations of length of the lethal iceball below the 
tips of the cryoprobes were measured (table 3.18). No significant differences 
were observed between the 100% and the 20% gas flow experiments. No 
comparison was made between experiment 4 icebalis due to the lack of lethal 
ice when frozen at 20% flow rate
Experiments 100% gas flow
20% gas 
flow Sig.
1 0.72 0.21
(1.44) (0.89)
2 2.6 1.58
(0.28) (1.37)
3 3.53 3.15
(0.08) (0.31)
4 3.14
(0.31) n/a
n/a: not applicable
Table 3.18. Means in mm (standard deviation) of the length of the lethal ice below the 
cryoprobes tips at 100% and 20% gas flow rates. Each experiment was performed three 
times. Comparisons were made between the means of the 100% and the 20% thicknesses for 
each experiment using independent samples t- test. The differences were not significant. 
Iceball 4 at 20% freeze rate did not have lethal ice.
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The differences between the means of the four icebalis at 100% gas flow 
(table 3.19) were significant [one way ANOVA (p= 0.012)]. This was 
exclusively due to the significantly shorter lethal ice of experiment 1. There 
were no significant differences between the other icebalis.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 -1.88 *
Experiment 1 vs. 3 -2.81 11
Experiment 1 vs. 4 -2.42 H
Experiment 2 vs. 3 -0.92
Experiment 2 vs. 4 -0.54
Experiment 3 vs. 4 +0.38
*  Significant at p value of 0.05 
H Significant at p value of 0.01
Table 3.19. The mean difference in mm of the lethal ice lengths below the tips of the 
cryoprobes between each experiment at 100% gas flow rate using the Least Significant 
Difference (LSD). The negative sign (-) indicates smaller while the positive sign (+) indicates 
larger.
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3.1.8 The Cooling Rate
Thermal records In the centre of the iceball at the maximum dimension levels 
at 0, 2, 5, 7 and 10 minutes of freezing were plotted (figure 3.9). The means 
and standard deviation of the 0-5 minutes cooling rates (table 3.20) were 
calculated as described in chapter 2 (2.1.17). By reducing the freezing rate to 
20%, the 0-5 minutes cooling rate declined significantly in all the experiments
Experiments
0-5 min cooling rate (°C/min)
100% gas 
flow
20% gas 
flow
Sig.
1 18.54
(0.71)
16.2
(1.49)
*
2 22.56
(1.55)
18.8
(1.17) §
3 20.64(0.8)
16.28
(1.34) §
4 19.7(0.58)
8.03
(0.29) §
* Significant at p value of 0.05 
§ Significant at p value of 0.001
Table 3.20. Means (standard deviation) of the 0-5 minutes cooling rates in the centre of the 
iceball at the maximum dimension levels at 100% and 20% gas flow rates. Each experiment 
was performed three times. Comparisons were made between the means of the 100% and 
the 20% thicknesses for each experiment using independent samples t- test.
159
1f
//Jl
/
’
-
-/•
£o**—
C/>TOO)
OO
1
’
fi
■
11
r
c
E
CD
Eh-
w
COo>
o
CM
(qJ 8jn;ej0duu9i (0o) 0jn}ej0duu0i
/
/
>
'
/ >
o
05
00
<1>
<o =3
C
F'—'
ET <D
EOQ 1 -
CM
O
5o
>4—
V)
COO)
OO
/1
■/I /
7
/•y'
-C'
0)
-t-J3C
£
(0
E
i-
$o
>+—
C/5
CO
O )
o
CM
o o o o o o  o o o o o o o o o
'f (O (N r- r-(Nn'TK)(ON<0®0
O
r
i
£. r~ ^  O / . ^ — $co4-> ^ / CO o- <o 3 5=
J .E co. u, £ O) .E w - in F 25.vP. ^ CD S'
£  o)
,, CD >PF °•E O .7'
’T JS O'
.E O
■7
£
o o o o o o o o o o o o o o o  _ rroocMr— (^NrtTj-tn(ON<x>a)o ^
(0 o) 0jn^ej0diu0i
0 c r o0 c1 c0 cM *0 c 
(
0 c 
Do
DOC - CM 0
) ©jn
D C?
IB.
D CT U 
10(
D C0 <1
iui
D C 0 1"
3J
D C- 0D C 0 CD C ? CD3
■ I
11 1
- f- .—- o ' 1
I 3  F=
i
l'~ <0 <  +-> o
i .E  co V / .E  w
f
- <0 X
^  O)
^  <n ^
/ E °
i -  ° ■
■ - =l vO
/ - «  H  CM
. -
.*4 /
O O O O O O O O O O O O O O O  r cn CN V- v-CNir)'Tl/)©NCOO) 0 ^
( 0 o) 0 J n j e j 0 d 0 0 i
D Cr oD C D CD C M D C 
( :
D CD C - C
e
D C M O
jn^
D C0 ^
BJ
D C
T “
e d
D C ? ^
LU
D C 
? h
9 1
D C- 0D C D C3 C » C3 13
CO CO o
( O o )  8 J n i B j 0 d u u 9 i (0 o) 0jrnej0dLU0i
* -
c
0
El_
0
CL
X
LU
CO
c
0
E
0
CL
X
LU
CM
c
0
E
0CL
X
LU
c
0
ES—
0
CL
X
LU
to
CO
o>
o
CM
■O
c
CO
oo
CO
o
■(/>
c
CO
ETD
E
3
E
x
CO
E
COsz■*->
CO
"co.aco
o
co
<o
°  co­
co CO
£  !  
cz— CO CO CO
4—1 I—c  x : 
co *-* 
E
E  co
I  S.
a>
CO
co
32 o 
co F
g - E  
E  co 
co Q- 
I- XCO
o> x :
«  CO 
CO LU
I *O) Xi 
i ■ CO
o
One way ANOVA suggested that the differences between the cooling rates of 
the four icebalis at 100% gas flow were significant (p=0.004). Further analysis 
using the LSD test (table 3.21) showed that iceball 2 had the fastest cooling, 
while Iceball 1 had the lowest cooling rate, although it did not differ 
significantly from iceball 4.
Comparison Difference(mm)
Sig.
Experiment 1 vs. 2 -4.02 §
Experiment 1 vs. 3 -2.1 *
Experiment 1 vs. 4 -1.16
Experiment 2 vs. 3 +1.92
Experiment 2 vs. 4 +2.86 H
Experiment 3 vs. 4 +0.93
* Significant at p value of 0.05 
If Significant at p value of 0.01 
§ Significant at p value of 0.001
Table 3.21. The mean difference of the 0-5 minute cooling rates in degree C/min between 
each experiment at 100% gas flow rate using the Least Significant Difference (LSD). The 
negative sign (-) indicates smaller while the positive sign (+) indicates larger.
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3.1.9 The Ablative Ratio
This ratio was estimated by dividing the kid zone by the total iceball volume. 
Comparisons of the means of the ratios between the 100% and the 20% gas 
flow using the independent samples t- test were made (table 3.22). This 
showed that the ablative ratios decreased significantly by reducing the 
freezing rate for all the icebalis except in experiment 2, where the changes 
were marginal.
Exp.
100% gas flow 20% gas flow
Sig.Total ice
volume
(cc)
Kill zone
volume
(cc)
Ablative 
ratio (%)
Total ice
volume
(cc)
Kill zone
volume
(cc)
Ablative 
ratio (%)
1 57.68
(3.91)
16.4
(0.92)
28.45
(0.37)
48.83
(2.33)
11.09
(0.81)
23.7
(0.78) §
2 60.92
(3.56)
17.02
(1.22)
27.93
(0.42)
53.43
(1.85)
12.95
(1.56)
24.19
(2.21) §
3 74.12
(1-55)
17.61
(1-13)
23.75
(1.2)
49.83
(2.11)
9.56
(0.44)
19.2
(0.81) §
4 49.59
(2.11)
11.33
(1.04)
22.81
(1.11)
11.37
(1.2)
0
(0)
0
(0 ) §
§ Significant at p va ue of 0.001
Table 3.22. Means (standard deviation) of the total iceball and the kill zone volumes. The 
ablative ratio is the ratio of the kill zone /  total iceball volumes. Each experiment was 
performed three times. Comparisons were made between the ablative ratios of the 100% and 
20% for each experiment using independent samples t- test.
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The differences between the 100% icebalis ablative ratios were significant 
[one way ANOVA (p=<0.001)]. Post hoc test (LSD) between the four groups 
(table 3.23) concluded that there were insignificant differences between 
icebalis 1 and 2, both of which had significantly larger ablative ratio than 3 and
4. Iceball 4 had smaller ablative ratio than iceball 3, but was not statistically 
significant.
Comparison Difference(mm) Sig.
Experiment 1 vs. 2 +0.52
Experiment 1 vs. 3 +4.7 §
Experiment 1 vs. 4 +5.64 §
Experiment 2 vs. 3 +4.17 §
Experiment 2 vs. 4 +5.11 §
Experiment 3 vs. 4 +0.94
§ Significant at p value of 0.001
Table 3.23. The mean difference of the ablative ratio between each experiment at 100% gas 
flow rate using the Least Significant Difference (LSD). The negative sign (-) indicates smaller 
while the positive sign (+) indicates larger.
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3.1.10 The Coefficient of Variance (CV)
Table 3.24 summarises the CV for the data within each experiment and 
between all the experiments. The CV for the data between the experiments 
has always been larger than the CV within experiments. The CV for the lethal 
ice width, depth and length between the experiments at 20% gas flow rate 
were significantly large due to the lack of lethal ice in experiment 4.
Parameter
100% gas flow 20% gas flow
Between
experiments
Within
experiments
Between
experiments
Within
experiments
Iceball width
Total ice 0.84% 0.04% 1.86% 0.03%
Lethal ice 0.37% 0.05% 33.90% 0.02%
Iceball depth
Total ice 0.69% 0.09% 5.42% 0.04%
Lethal ice 0.02% 0.04% 19.92% 0.04%
Iceball length
Total ice 2.79% 0.01% 13.13% 0.04%
Lethal ice 5.13% 0.01% 33.32% 0.09%
Probe-lethal zone edge distance 5.87% 0.04% 0.11%* 0.02%
Non-Iethal ice 
thickness
Across width 0.55% 0.04% 0.19%* 0.04%
Across depth 0.91% 0.07% 0.06%* 0.02%
At the top 3.11% 0.16% 1.66%* 0.20%
Lethal ice below tip of probes 1.86% 0.26% 3.94%* 0.37%
0-5 cooling rate 0.43% 0.04% 4.47% 0.09%
Ablative ratio 0.96% 0.03% 22.82% 0.09%
* CV was measured between experiments 1 to 3 due to lack of lethal ice in experiment 4
Table 3.24 Coefficient of variance (%) for the data within each experiment and between the 
experiments for all the parameters at 100% and 20% gas flow rates. The smaller the CV 
value, the less dispersed is the data around the mean.
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3.2 Health Related Quality of Life of Salvage Cryotherapy on 
Patients with Localised Prostate Cancer Recurrence 
after Radiation Failure
A total of 47 patients have been recruited to date, 12 of whom have not 
received androgen deprivation, while the remaining 35 patients received 
androgen deprivation from before cryotherapy and during follow-up. The 
recruitment is ongoing and the results are preliminary.
3.2.1 Cancer Specific Quality of Life (EORTC QLQ-C30)
The mean baseline and up to 12 months follow-up scores are summarised in 
table 3.25. The scores suggest that the majority of the domains have 
deteriorated temporarily within 6 weeks to 3 months after cryotherapy. This 
included: global health, physical function, role function, cognitive function, 
social function, fatigue, nausea and vomiting, pain, loss of appetite, diarrhoea 
and financial problems. Emotional function, social function and insomnia 
have been noted to improve after 9 months. All the mean score changes do 
not exceed 10% from the baseline score, hence; represent only “a little 
change” in quality of life measured as assessed by Osoba et al (1998). The 
trend of changes in the global health domain score, which is illustrated in 
figure 3.10, shows a “little” deterioration and seems to return to pre-treatment 
level at 9 months.
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Figure 3.10. Box and whisker plot of the global health domain of the QLQ C-30 before and 
after cryotherapy for the whole group. The higher the score represents the better outcome.
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3.2.2 Prostate Cancer Specific Quality of Life (PR-25)
The preliminary results of the PR25 is summarised in table 3.26.
EORTC PR25 -  Urinary Problems
The trend of changes in the mean scores of the urinary problems domain is 
illustrated in figure 3.11. The clinical significance of the changes in the mean 
scores has not been assessed before, but likely to be similar to that of the 
QLQ- C30 questionnaire due to the similarity in the structure of the 
questionnaires. The clinical significance for the changes in the score of the 
QLQ- C30 questionnaire was assessed by Osoba et al (1998)(see page 123). 
The urinary problems worsen “moderately” at 6 weeks follow-up, but then 
gradually improved to become “clinically insignificant” at 9 months.
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Figure 3.11. Box and whisker plot of the urinary problems domain of the EORTC PR25 before 
and after cryotherapy for the whole group. The higher the score represents the worse outcome. 
Patient no. 18 had consistently the worst score (pre- and post-cryotherapy).
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EORTC PR25 -  Urinary Incontinence Aid Bother and Urinary Incontinence
Urinary Incontinence Aid Bother (question 8) is relevant to patients with 
incontinence, therefore, closely related to question 6 of the PR25 questionnaire 
which assesses urinary incontinence. Question 6 is an important outcome 
measure, and also included in the Urinary Problems domain described (table 
3.26). We have reported the raw scores of both question 6 (figure 3.12) and 
question 8 (figure 3.13).
The trends in incontinence score (figure 3.12) suggested that incontinence 
increased after salvage cryotherapy, the majority were regarded as “A little”. 
Urinary aid bother has worsened following salvage cryosurgery. However, 
surprisingly, the percentage of patients who responded to the urinary aid 
bother question, i.e. considering themselves incontinent, has not changed after 
cryotherapy (figure 3.13 and table 3.26).
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Figure 3.12. Urinary incontinence (question 6 of PR25) at baseline and post cryotherapy.
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Figure 3.13. Urinary incontinence aid bother (question 8 of PR25) at baseline and post 
cryotherapy.
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EORTC PR25 -  Bowel Problems
This domain assesses abdominal bloating, faecal incontinence, pre-rectal 
bleeding and limitation due to bowel symptoms. The trend of this domain 
scores were heterogeneous and seemed not to change with time (figure 3.14 
and table 3.26).
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Figure 3.14. Box and whisker plot of the bowel problems domain of the EORTC PR25 before 
and after cryotherapy for the whole group. The higher the score represents the worse outcome.
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EORTC PR25 -  Treatment Symptoms
This domain assesses a variety of symptoms including hot flushes, nipple and 
breast soreness, ankle swelling, weight changes and loss of masculinity.
The scales data, which is summarised in table 3.26 and figure 3.15, showed no 
changes of clinical significance after cryosurgery. There were difference 
observed at baseline between hormone naive and patients received androgen 
deprivation, in favour of the former group (figure 3.16). However, from 9 
months follow-up, the two groups became comparable. This should be 
interpreted with caution as the number of patients in each group was uneven.
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Figure 3.16. Box and whisker plot of the treatment symptoms domain of the EORTC PR25 
before and after cryotherapy by treatment group. The higher the score represents the worse 
outcome.
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EORTC PR25 -  Sexual Activity and Sexual Function
The scaled scores of sexual activity are presented in figure 3.17 and table 
3.26. This showed no overall clinically significant changes in the sexual activity 
after cryotherapy. Comparing hormone naive and hormone treated patients, 
there no significant difference at the baseline trend (table 3.26 and figure 3.18). 
The only clinically significant changes after cryosurgery was observed in the 
hormone naive group at 6 weeks which showed “a little” changes in sexual 
activity. However, these scores should be interpreted with caution due to the 
small number and disparity in the number of patients between the two groups.
The sexual function domain questions are relevant to sexually active patients, 
and only small number answered them (table 3.26 and figure 3.19). The overall 
scores were heterogeneous, but there was a trend of higher sexual function in 
the hormone naive group (table 3.26).
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Figure 3.17. Box and whisker plot of the sexual activity domain of the EORTC PR25 before 
and after cryotherapy for the whole group. The higher the score represents the better outcome.
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Figure 3.18. Box and whisker plot of the sexual activity domain of the EORTC PR25 before 
and after cryotherapy by treatment group. The higher the score represents the better outcome.
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Figure 3.19. Box and whisker plot of the sexual function domain of the EORTC PR25 before 
and after cryotherapy for the sexually active patients only. The higher the score represents the 
better outcome.
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Urinary
Problems
Urinary 
Incontinence 
Aid Bother*
Bowel
Problems
Treatment
Symptoms
Sexual
Activity
Sexual
FunctionH
Whole Group
Baseline n= 47 20.9 (16.2) 12.5 (24.) n=8 6.9 (8.5) 11.7(10.0) 25.9 (30.5) 13.0(11.8) n=9
6 Weeks n=41 35.8(21.1) 38.9(25.1) n=6 8.7 (14.4) 12.6(11.7) 21.1 (26.5) 8.3(11.5) n=8
3 Months n=39 27.0 (19.9) 20.8 (35.4) n=8 5.6 (10.1) 13.5(12.0) 24.1 (25.6) 13.9(8.0) n=8
6 Months n=31 26.5 (22.5) 77.8 (38.5) n=3 10.7(16.2) 16.7 (14.0) 25.8 (28.3) 15.7(13.3) n=6
9 Months n=29 24.3(22.1) 53.3 (44.7) n=5 8.8(19.1) 13.2 (12.4) 24.1 (28.7) 10.2(11.3) n=6
12 Months n=19 24.9 (24.8) 66.7 (0) n=3 7.3 (12.9) 12.9(11.7) 24.6 (32.6) 9.7 (7.0) n=4
Cryotherapy alone
Baseline n= 12 22.0(21.1) 50.0 (23.6) n=2 8.6 (8.4) 6.3 (4.2) 25.0 (24.1) 24.1 (8.5) n=3
6 Weeks n=10 35.2 (24.2) 44.4(19.3) n=3 7.4(14.1) 9.3 (7.3) 16.7(13.6) 16.7(235) n=2
3 Months n=10 28.0(26.1) 100 n=1 7.1 (12.2) 11.7(11.3) 23.3 (21.1) 19.4 (7.4) n=3
6 Months n=6 24.2 (34.7) 100 n=1 4.2 (8.4) 12.0(15.9) 27.8 (17.2) 24.1 (8.5) n=3
9 Months n=6 30.7 (36.2) 100 n=1 10.4 (20.9) 13.9(13.0) 25.0(17.5) 20.4 (3.2) n=3
12 Months n=5 24.3 (33.7) 66.7 n=1 2.1 (4.2) 11.1 (16.2) 23.3(19.0) 16.7 n=1
Cryotherapy and 
hormonal therapy
Baseline n= 35 20.5 (14.4) 0 n=6 6.1 (8.7) 13.5(10.7) 26.3 (32.8) 7.4 (9.1) n=6
6 Weeks n=31 35.9 (20.6) 33.3 (33.4) n=3 9.2 (14.8) 13.6 (12.6) 22.6 (20.8) 5.6 (6.1) n=6
3 Months n=29 26.6 (17.9) 9.5 (16.2) n=7 5.1 (9.7) 14.1 (12.4) 24.4 (27.4) 10.6 (6.9) n=5
6 Months n=15 27.4 (16.4) 66.7 (47.2) n=3 13.3(18.1) 18.7(13.2) 25.0 (32.5) 7.4 (12.8) n=3
9 Months n=23 22.5(17.1) 41.7(41.9) n=4 8.5(19.3) 13.1 (12.5) 23.9 (31.3) 0 n=3
12 Months n=14 25.1 (22.4) 66.7 (0) n=2 9.0 (14.4) 13.5 (10.4) 25.0 (36.8) 7.4 (6.4) n=3
Table 3.26. EORTC PR25 mean scores out of 100 (standard deviation). For urinary problems, urinary 
incontinence aid bother, bowel problems and treatment symptoms domains: the higher the score represents 
the worse the outcome. While for sexual activity and function: the higher the score represents the better the 
outcomes.
* This question is relevant to patients with incontinence only. The number (n) of the patients responded to this question is 
shown separately in each cell.
II This question is relevant to sexually active patients. The number (n) of the patients responded to this question is shown 
separately in each cell.
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3.2.3 The International Index of Erectile Function (IIEF-5)
The IIEF-5 scores were compatible with the sexual activity domain scores of 
the EORTC PR-25. The mean scores at baseline, 6months and 12 months 
are demonstrated in figures 3.20, 3.21 and table 3.27. The trend showed that 
the only 6 patients (14%) were considered potent at baseline (IIEF-5 score 
>12). Only one patient remained potent after cryotherapy. There was a trend 
towards higher IIEF score at baseline in the hormone naive compared to the 
hormone treated group as demonstrated in figure 3.22 and table 3.27; 
however, no differences were noted at follow-up.
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Figure 3.20. Box and whisker plot of the International Index of Erectile Function-5 (IIEF-5) 
before and after cryotherapy for the whole group. The higher the score represents the better 
outcome.
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Figure 3.22. Box and whisker plot of the IIEF-5 score before and after cryotherapy by 
treatment group. The higher the score represents the better outcome.
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3.2.4 International Prostate Symptom Score (IPSS)
The scores are presented in figure 3.23 and table 3.27. The only clinically 
significant (=> 4 points) worsening occurred at 6 weeks follow-up. This is in 
agreement with urinary problems domain scores of the EORTC PR-25 
described earlier (3.2.2). The scores of quality of life due to urinary symptoms 
are presented in table 3.26 and figure 3.24 which suggested a temporary 
deterioration at 6 weeks follow-up. From 3 months after cryosurgery, the 
scores became parallel to the baseline score.
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Figure 3.23. Box and whisker plot of the International Prostate Symptom Score before and 
after cryotherapy for the whole group. The higher the score represents the better outcome.
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Figure 3.24. IPSS QoL at baseline and post cryotherapy for the whole group.
3.2.5 Erectile Dysfunction Effect on Quality of Life (ED-EQoL)
This question is relevant only to patients considering themselves to have ED. 
The baseline, 6 months and 12 months means scores are presented in figures 
3.25 and 3.26, and table 3.27. At baseline, 63% of the patients considered 
that their erectile dysfunction have mild effect on QoL. This became worse at 
6 months with 48% of the patients considering that their erectile dysfunction to 
have moderate to severe effect on QoL; however it improved back to baseline 
level by 12 months.
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Figure 3.25. Box and whisker plot of the Erectile Dysfunction Effect on Quality of Life (ED- 
EQoL) before and after cryotherapy for the whole group. The higher the score represents the 
more severe effect of ED on QoL.
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Figure 3.26. ED-EQoL at baseline and post cryotherapy for the whole group.
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IIEF-5 ED-EQoL*
IPSS
IPSS QoL
Whole Group
Baseline n=47 4.5 (7.3) 13.4(13.4) n=41 9.4 (6.5) 2.8 (1.7)
6 Weeks n=41 - - 14.5 (7.9) 3.2(1.5)
3 Months n=39 - - 11.6(7.5) 2.7(1.5)
6 Months n=21 2.7 (3.2) 16.0(15.2) n=21 9.5 (6.9) 2 .4 (17 )
9 Months n=29 - - 11.0(8.1) 2 .6 (15 )
12 Months n=19 3.1 (3.9) 10.6(12.0) n=18 12.1 (9.5) 2 .4 (16 )
Cryotherapy alone -
Baseline n=12 7.0 (9.3) 15.9(18.3) n=10 6.0 (4.6) 2.3 (2.0)
6 Weeks n=10 - - 13.1 (6.8) 3 .3 (18 )
3 Months n=10 - - 11.9 (9.0) 2 .8 (15 )
6 Months n=6 2.8 (2.0) 15.3(20.6) n=6 9.5 (8.8) 2 .2 (19 )
9 Months n=6 - 9.8(10.4) 2.5 (2.1)
12 Months n=5 3.2 (3.2) 15.4(17.6) n=5 10.8(11.7) 2.6 (2.3)
Cryotherapy and 
hormonal therapy
Baseline n=35 3.6 (6.4) 12.5(11.6) n=31 10.6 (6.7) 2.9 (1.5)
6 Weeks n=31 - - 14.9 (8.2) 3 .2 (15 )
3 Months n=29 - - 11.4 (7.1) 2 .7 (15 )
6 Months n=15 2.7 (3.6) 16.2(13.5) n=15 9.4 (6.4) 2 .4 (17 )
9 Months n=23 - 11.4 (7.7) 2.6 (1.4)
12 Months n=14 3.0 (4.3) 8.8 (9.4) n=13 12.6 (9.0) 2 .3 (16 )
Table 3.27. International Index of Erectile Function -5 (IIEF-5), Erectile Dysfunction Effect on 
Quality of Life (ED-EQoL), International Prostate Symptoms Score mean and IPSS Quality of 
Life (QoL) (standard deviation). IIEF-5 score 1-25, with higher score represents better 
outcome. The QD-EQoL score 0 to 60, with score <15 considered mild, 15-29 moderate and > 
30 severe effect of ED on QoL. The IPSS score 0-35, with higher the score represents worse 
outcome. IPSS QoL score 0-6, the higher the score corresponds to worse outcome.
* This question is relevant for men who have ED only. The number of the patients who 
responded is displayed in each cell.
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3.2.6 Taunton Psychosocial Morbidity Questionnaire (TPSM)
The mean scores of TPSM for patients with partners and their partners are 
presented in table 3.28. For the patients, the scales of the treatment and 
general cancer distress domains showed a gradual improvement post 
cryosurgery. Distress from pain, urinary symptoms, physical and social 
limitations showed a temporary worsening after cryosurgery for 3-6 months 
before returning to pre-cryosurgery scores. Worry for sexual function has not 
changed after cryosurgery.
The severity of worry due to treatment, pain, social limitation and general 
cancer distress were more problematic in the partners than the patients at 
baseline. Partners had less distress from sexual function at baseline 
compared to the patients. The magnitude and timescale of the scores 
changes of the partners were similar to those of the patients themselves.
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3.3 The Impact of Iceball Temperature on HQoL following 
Salvage Cryotherapy
Comparisons were made between the lowest temperatures at the apex of the 
prostate, the external urethral sphincter and the Denonvillier’s fascia during 
salvage cryosurgery and the 6weeks -baseline differences in the HQoL 
domains/items scores. To date, temperature data were available for 14 
patients (table 3.29). The table also shows that some patients did not in fact 
get adequate cryotherapy as the temperature at the apical region of the 
prostate failed to reach subzero.
There was no significant correlation between the lowest temperature at the 
apex of the prostate, the external urethral sphincter or the Denonvillier’s fascia 
and the impact on the HQoL domains/ items at 6 weeks (table 3.30).
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Chapter
4
Discussions
and
Conclusions
4.1 In-vitro Assessment of Three Different Cryoprobes 
Used for Prostate Cryosurgery
In our study, we have carried out four in vitro experiments to analyse and 
compare the dimensions of the lethal, non lethal and total iceballs, ablative 
ratio and the cooling rate of iceballs produced by three different cryoprobes. 
We have also assessed the effect of reducing the cooling rate on these 
parameters by decreasing the rate of the freezing gas flow to 20%. The 
probes were tested in configurations similar to the anterior probes 
arrangement during clinical situations. We assessed the 2.4mm and the 
3.4mm diameter probes, each in two probe model placed 18mm apart This 
was repeated but with reducing the distance between the probes to 15mm. 
We did not investigate the effect of increasing the distance between the 
probes. The fourth experiment was carried out on the 1.47mm diameter 
probes. We used 8 probes divided into two rows kept at 10mm apart To date, 
there is no published data on similar experiments. We did not assess the 
effect of changing the distances between the 3.4mm and 1.47mm probes.
From our study, it is not possible to suggest a complete protocol for prostate 
cryosurgery as we did not examine the posterior cryoprobes; in addition, 
prostate size and shape varies widely amongst patients.
The maximum width mean (SD) of lethal zone of the 2.4mm probes 18mm 
apart at 100% gas flow rate was 37.23mm (0.62). This appeared to be 
adequate to cover the width of the majority of anterior part of the prostate of 
the 40 patients, which measured 31.23mm (SD 4.43), treated at the Royal
189
Surrey county Hospital. The lethal ice zone width has decreased by 
approximately 3 mm when the distance between the 2  probes was reduced to 
15mm. This indicates that the thickness of the lethal ice outside the probes 
did not change, and this was demonstrated when we measured the lethal ice 
thickness. However, we could not explain the lack of comparable reduction in 
the total iceball width. The 3.4mm probe did not add any significant lethal ice 
width. The lethal iceball width of the 1.47mm cryoneedles at 100% gas flow 
rate was the largest, measuring 39.38mm (SD 2.36). in this experiment, the 
cryoneedles were arranged in 2 rows of 4 needles each, and the distance 
between 2  adjacent needles was 10mm. Therefore, the length of each row of 
cryoneedles equalled 30mm. Hence, we concluded that there is little lethal ice 
created outside the cryoneedles, and this will be discussed later in the 
chapter.
No differences were observed between the lethal ice depths of the four 
iceballs when frozen at 100% gas flow rate. We expected to witness a 
significant increase in the lethal ice depth when we reduced the distance 
between the 2.4mm cryoprobes by 3mm in experiment 2; however, the 
increase was not statistically significant
The means of the lethal ice depths ranged between 23.53 -  24.26mm. This is 
adequate to cover the anterior prostate depths of our 40 patients, which had a 
mean measurement of 17.18mm.
Measuring the total ice depths at 100% gas flow, we noticed that they were 
statistically comparable, except in the 1.47mm cryoneedles, which was
190
significantly shorter. This, indicated that for a similar lethal ice depth, the
1.47mm cryoneedles had less non-lethal ice. This was confirmed when we 
compared the non-lethal ice thickness across the depth, which will be 
discussed later.
Unlike the depth, the length of the lethal ice zone increased significantly when 
the distance between the two 2.4mm probes was reduced by approximately 
3mm (from a mean of 35.71mm to 39.3mm). The mean (SD) length of the 40 
anterior prostates lengths was 35.2 (5.8). We concluded that when placing 
2.4mm probes 18mm and 15mm apart, the lethal ice covered the length of the 
prostate in approximately half and less than 75% of our patients respectively. 
The most significant difference was noted in the 1.47mm cryoneedles, which 
produced significantly short lethal ice [mean (SD) of 22.62mm (0.48)]. All of 
the 40 prostate we measured had prostate length of more than 23mm; 
therefore, this iceball is inadequate to freeze the apical region (see figure 2.4) 
of our patients’ prostates. In clinical situations, when it is felt the prostate 
gland is longer than the iceball, a “pull back” technique is applied as 
discussed in chapter 1 (1.3.4.7). In this technique, the freezing probes are 
pulled back by few millimetres after the first freeze, ensuring iceball coverage 
of the apical region in the second freeze. However, the prostate length at 
which the “pull back” technique is applied varies amongst urologists.
Lam et al (2004) and Fahmy and Bissada (2003) suggested to perform “pull 
back” when the prostate length is greater than 27mm using the Seednet™ 
cryoneedles. Zisman et al (2001) recommended similar prostate length,
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however, they considered the lethal ice to be £  -20° C instead of £ -40° C. 
Witzch et a l  (2005) performed cryosurgery on 80 patients using between 9 -  
17 cryoneedles (Seednet™). They performed “pull back” for prostates longer 
than 35mm.
Lee et al (1999) did not specify the length of the prostate; they pulled back the 
posterior probes by 1cm if they believed that apical kill was not achieved 
using the 3.4mm Cryocare™ probes. Rewcastle et al (1998) have developed 
a computer model to predict thermal distribution around 3.4mm cryoprobe. 
From the 10 minute isotherm graph, the maximum lethal ice length (^-40°C) 
could be estimated between 26-27mm only. However, the model was based 
on single probe using the thermal properties of water. To date, there are no 
published reports on the 2.4mm Cryocare™ probes.
The distance between the centre of the freezing probe and the -40° isotherm 
reflects the maximum distance at which the freezing probes should be placed 
away from the prostatic capsule during the procedure. This distance was 
almost equal statistically between the 3 iceballs of Cryocare™ probes when 
frozen at 100% gas flow rate with a mean distance ranging between 10.81 -  
11.74mm. However, for the Seednet™ cryoneedles, the distance between the 
freezing probe and the-40° isotherm was only 3.28mm (SD 0.96).
Larson et al (2000) performed prostate cryosurgery on 6 patients scheduled 
for radical prostatectomy using a single 3.4mm cryoprobe to determine the 
critical lethal temperature and its location within the iceball. They observed
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that temperatures of £ -41.4°C were required to cause prostatic necrosis after 
two freeze cycles of 7.5 to 10 minutes of freezing on full gas flow. Using 
thermosensors, they concluded that the radius of the zone of necrosis was 
6mm. When using single freeze, temperatures of ^ -61.,7°C were required to 
produce necrosis, which was located at 4.1 mm radius. These measurements 
are less than pur experiment One hypothesis to explain this dissimilarity is 
the difference in the number of probes used (one vs. two) and the effect of 
prostate perfusion in vivo which will discussed later in the chapter. Rewcastle 
and colleague’s (1998) computer model (based on water thermal properties) 
isotherm graphs estimated the radius of the -40°C isotherm to be 
approximately 5-6mm using a single 3.4mm probe after 10 minutes of 
freezing. In another study, the same group (Rewcastle et al, 1999a) have 
estimated that the -40°C isotherm is located 8.6 mm from a single 3.4 
cryoprobe surface based on theoretical thermal gradient about an infinitely 
long cryoprobe with surface temperature of -186°C.
Clinically, it has been recommended that 3.4mm cryoprobes to be placed 
within 10mm of the prostate margin (Donnelly and Saliken, 2002; Lee et al, 
1999). Zisman et al (2001) believed that the -20°C isotherm is located at a 
radius of 10mm of a single cryoneedle iceball after 10 minutes of freezing. 
They, together with Fahmy and Bissada (2003), have suggested to place the 
posterior group of the Seednet™ cryoneedles 5-7mm from the prostatic 
capsule.
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Although the non-lethal ice zone does not eradicate prostate cancer cells 
effectively, it can cause tissue damage (Larson et al, 2000) to the rectum and 
urethra. Therefore, the thinner the non-lethal ice thickness, the less risk of 
collateral damage. Larson et al (2000) have observed that the critical 
temperature for tissue damage ranged between -38.5°C to -20J°C  
(mean -29.6°C ) after a double freezing cycle. This was located 1.5 mm 
outside the critical lethal temperature of -41.4°C. We have measured and 
compared the thickness of non-lethal ice (from the 0°C to -40°C) in three 
places as an indicator for the risk of collateral tissue damage.
The thickness of the non-lethal iceball at 100% gas flow was measured and 
compared between the iceballs. The cryoneedles’ iceball had the highest non- 
lethal ice thickness when measured across the width of the iceball, but the 
least non-lethal ice thickness across the depth. The differences in the non- 
lethal ice across the width may have little clinical implications as the lethal ice 
is normally allowed to encompass the neurovascular bundles during freezing 
(see 1.2.2.7); hence the incidence of impotence is high after cryosurgery. 
Across the depth, the prostate is bounded by the pubic bone anteriorly and 
the Denonvillier’s fascia posteriorly. Cases of osteitis pubis due to iceball 
extension have been reported (Connolly et al, 1996), while the rate of recto- 
urethral fistula, which results from iceball extension to the rectum during 
salvage cryosurgery, ranges between 0-3.4%. Therefore, we may conclude 
that the Seednet™ cryoneedles may have less risk of osteitis and recto- 
urethral fistula. However, this should be interpreted with caution particularly, 
the risk of rectal damage because -  as explained in chapter 1 (1.2.2.7) - four
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probes are commonly used in the posterior group rather than two (as used in 
our experiments) in the Cryocare™ system, therefore, comparisons may not 
be accurate.
The thickness of the non-lethal ice at the top was largest in the 3.4mm 
cryoprobe and the 147mm cryoneedles measuring 13.34 mm (SD 1.83) and
11.34 mm (SD 0.65) respectively compared to the 2.4mm probe’s iceballs 
which was approximately half these thicknesses. The clinical impact is that 
the top of the iceball corresponds to the apical region of the prostate which is 
close to the external urethral sphincter; therefore, we concluded that the risk 
of sphincter damage and incontinence is less when using the 2.4mm 
cryoprobes.
Lam and colleagues (2QQ4) suggested to extend the iceball 2 to 4mm beyond 
the apex of the prostate when using the 1.47mm cryoneedles. If this indicates 
the distance between the edge of the iceball and the -40°C isotherm, then it is 
significantly shorter than our experimental measurements.
Rewcastle and colleagues’ (1998) computer model’s graph at 10 minutes 
predicted that the thickness of the 0°C to -40°C zone is approximately 9- 
10mm at the top of an iceball created by a single 3.4mm cryoprobe. This is 
less than our experiments perhaps due to the fact that Rewcastle’s simulation 
was based on a single probe and using water thermal properties. However, 
using the same computer model, the non-lethal zone thickness across the 
side of a single 3.4mm cryoprobe’s iceball was comparable to our 
experimental measurements across the width (measuring between 7-8mm).
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Theodorescu (2004) showed, that the thickness of the 0°C to -40°C zone is 
4mm for an iceball created by 3 Seednet™ cryoneedles arranged in a 
triangular fashion.
The thickness of the lethal ice below the tips of the cryoprobe indicate how 
close to place the cryoprobe from the base of the prostate (see figure 2.4). 
We have concluded that there is very little lethal ice below the cryoprobe tips 
in experiment 1 (2.4mm probe, 18mm apart) regardless of the gas flow rate. 
In fact, on two occasions, no lethal ice could be measured beyond the 
cryoprobe tips. Therefore, in clinical situations, these probes should be placed 
deep in until they reach the base of the prostate.
In experiment 2, when we reduced the distance between the probes to 15mm, 
there was approximately 2mm more lethal ice below the cryoprobes tips. This 
was expected as we have previously concluded that after reducing the 
distance between the cryoprobes, the entire length of the lethal ice increased 
by approximately 4mm. There was approximately 3mm lethal ice below the 
3.4mm and the 1.47mm probes tips at 100 gas flow rates.
We have not measured the thickness of non-lethal ice below the cryoprobe 
tips as no bladder damage has been previously reported. We hypothesised 
that this could be from the large heat sink effect of the urinary bladder which 
would be full of urine that is maintained warm by the urethral warming 
catheter during the procedure as described in chapter 1 (1.2.2.7). Zippe 
(1996) suggested that the iceball does not extend 5mm below the tip of liquid
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nitrogen probes due to the heat sink effect of the bladder. Such effect on the 
argon-based probes has not been assessed previously or during our 
experiments.
The computer model graph of Rewcastle et al (1998) suggested that 
approximately 10mm of ice is present below the tip of a single 3.4mm probe, 
3mm of which is lethal.
Clinically, Lee et al (1999) advocated that the tips of the two posterio-lateral 
probes should extend through the posterior capsule using the 3.4mm 
Cryocare™ probe. Zisman et al (2001) explained their operative technique 
was based on the fact that the 1.47mm cryoneedles produces ice 5mm 
beyond the tip.
We have assessed the effect of reducing the argon gas flow rate from 100% 
to 20% on all the measurements. The most significant difference was 
observed in the 1.47mm cryoneedles as the iceball failed to produce any 
lethal ice when frozen at 20%. Lethal iceball dimensions have also reduced in 
the first three experiments, more pronouncedly in experiment 3. Therefore, we 
can conclude that freezing using 20% gas flow is not as efficient as 100% gas 
flow rate particularly when using the Seednet™ system. The effect of reducing 
the gas flow rate on the non-lethal ice thickness and lethal ice thickness below 
cryoprobe tips was minimal.
We have measured and compared the 0-5 minutes cooling rates in the centre 
of the iceball at the maximum dimension level of the 4 experiments at 100% 
and 20% gas flow rates. Although, statistically, experiment two’s iceball had
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the fastest cooling rate, the differences were too small and there is no 
evidence to suggest any clinical significance. The most significant difference 
was noted between the 100% and 20% gas flow rates in experiment 4. 
Tatsutani et al (1996) have experimented on a prostate adenocarcinoma cell 
line (ND-1). These cells were frozen at 1, 5 and 25 °C/min cooling rates. They 
concluded that there was a little difference in terms of cell destruction 
between the 1 and 5°C/min cooling rates, while, the 25°C/min cooling rate 
was significantly more lethal. Bischof et al (1997) carried out similar 
experiments on the AT-1 rat prostate tumour at cellular and tissue level. They 
concluded that there were little differences (in terms of cell viability) between 
different cooling rates (ranging from 5 to 50 °C/min) when the cells or tissue 
were frozen to -40°C.
Although measurement of the ablative ratios was based on assumptions as 
described before in chapter 2 (2.1.18), it has value when comparing the 
iceballs. In addition, we observed that the value of the ablative ratio was 
consistent with the other measured parameters, adding to its validity.
The highest ablative ratio was observed in the 2.4mm cryoprobe regardless 
whether they were 18 or 15mm apart. The smallest ratio was seen in the 
Seednet™ system iceball, with only 22.81% of the iceball was lethal when 
frozen at 100%. This is probably owing to the short length of the iceball and 
the fact that the lethal ice length was approximately only half the total iceball 
length. The lethal ice length of the 2.4mm probe’s iceball was in the region of 
2/3 of the total iceball length.
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The ablative ratio of the 3.4mm cryoprobe did not differ significantly from the 
Seednet™ iceball measuring 23.75%. This is perhaps due to the increase in 
non lethal ice at the top of the iceball. There were statistically significant 
reductions in all the ablative ratios when the gas flow rates were reduced to 
20%.
Limitations of the Study
1. In vivo assessment of the iceballs is the most accurate way to compare 
different cryoprobes, but for reasons explained earlier in chapter 1 (1.4), 
it is not possible to precisely map the temperature of the iceballs in vivo 
during prostate cryosurgery. We anticipate that the iceball will be smaller 
in vivo due tissue perfusion. Bhattacharya and Mahajan (2003) 
concluded that sheep gelatine and cow liver’s thermal conductivity 
increases with increasing temperature. They also demonstrated that 
thermal conductivities of various organs of a living pig were higher 
compared to the reported in vitro values. These differences were 
different between different organs, and were directly dependant on tissue 
perfusion. Prostate perfusion varies greatly according to the volume of 
the prostate; patient’s age; PSA value; history of prostate irradiation and 
hormonal therapy (reviewed by Vulpen et al, 2002). Therefore, it is not 
possible to standardize in vivo thermal conductivity of the prostate. In 
addition to the increase in the metabolic heat generation, blood flow 
through big vessels (e.g. neurovascular bundles) act as a “heat sink” 
which may further reduce the iceball size and the cooling rate. Therefore,
199
despite the similarities between thermal properties of the prostate and 
the freezing medium (bovine muscle), differences between the iceballs 
properties are expected. However, the four experiments were conducted 
in similar conditions; consequently, comparisons between the four 
iceballs are still valuable.
2. The configuration of the probes used in the experiments was similar to 
the configuration of the probes responsible for freezing the anterior part 
of the prostate. However, we have not assessed the effect of the 
posterior probes’ iceball which fuses with anterior iceball during the later 
part of the freezing phase. We have also not assessed the heat sink 
effects of the urethral warming catheter and the neurovascular bundles in 
the middle and on each side of the iceball respectively.
Conclusions
We have compared the properties of the iceballs formed using three different 
types of freezing probes under similar conditions in vitro. We have also 
assessed the effect of reducing the rate of the freezing gas flow from 100% to 
20% on the iceball properties.
The 2.4 mm diameter probes produced an iceball with the highest ablative 
ratio and the least non-lethal ice thickness. When the probes are place at 
18mm apart; they should be inserted deep into the prostate until they reach 
the base as there was a little lethal ice below the tips of the probes. Reduction 
of the distance between the probes to 15mm resulted in an increase in the
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length of lethal ice at the expense of the width. Hence, if the shape of the 
prostate is relatively narrow and long, the distance between the probes can be 
reduced.
Although the more invasive 3.4mm diameter probes produced a larger iceball 
it had a lower ablative ratio than that produced by the 2.4mm probe, perhaps 
due to significant volume of non-lethal ice at the top. Therefore, the 3.4mm 
diameter probes are potentially associated with higher risk of external urethral 
sphincter damage and incontinence.
The most important feature of the 1.47mm diameter cryoneedles was that 
they produced significantly short lethal ice which was inadequate to cover the 
length of the entire 40 patient’s prostate treated with cryosurgery in our 
centre. Therefore, a “pull back” technique is required in almost every patients 
unless the prostate length is less than 23mm. The iceball had the lowest 
ablative ratio and the cryoneedles should be placed very close to the prostatic 
capsule.
Reduction of the freezing gas flow rate to 20% resulted in decrease in lethal 
iceball dimensions, cooling rates and the ablative ratios for all the iceballs. 
However, the most significant changes were observed in the 1.47mm 
cryoneedles (Seednet) as it failed to produce lethal ice at 20% gas flow rates. 
Therefore, we recommend that if possible, freezing should be performed at 
the highest gas flow rate especially when using the 1.47mm cryoneedles.
201
4.2 Health Related Quality of Life of Salvage Cryotherapy 
on Patients with Localised Prostate Cancer Recurrence 
after Radiation Failure
Recommendations are currently lacking regarding which specific 
questionnaires are preferable for assessment of QoL after treatment for early 
prostate cancer as a primary or salvage modality. It is likely that EORTC QLQ 
C30 and PR25 will continue to be used in European countries due to its 
availability/ fields testing in several European languages, although the full 
validation of PR25 is still ongoing.
The results were presented using the scales of various questionnaires. 
Individual key items were also presented separately as a percentage of 
patients with moderate or severe symptoms to add more value to the PR25 
questionnaire, as it is still awaiting complete validation. It may also be easier 
for clinicians to interpret the answers to single questions than understand the 
complexities of a multi-scale structure.
The results should be interpreted with caution due to the small number of 
recruited patients to date, particularly at 6 months follow-up, which was due to 
an administration error resulting in a group of patients missing their 
questionnaires. Direct comparisons between hormone treated and hormone 
naive patients could not be done accurately due to the small and uneven 
numbers of patients in both groups.
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From the trend of the changes in the data, it seems that the impact of salvage 
cryotherapy on global health is temporary and lasting less than 9 months, 
indicating that patients do not regard salvage cryotherapy to have long-term 
harmful effects. However, more patients, longer follow-up and comparison 
with other salvage therapies are required.
There is a trend for "a little” improvement in insomnia from 3months follow-up 
which could be due to less nocturia. At 6 weeks follow-up, 50% of the patients 
reported that urinating at night disturbed their sleep by “quite a bit” or “very 
much” compared to only 15% at 3 month.
The data of the IPSS scores suggest that deterioration in urinary symptoms is 
of clinical significance for less than 3 months post-operatively. The changes 
from 3-12 months were not clinically significant. More detailed assessment 
with EORTC -PR25 questionnaire suggests that initial worsening in urinary 
symptoms becomes none clinically significant from 9 months onwards. 
However, more patients are required to confirm these findings.
Urinary incontinence seems to increase after salvage cryotherapy. At 6 weeks 
follow-up, 21.9% of the patients reported “quite a bit” or “very much” 
incontinence compared to 4.3% pre-operatively. Although the incontinence 
rate falls to affect 13.1 % of the patients at three months it rises to 26.3% at 12 
months. The reason for this late rise is unclear; one explanation is that many 
of the patients with the longest period of follow-up underwent surgery in the 
early part of the operator’s learning curve when imprecise placement of the
203
probes might have damaged the external sphincter. However, more data are 
required to confirm this suggestion. 12 patients responded to the urinary 
incontinence “aid bother”. Only 3 responded in the category “quite a bit”. One 
was incontinent before the operation.
The majority (41 out of 47) of the patients were impotent before the salvage 
cryosurgery (IIEF-5 <12). One of the factors which could influence this is that 
approximately 75% of the patients were on hormonal treatment. However, it is 
worth mentioning that 3 out of the 6 potent patients before the operation were 
on hormonal treatment, but the number is small to achieve conclusions. Both 
the IIEF-5 and the PR-25 sexual function questions and sexual activity 
suggest that salvage cryotherapy does not cause sexual impairment of clinical 
significance, which is in contrast to previously reported cross-sectional data 
(Anastasiadis et al, 2003). The reason for this discrepancy is the small 
number of potent patients in our series and the lack of published longitudinal 
data especially in men with concomitant hormonal treatment. It is worth 
mentioning that out of the six potent patients before cryosurgery, only one 
remains potent, hence, we anticipate that with more data, salvage cryosurgery 
will be confirmed as a causal factor in the development of ED.
Patients’ treatment worry and general cancer distress have shown trends of 
improvement after salvage cryotherapy. This is in parallel with improvement in 
emotional functioning of the EORTC QLQ-C30 questionnaire. It is interesting 
that the partners showed a similar pattern of changes but to a greater degree 
intensity. Remarkably, the only area where patients are more worried than
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their partners is the impairment of sexual function. However the trends of the 
EDQoL scores suggest that in the long run ED does not in fact affect quality of 
life in the majority of patients. This may be partly due to small number of 
potent patients at baseline, and also patients’ expectations of high incidence 
of ED after salvage cryotherapy
Our preliminary results of the HQoL assessment were comparable to the 
results of Robinson et al. (2006) who assessed HQoL two years after salvage 
cryotherapy using EORTC QLQ-C30 and UCLA-PCI questionnaires. Out of 
the 46 patients recruited in their study, 13 were on hormonal therapy prior to 
cryosurgery. There was a temporary worsening of all the domain and 
subscale scores, which returned to baseline levels, with the exception of 
urinary and sexual function which remained impaired.
Limitations of the Study
1. This study is at present immature in terms of recruitment and follow- 
up.
2. The majority of the patients (75%) were hormonally treated which 
may result in significant confounding due to possible side effects 
including hot flushes, loss of libido and sexual function, asthenia 
and breast pain (Iversen et al, 2000; Sieber et al, 2004).
We plan to address this by increasing recruitment of hormone naive 
patients to achieve statistical power.
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Conclusions
Although the study is still immature; the preliminary data suggest that 
deterioration in general health is limited to a period of less than 9 months. 
Incontinence seems to increase; however, this still compares favourably with 
other salvage modalities (reviewed by Ahmed et al, 2005). Sexual activity and 
function were difficult to assess due to the small number (19%) of sexually 
active men at baseline.
4.3. The Impact of Iceball Temperature on HQoL during 
Salvage Cryotherapy
We assessed the correlation between the temperatures at the apex of the 
prostate, the external urethral sphincter and at the Denonvillier’s fascia during 
cryosurgery and the impact on HQoL following salvage cryotherapy. If we 
proof that such a correlation exists, then we may be able to reduce the impact 
on HQoL after salvage cryotherapy by choosing different freezing probes or 
by modifying the technique. During cryosurgery, non-lethal ice may reach the 
external urethral sphincter or the Denonvillier’s fascia (see 1.2.2.7) resulting in 
urinary incontinence or recto-urethral fistula respectively, with the lower 
temperatures, the more risk of collateral damages (Larson et al. 2000). 
Urinary and bowel related side-effects of prostate cancer treatment have a 
negative impact on HQoL (Helgason et al. 1998). Therefore, we anticipated 
that patients with lower temperature at the external urethral sphincter or
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Denonvillier’s fascia would sustain more tissue damage, and hence, more co­
morbidities and worst impact on HQoL.
In our study, we could not demonstrate such a correlation between lowest 
iceball temperatures and HQoL impact; however, this should be interpreted 
with caution due to the small number of patients included in the study. We 
anticipate that with more data, it may be possible to demonstrate that a 
correlation between the lowest temperature at the external urethral sphincter 
or Denonvillier’s fascia and HQoL impact exists.
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Chapter
5
Appendices
Appendix A
Thermal Map of Horizontal Slices of the Four Iceballs Created 
from the 10 Minutes Mean Temperatures
Temperature mapping of experiment 1 iceball horizontal slices (level 3-6) at 
100% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 1 iceball horizontal slices (level 7-12) at
100% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 1 iceball horizontal levels (level 3-8) at
20% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 1 iceball horizontal levels (level 9-12) at
20% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 2 iceball horizontal levels (level 3-8) at
100% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 2 iceball horizontal levels (level 9-12) at
100% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 2 iceball horizontal levels (level 3-8) at
20% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 2 iceball horizontal levels (level 9-12) at
20% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 3 iceball horizontal levels (level 2-7) at
100% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 3 iceball horizontal levels (level 8-13) at
100% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 3 iceball horizontal levels (level 3-8) at
20% freezing rate after 10 minutes of freezing
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Temperature mapping of experiment 3 iceball horizontal levels (level 9-13) at
20% freezing rate after 10 minutes of freezing
20%3.4mm/18mm
Level 9
10 mm above tip level
20%3.4mm/l8mm
Level 12
5 mm below tip level
20%3.4mm/18mm
Level 11 
Tip level
20%3.4mm/18mm
Level 13
10 mm below tip level
Temperature zones: Do° to -19.9° Q  -20° to -39.9° D  >-40°
Level 10
5 mm above tip level
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Temperature mapping of experiment 4 iceball horizontal levels (level 6-11) at
100% freezing rate after 10 minutes of freezing
100%1.47mm/10mm
Level 6
25 mm above tip level
o o o o o o o
o o o o o o o
Level 7
20 mm above tip level
1.47mm/10mm
Level 8
15 mm above tip level
Level 9
10 mm above tip level
1.47mm/10mm 100%
1.47mm/10mm
Level 10
5 mm above tip level
1.47mm/10mm
Level 11 
Tip level
Temperature zones: D  0° to -19.9° D  -20° to -39.9° D  ^ -40°
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Temperature mapping of experiment 4 iceball horizontal levels (level 12-13) at
100% freezing rate after 10 minutes of freezing
Level 12
5 mm below tip level
100%1.47mm/10mm
Level 13
10 mm below tip level
Temperature zones: D o 0 to -19.9° O  -20° to -39.9° □  >-40°
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Temperature mapping of experiment 4 iceball horizontal levels (level 8-11) at
20% freezing rate after 10 minutes of freezing
20%1.47mm/10mm
Level 9
10 mm above tip level
20%1.47mm/10mm
Level 8
above tip level
20 %1.47mm/10mm
Level 11 
Tip level
20%1.47mm/10mm
Level 10
5 mm above tip level
Temperature zones: D  0° to -19.9° D  -20° to -39.9°
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Appendix B
Patients Questionnaire Booklet
General Health Questionnaire (EORTC QLQ C30 v3)
We are interested in some things about you and your health. Please answer all of the 
questions yourself by circling the number that best applies to you. There are no "right" or 
"wrong" answers. The information that you provide will remain strictly confidential.
Please fill in your initials:
Today's date (Day, Month, Year):____________ I I __________________________________
Not at 
All
A
Little
Quite 
a Bit
Very
Much
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase? 2 3 4
2. Do you have any trouble taking a Iona walk? 1 2 3 4
3. Do you have any trouble taking a short walk outside 
of the house? 1 2 3 4
4. Do you need to stay in bed or a chair during the day? 1 2 3 4
5. Do you need help with eating, dressing, washing 
yourself or using the toilet? 1 2 3 4
During the past week: Not at 
All
A
Little
Quite 
a Bit
Very
Much
6. Were you limited in doing either your work or other 
daily activities? 1 2 3 4
7. Were you limited in pursuing your hobbies or other 
leisure time activities? 1 2 3 4
8. Were you short of breath? 2 3 4
9. Have you had pain? 1 2 3 4
10. Did you need to rest? 1 2 3 4
11. Have you had trouble sleeping? 1 2 3 4
12. Have you felt weak? 1 2 3 4
13. Have you lacked appetite? 1 2 3 4
14. Have you felt nauseated? 1 2 3 4
15. Have you had vomiting?
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1 2 3 4
During the past week: Not at A Quite Very
16. Have you been constipated?
All Little
1 2
a Bit
3
Much
4
17. Have you had diarrhoea? 1 2 3 4
18. Were you tired? 1 2 3 4
19. Did pain interfere with your daily activities? 1 2 3 4
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 1 2 3 4
21. Did you feel tense? 1 2 3 4
22. Did you worry? 1 2 3 4
23. Did you feel irritable? 1 2 3 4
24. Did you feel depressed? 1 2 3 4
25. Have you had difficulty remembering things? 1 2 3 4
26. Has your physical condition or medical treatment 
interfered with vour familv life? 1 2 3 4
27. Has your physical condition or medical treatment 
interfered with vour social activities? 1 2 3 4
28. Has your physical condition or medical treatment 
caused you financial difficulties? 1 2 3 4
For the following questions please circle the number between 1 and 7 
that best applies to you
29. How would you rate your overall health during the past week?
1 2 3 4 5 6 7
Very poor Excellent
30. How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Very poor Excellent
© Copyright 1995 EORTC Study Group on Quality of Life. All rights reserved. Version 3.0
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Specific Symptoms Related to Prostate Problems (EORTC QLQ - PR25)
Patients sometimes report that they have the following symptoms or problems. Please 
indicate the extent to which you have experienced these symptoms or problems during the 
past week. Please answer by circling the number that best applies to you.
During the past week Not at 
all
A
little
Quite 
a bit
Very
much
31. Have vou had to urinate freauentlv durina the dav? 1 2 3 4
32. Have vou had to urinate freauentlv at niaht? 1 2 3 4
33. When you felt the urge to pass urine, did you have 
to hurry to get to the toilet? 1 2 3 4
34. Was it difficult for you to get enough sleep, because 
you needed to get up frequently at night to urinate? 1 2 3 4
35. Have you had difficulty going out of the house 
because you needed to be close to a toilet? 1 2 3 4
36. Have you had any unintentional release (leakage) 
of urine?
1 2 3 4
37. Did you have pain when you urinated? 1 2 3 4
I ANSWER QUESTION 38 ONLY IF YOU WEAR AN INCONTINENCE AIDI
j 38. Has wearing an incontinence aid been a problem 1 2 
j foryou?
3 4
Please answer the following questions 
During the past week
39. Have your daily activities been limited by your 
urinary problems? 1 2 3 4
40. Have your daily activities been limited by your bowel 
problems? 1 2 3 4
41. Have you had any unintentional release (leakage) 
of stools? 1 2 3 4
42. Have you had blood in your stools? 1 2 3 4
43. Did you have a bloated feeling in your abdomen? 1 2 3 4
44. Did you have hot flushes? 1 2 3 4
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During the last 4 weeks...
45. Have you had sore or enlarged nipples or breasts?
46. Have you had swelling in your legs or ankles?
47. Has weight loss been a problem for you?
48. Has weight gain been a problem for you?
49. Have you felt less masculine as a result of your 
illness or treatment?
50. To what extent were you interested 
in sex?
51. To what extent were you sexually active (with or 
without intercourse)?
N
I
at A Quite Very
little a bit much
2 3 4
2 3 4
2 3 4
2 3 4
2 3 4
4
4
PLEASE ANSWER THE NEXT FOUR QUESTIONS ONLY
SEXUALLY ACTIVE OVER THE LAST 4 WEEKS
52. To what extent was sex enjoyable for you?
53. Did you have difficulty getting or maintaining an 
erection?
54. Did you have ejaculation problems (eg dry 
ejaculation)?
55. Have you felt uncomfortable about being sexually 
intimate?
FYOU HAVE BEEN
2
2
3
3
3
3
4
4
4
4
© Copyright 1999 EORTC Study Group on Quality of Life. All rights reserved.
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International Index of Erectile Function (HER
These questions ask about the effects your erection problems have had on your sex life 
over the oast 4 weeks. Please answer the following questions as honestly and clearly as 
possible. In answering these questions, the following definitions apply:
Sexual activity includes intercourse, caressing, foreplay and masturbation
Sexual intercourse is defined as vaginal penetration of the partner
(you entered your partner)
Sexual stimulation includes situations like foreplay with a partner, looking at 
pictures, etc
Ejaculate: the ejection of semen from the penis (or the feeling of this)
1. Over the oast 4 weeks, how often were you able to get an erection during sexual 
activity?
Please tick one box only
□ No sexual activity 0
□ Almost always or always 5
□ Most Times (much more than half the time) 4
□ Sometimes (about half the time) 3
□ A few times (much less than half the time) 2
□ Almost never or never 1
2. Over the oast 4 weeks, when you had erections with sexual stimulation, how often 
were your erections hard enough for penetration?
Please tick one box only
□  No sexual stimulation 0
□  Almost always or always 5
□  Most Times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A few times (much less than half the time) 2
□  Almost never or never 1
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The next three questions will ask about the erections you may have had during sexual
intercourse.
3. Over the past 4 weeks, when you attempted sexual intercourse, how often were 
you able to penetrate (enter) your partner?
Please tick one box only
□ Did not attempt intercourse 0
□ Almost always or always 5
□ Most times (much more than half the time) 4
□ Some times (about half the time) 3
□ A few times (much less than half the time) 2
□ Almost never or never 1
4. Over the past 4 weeks, during sexual intercourse, how often were you able to 
maintain your erection after you had penetrated (entered) your partner?
Please tick one box only
□ Did not attempt intercourse 0
□ Almost always or always 5
□ Most times (much more than half the time) 4
□ Sometimes (about half the time) 3
□ A few times (much less than half the time) 2
□ Almost never or never 1
5. Over the past 4 weeks, during sexual intercourse, how difficult was it to maintain 
your erection to completion of intercourse?
Please tick one box only
□ Did not attempt intercourse 0
□ Extremely difficult 1
□ Very difficult 2
□ Difficult 3
□ Slightly difficult 4
□ Not difficult 5
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6. Over the past 4 weeks how many times have you attempted sexual intercourse?
Please tick one box only
□  No attempts 0
□  1-2 attempts 1
□  3-4 attempts 2
□  5-6 attempts 3
□  7-10 attempts 4
□  11+ attempts 5
7. Over the past 4 weeks, when you attempted sexual intercourse how often was it 
satisfactory for you?
Please tick one box only
□ Did not attempt intercourse 0
□ Almost always or always 5
□ Most times (much more than half the time) 4
□ Sometimes (about half the time) 3
□ A few times (much less than half the time) 2
□ Almost never or never 1
8. Over the past 4 weeks, how much have you enjoyed sexual intercourse? 
Please tick one box only
□  No intercourse 0
□  Very highly enjoyable 5
□  Highly enjoyable 4
□  Fairly enjoyable 3
□  Not very enjoyable 2
□  No enjoyment 1
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9. Over the past 4 weeks, when you had sexual stimulation or intercourse how often 
did you ejaculate?
Please tick one box only
□  No sexual stimulation/intercourse 0
□  Almost always or always 5
□  Most times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A few times (much less than half the time) 2
□  Almost never or never 1
10. Over the past 4 weeks, when you had sexual stimulation or intercourse how often 
did you have the feeling of orgasm (with or without ejaculation)?
Please tick one box only
□  No sexual stimulation/intercourse 0
□  Almost always or always 5
□  Most times (much more than half the time) 4
□  Sometimes (about half the time) 3
□  A few times (much less than half the time) 2
□  Almost never or never 1
No sexual stimulation/intercourse
Al ost always or always
Most times (much more than half the time)
Sometimes (about half the time)
 fe  ti es ( uch less than half the ti e)
l ost never or never
r t  o t    v   l ti l ti  r i t r r
o sexual sti ulation/intercourse
l t l  r l
st ti es ( c  re t a  alf t e ti )
ti  ( t lf t  ti )
  i   l   l   
l    
The next two questions ask about sexual desire. Let’s define sexual desire as a feeling 
that may include wanting to have a sexual experience (for example masturbation or 
intercourse), thinking about having sex, or feeling frustrated due to lack of sex.
11. Over the past 4 weeks how often have you felt sexual desire?
Please tick one box only
□ Almost always or always 5
□ Most times (much more than half the time) 4
□ Sometimes (about half the time) 3
□ A few times (much less than half the time) 2
□ Almost never or never 1
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12. Over the past 4 weeks how would you rate your level of sexual desire?
Please tick one box only
□  Very high 5
□  High 4
□  Moderate 3
□  Low 2
□  Very low or none at all 1
13. Over the past 4 weeks how satisfied have you been with your overall sex life?
Please tick one box only
□ Very satisfied 5
□ Moderately satisfied 4
□ About equally satisfied and dissatisfied 3
□ Moderately dissatisfied 2
□ Very dissatisfied 1
14. Over the oast 4 weeks how satisfied have vou been with vour sexual relationship 
with your partner?
Please tick one box only
□  Very satisfied 5
□  Moderately satisfied 4
□  About equally satisfied and dissatisfied 3
□  Moderately dissatisfied 2
□  Very dissatisfied 1
15. Over the oast. 4 weeks how do vou rate vour confidence that you can pet and keep 
your erection?
Please tick one box only
□  Very High 5
□  High 4
□  Moderate 3
□  Low 2
□  Very low
Thank you for completing this questionnaire.
1
Supplementary Questionnaire
We need to know to what extent your treatment affects the amount of time and help you 
require from the local health services and from your family or friends.
The questions below should be answered in relation to those services you have required 
since the last questionnaire and are to do with all those services which relate to the 
treatment you are having within this study. If you have not previously completed a 
questionnaire then please complete this section for the past 3-months.
Since the last assessment
1. Have you been to your own doctor for any reason? YesD NoD
Number of times
2. Has your own doctor visited you at home for any reason? YesD NoD
Number of times
3. Have you visited your nurse or surgery/health clinic for any reason? YesD NoD
Number of times
4. Has the nurse visited you at home for any reason? YesD NoD
Number of times
5. Have you required any help from social services/any voluntary group? YesD NoD
Number of times
6. Have your family or friends taken time from work to help you at any time? YesD NoD
Number of times
7. Have you needed to pass a catheter at home since being treated? YesD NoD
If so for how many weeks did treatment continue? ________Weeks
8. Are you currently receiving any treatment for problems in getting or maintaining erections 
of the penis? YesD NoD
If so for how long have you been receiving such treatment?
What is the name of the treatment (eg Viagra11^  you are receiving?
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i
International Prostate Symptom Score (IPSS1
Please complete this form which you may have seen previously in clinic, it relates to your current 
ease of urination. Please ring the closest answer to how you have felt over the last month. Thank 
you.
Date: Not at 
all
Less 
than 1 
time in 
5
Less 
than 
half the 
time
About 
half 
the time
More 
than half 
the time
Almost
always
Your
score
1 Incomplete emptying
Over the past month, how often 
have you had a sensation of not 
emptying your bladder completely 
after you finish urinating?
0 1 2 3 4 5
2 Frequency
Over the past month, how often 
have you had to urinate again less 
than two hours after you finished 
urinating?
0 1 2 3 4 5
3 Intermittency
Over the past month, how often 
have you found you had stopped 
and started again several times 
when you urinated?
0 1 2 3 4 5
4 Urgency
Over the past month, how often 
have you found it difficult to 
postpone urination?
0 1 2 3 4 5
5 Weak Stream
Over the past month, how often 
have you had a weak urinary 
stream?
0 1 2 3 4 5
6 Straining
Over the past month, how often 
have you had to push or strain to 
begin urination?
0 1 2 3 4 5
5 Times
None 1 Time 2 Times 3 Times 4 Times or more
7 Nocturia
Over the past month, how many 
times did you most typically get 
up to urinate from the time you 
went to bed at night until the time 
you got up in the morning?
0 1 2 3 4 5
Total l-PSS Score - - - - - -
Quality of Life due to Urinary 
Symptoms
Delighted Pleased Mostly
satisfied
Mixed 
Equally 
satisfied & 
dissatisfied
Mostly
dissatisfied
Unhappy Terrible
If you were to spend the rest of 
your life with your urinary condition 
just the way it is now, how would 
you feel about that?
0 1 2 3 4 5 6
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Patient's Questionnaire (TPSM)
These questions attempt to measure some of the effects of your prostate cancer upon 
you. We will ask your partner to complete a similar questionnaire (if you have one). 
Please read each question carefully and answer by ticking the appropriate box. Answer 
according to how you are feeling at the moment.
• Are you worried or concerned about the fact that you have cancer?
□ Not at all (o) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Are you worried or concerned about what might happen in the future?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
* Are you having any difficulty in coping with your feelings or emotions 
resulting
from your cancer?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
* Your day to day activities might include chores around the house, going 
shopping or your job. Do you find yourself restricted in these sort of activities, 
because of your cancer?
□ Not at all (0) □ A little (i> □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
* Your social life might include seeing friends, going for day trips and your
hobbies. Has your social life become restricted, for whatever reason, as a result 
of your cancer?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
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From now on, first answer YES or NO, then answer the second part of the question only if
asked to do so.
• Are you receiving any treatment for your cancer?
□ Yes □ No
IF YOU ANSWERED YES, how much does the treatment worry you?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
IF YOU ANSWERED NO, how much does this worry you?
□ Not at all (0) D A  little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Do you have any pain?
□ Yes □ No
IF YOU ANSWERED YES, how much does this pain worry you?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Do you have any urinary problems?
□ Yes □ No
IF YOU ANSWERED YES, how much does these problems worry you?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Do you have difficulty doing the things that you used to be able to do, as a result 
of your cancer?
□ Yes □ No
IF YOU ANSWERED YES, how much does this worry you?
□ Not at all (o) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Has your sex life been changed by your cancer diagnosis or treatment?
□ Yes □ No
IF YOU ANSWERED YES, how much does this worry you?
□ Not at all (o) □ A little (1) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
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Quality of Life Questionnaire (ED-QoL)
This questionnaire only applies to men who have problems getting an erection. If you never 
have problems getting an erection DO NOT complete this questionnaire.
This questionnaire asks for your views about your erectile problem. Please read each item 
and place a tick in the box opposite the reply which comes closest to how you feel.
Not 
at all
A little
Somewhat
Quite a lot A great 
deal
1. As a result of your erectile 
difficulties, do you blame yourself for 
being unable to satisfy your partner?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
2. Does your inability to produce an 
erection with your partner make you 
feel guilty?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
3. Do you feel less desirable as a 
result of your erectile difficulties?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
4. Do you feel hurt by your partner’s 
response to your erectile difficulties?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
5. Does the fact that you are unable to 
produce an erection make you feel 
less of a man?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
6. Do you feel angry or bitter that you 
cannot produce an erection?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
7. Do you feel a failure because of 
your erectile difficulties?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
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Please read each item and place a tick in the box opposite the reply which comes closest 
to how you feel.
Not 
at all
A little
Somewhat
Quite a lot A great 
deal
8. Does your partner feel let down by 
your inability to produce an 
erection?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
9. Are you worried that your erectile 
problems have affected the 
closeness between you and your 
partner?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
10. Does your erectile failure make 
you worry about how your life will 
develop in the future?
□ o
Not at 
ail
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
11. Is your sense of identity altered by 
your lack of erectile function?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
12. Are you preoccupied by your 
erection problems?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
13. Do you feel sad or tearful as a 
result of your erectile difficulties?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
14. Do you feel that other people are 
happier than you are because they 
are sexually fulfilled?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
15. Is your self esteem damaged by 
your erectile problems?
□ o
Not at 
all
□ 1
A little
□ 2
Somewhat
□ 3
Quite a lot
□ 4
A great 
deal
© 1998 Taunton and Somerset NHS Trust
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Appendix C
Partner’s Questionnaire
These questions attempt to measure some of the effects of your partner’s prostate 
cancer upon you. Please read each question carefully and answer by ticking the 
appropriate box and answer according to how you are feeling at the moment.
• Are you worried or concerned about the fact that your partner has cancer?
□ Not at all (0) □ A little oj □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Are you worried or concerned about what might happen in the future?
□ Not at all (o) □ A little o) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
* Are you having any difficulty in coping with your feelings or emotions 
resulting from your partner’s cancer?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
* Your day to day activities might include chores around the house, going 
shopping or your job. Do you find yourself restricted in these sort of 
activities, because of your partner’s cancer?
□ Not at all (0) □ A little (1) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
* Your social life might include seeing friends, going for day trips and your
hobbies. Has your social life become restricted, for whatever reason, as a 
result of your partner’s cancer?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
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From now on, first answer YES or NO, then answer the second part of the question
only if asked to do so.
• Is your partner receiving any treatment for his cancer?
□ Yes □ No
IF YOU ANSWERED YES, how much does the treatment worry you?
□ Not at all (0) □ A little (d □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
IF YOU ANSWERED NO, how much does this worry you?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Does your partner have any pain?
□ Yes □ No
IF YOU ANSWERED YES, how much does this pain worry you?
□ Not at all (0) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Does your partner have any urinary problems?
□ Yes □ No
IF YOU ANSWERED YES, how much do these problems worry you?
□ Not at all (o) □ A little (d □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
• Does your partner have difficulty doing the things that he used to be able 
to do, as a result of his cancer?
□ Yes □ No
IF YOU ANSWERED YES, how much does this worry you?
□ Not at all (0) □ A little (d □ Somewhat (2) □ Quite a lot (3) D A  great deal (4)
• Has your sex life been changed by your partner’s cancer diagnosis or treatment? 
□ Yes □ No
IF YOU ANSWERED YES, how much does this worry you?
□ Not at all (o) □ A little (i) □ Somewhat (2) □ Quite a lot (3) □ A great deal (4)
239
Appendix D 
Publications
Articles Published in peer-reviewed journal
Ismail M, Ahmed S, Kastner C and Davies J.
Salvage cryotherapy for recurrent prostate cancer after radiation failure: a 
prospective case series of the first 100 patients. BJUI 2007; 100: 760-764.
Ahmed S and Swinn M.
Treatment of localised prostate cancer using high-intensity focused 
ultrasound. BJUI 2006; 98: 229.
Ahmed L, Ahmed S and Davies J.
The history of cryosurgery. J Endourol. 2006; 20: 21-24.
Ahmed S, Lindsey B, Davies J.
Emerging minimally invasive techniques for localised prostate cancer 
treatment. BJUI 2005; 96:1230-1234.
Ahmed S and Davies J.
Managing the complications of prostate cryosurgery. BJUI 2005; 95:480-1. 
Ahmed S, Lindsey B and Davies J.
Salvage cryosurgery for locally recurrent prostate cancer following 
radiotherapy. Prostate Cancer and Prostatic Disease 2005; 8:31 -35.
Book chapter
Ahmed S.
A history of cryosurgery, In: Mattelaer JJ (ed) de Historia Urologiae 
Europaeae (Vol 13). Historical Committee EAU, Belgium, 2006: 145-155.
Article Submitted to peer-reviewed journal
Ahmed S, Davies J and Chinn D.
Cryosurgery of the Prostate: Comparison of the Thermal Properties of Three 
Different Freezing Probes Iceball. Submitted to Cryobiology.
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